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Abstract  
		
This study aimed to explore the utilization of C. fasciculata as a convenient model organism 
to study the cell biology and drug discovery vehicle of the pathogenic kinetoplastids. We 
specifically aimed to: (i) develop and validate aprotein A-TEV-protein C (PTP) tagged 
protein expression system for C. fasciculata, (ii) develop a Resazurin-reduction viability 
assay with C. fasciculata and use this for subsequent screening for anti-crithidial compounds 
from the GSK open access pathogen boxes, and (iii) to study the effects of ionizing gamma 
radiation on C. fasciculata. 
We report the construction of plasmid pNUS-PTPcH, which can be utilised to express PTP 
tagged kinetoplastids proteins in C. fasciculata for subsequent purification. As a proof of 
concept, we have shown that C. fasciculata can be efficiently transfected with this plasmid 
and facilitate the isolation of two protein complexes: replication factor C (RFC) and the 
exosome. We have demonstrated that the expressed PTP tagged-replication factor C subunit 3 
(PTP-RFC3) co-purifies with RFC1, RFC2, RFC4, RFC5 and RAD17, and that the PTP 
tagged exosome subunit RRP4 co-purifies with RRP6, EAP1, RRP45, RRP40, RRP41B, 
CSL4, EAP2, RRP41A and EAP4. In addition, this thesis reports the development of a 
resazurin-reduction cell viability assay in C. fasciculata and reveals attractive core chemical 
scaffolds present in more than one of the open access GSK pathogen boxes, which will be 
followed up against the actual pathogenic kinetoplastids. Furthermore, this study has 
demonstrated that compared to cultured forms of T. cruzi which undergo growth arrest for 96 
hours after exposure to 500 Gy of gamma radiation, C. fasciculata is able to recover and 
resume normal growth within 24 hours after being subjected to doses as high as 1000Gy.  
The constructed plasmid, the identified chemical scaffolds and the observed responses of C. 
fasciculata to gamma irradiation will help facilitate further studies aimed to discover novel 
drugs for kinetoplastid diseases. 
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1. Chapter 1: Background introduction 
	
1.1 Introduction 
Kinetoplastids comprise of a group of flagellated protozoans that cause fatal diseases in 
humans and other mammals. They are characterised by the presence of a DNA-containing 
region, known as a “kinetoplast,” in their single large mitochondrion (Stuart et al., 2008). 
Common human diseases that are caused by these kinetoplastids include; human African 
trypanosomiasis (HAT), also known as African sleeping sickness, which is caused by two of 
the three subspecies of Trypanosoma brucei (rhodesience and gambiense), human American 
trypanosomiasis also known as Chagas disease, which is caused by Trypanosoma cruzi; and 
various forms of leishmaniasis which are caused by different species of Leishmania (Burri 
and Brun, 2003).  T. brucei, T. cruzi and Leishmania species  are together further grouped 
into the Trypanosomatidae, commonly referred to as the ‘TriTryps’. It is estimated that about 
a half a billion-people living in tropical and subtropical areas of the world are at risk of 
contracting the diseases caused by the TriTryps, with more than 20 million individuals 
infected with the pathogens that cause them resulting in extensive suffering and more than 
100,000 deaths per year (Stuart et al., 2008). 
The cellular biology of the various kinetoplastids is very similar. For example, they are all 
motile protozoans with a single flagellum that originates near their large single 
mitochondrion and emanates from their flagellar pocket in the cell membrane, the only place 
where endo- and exocytosis also takes place. Their peroxisomes are modified to perform 
glycolysis, and thus referred to as glycosomes. Their plasma membrane is underlain with a 
corset of microtubules and their cell surface is highly decorated with species-specific 
molecules that are critical for their survival. They typically grow asexually although sexual 
recombination has been observed in T. brucei, T. cruzi, and in some Leishmania species. 
Nevertheless, they divide by binary fission, during which their nucleus does not undergo 
membrane dissolution or chromosome condensation (Stuart et al., 2008). Kinetoplastids have 
a unique genome organisation, which consists of unidirectional large gene clusters, which are 
transcribed polycistronically (Teixeira et al., 2011). They possess distinct genetic processes 
including RNA polymerase I-mediated transcription and trans-splicing of the immature RNA, 
which is followed by the addition of a 5’ mini-exon and 5’-polyadenylation to form mature 
RNA transcripts (Hajduk and Ochsenreiter, 2010). Although the kinetoplastids share such 
many similarities, they cause very distinctive forms of disease as shown in Table 1. 
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Table 1.  Details of some kinetoplastid diseases. The data was copied from Maudlin et al. 
(2004) and Lane et al. (1993). Non-standard abbreviations: CL (Cutaneous leishmaniasis), 
ML (Mucosal leishmaniasis) and VL (Visceral leishmaniasis). 
 
 
 
 Sleeping sickness Chagas disease  Leishmaniasis  
Stages Early (hemolymphatic) 
stage, late (CNS) stage 
Acute phase, 
indeterminant phase, 
chronic phase 
(cardiac and 
digestive forms) 
VL, CL 
Causative 
agent  
T.b. gambiense, T.b. 
rhodesiense 
T. cruzi ∼21 Leishmania 
spp. e.g., L. 
donovani (VL), L. 
braziliensis, L. 
major (CL) 
Host cell Extracellular, in blood, 
lymph, cerebral spinal fluid, 
and intercellular spaces 
Intracellular, in 
cytoplasm of heart, 
smooth muscle, gut, 
CNS, and adipose 
tissue cells 
Intracellular, in 
phagolysosomes of 
macrophages 
Vectors  Tsetse flies (∼20 Glossina 
spp.) (palpalis group, T.b. 
gambiense; morsitans 
group, T.b. rhodesiense) 
Reduviid bugs 
(∼12/∼138 
Triatominae spp.) 
(Triatoma, 
Rhodnius, and 
Panstrongylus spp.) 
Phebotomine 
sandflies (∼70 
Phlebotomus spp. in 
Old World, 
Lutzomyia spp. in 
New World) 
Mode of 
transmission  
Infected fly bite, congenital 
(rare), blood transfusion 
(rare) 
Contamination by 
feces of infected 
bugs (e.g., at bite 
site, in mucous 
membranes, in food 
or drink),blood 
transfusion, 
congenital, organ 
transplantation (rare) 
Infected fly bite 
Geographic 
distribution 
Sub-Saharan Africa (∼20 
countries) 
South and Central 
America (19 
countries) 
South and Central 
America, Europe, 
Africa, Asia (88 
endemic countries) 
Population 
at risk 
50 million 100 million 350 million 
Infected 70,000–80,000 8–11 million 12 million 
Deaths/year ∼30,000 14,000 51,000 (VL) 
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The general life cycles of kinetoplastids vary according to the invertebrate vector that is 
involved in the transmission. As described by Bartholomeu et al. (2014), Leishmania species 
multiply as promastigotes in the sand fly’s mid-gut. These parasites get injected into the 
human host as the fly is taking a blood meal and consequently get engulfed by macrophages. 
Inside the microphages, the parasites develop and proliferate as amastigotes and infect other 
surrounding cells after cell lysis (Fig 1a). 
 
Trypanosoma cruzi parasites proliferate as epimastigotes in the revuviid bug’s mid-gut and 
spread to colonise the bug’s intestines. In the intestines, the parasite develops into infective 
metacyclic promastigotes forms get excreted alongside the bug’s faeces (Fig. 1b). T. cruzi 
parasites target any host cell with a nuclear through recruitment of lysosomal or simply 
invagination the cell’s plasma membrane (Bartholomeu et al., 2014). They then proliferate 
into amastigotes and trypomastigotes in the cytosol and realised by lysis of infected cells, 
which are taken up by the surrounding cells (Ueno and Wilson, 2012). 
 
Unlike T. cruzi and most Leishmania species, T. brucei parasites proliferate outside the host 
cells for their entire life cycle (Bartholomeu et al., 2014) (Fig. 1c). The parasites proliferate 
in tsetse fly intestines as procyclic forms, which develop into infective metacyclic forms in 
the salivary glands. The metacyclic parasites are injected into the host through saliva when 
the fly is taking a blood meal and multiply in the host blood as procyclic trypomastigotes. 
However, since the T.brucei parasites cannot invade and hide inside the host cells like T. 
cruzi and L.major, the parasite had to adapt to a mechanism, which avoids being attacked by 
the host immune response. This is achieved by the parasite’s cell-surface “Variant surface 
glycoprotein” (VSG) which undergoes antigenic variation and avoid the parasite’s 
recognition by the host immune system (Horn and McCulloch, 2010). Through this 
mechanism, the parasites are always one-step ahead of the host immune responses. 
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Figure 1. Life cycles of the kinetoplastids. (a) L. major multiplies as promastigotes in the 
mid-gut of a sand fly and are transmitted to the host as metacyclic promastigotes during a 
blood meal. In the host, the parasites are phagocytosed by macrophages and the metacyclic 
forms are converted into amastigotes, which multiply numerous times before being released 
during cell lysis. (b) T. cruzi epimastigotes in the mid-gut of a bug transform into infective 
metacyclic trypomastigotes in the bug’s rectum and get excreted alongside the bud’s faeces to 
invade the host’s nucleated cells. (c) T. brucei multiplies as procyclic forms in the intestinal 
tract of tsetse fly and transformed into infective metacyclic forms in the fly’s salivary glands. 
When taking the blood, the fly injects the parasites into the host blood, which then proliferate 
as procyclic trypomastigotes (Copied from Bartholomeu et al., 2014). 
 
1.2 Current treatment for disease caused by kinetoplastids 
The current HAT treatment is based on five drugs which were developed decades ago, all of 
which have been reported to possess adverse side effects, challenges in efficacy, 
administration, and compliance. As recently reviewed by in Field and colleagues (Field et al., 
2017), the first stage of HAT caused by T.b. rhodesiense and T.b. gambiense is treated by 
suramin and pentamidine, respectively. However, both of these drugs are administered 
intraparenterally and are associated with toxicities. Melarsoprol is effective against second-
stage HAT caused by both T.b. rhodesiense and T.b. gambiense while eflornithine is only 
active for second-stage HAT caused by T.b. gambiense. The arsenical melarsoprol is 
administered intravenously for 10 days and is highly toxic causing substantial levels of drug-
related mortality due to reactive encephalopathy (Kennedy, 2013). The number of treatment 
failures after arsenical melarsoprol administration continue to increase due to drug resistance 
or other unknown factors. The pharmacokinetic studies on melarsoprol led to the treatment 
regimen being changed to a 10-day course rather than the previous 21- to 35-day course, thus 
improving patient compliance and reducing hospital costs (Kennedy et al., 2013). Being 
polyamine biosynthesis inhibitor, eflornithine has been commonly administered for HAT 
cases caused by infection with T.b. gambiense, which are resistant to treatment with 
melarsoprol (Malvy and Chappuis, 2011). The drug is suitable for second stage of disease 
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and is not effective against T.b.rhodesience. It is usually administered over 14 days as four 
daily intravenous infusions and has less severe adverse reactions compared to melarsoprol. 
However, administering 56 intravenous infusions present a logistical drawback especially in 
resource-limited settings. Nifurtimox-eflornithine combination therapy (NECT) have been 
shown to be effective in cases of second-stage HAT that are either refractory to treatment 
with melarsoprol alone or in situations where ornithine is unavailable. NECT has reduced 
treatment period and less costly than eflornithine monotherapy (Simarro et al, 2012). 
Moreover, the lack of paediatric formulations for some of the mentioned drugs together with 
contraindications for pregnant women and those of childbearing age further limit the use of 
these drugs. Vaccine development for HAT faces the challenge of parasite’s antigenic 
variation whereby the parasites make several antigenic variants by alternate expression and 
recombination of a repertoire of VSG-encoding genes, allowing them to escape the host 
immune response (LaGreca and Magez, 2011). 
 
Only two drugs, nifurtimox and benznidazole are currently available for treating Chagas 
disease. These drugs are orally administered but faces side effects, a long treatment period 
(>60 days) and variation in sensitives to the parasites (de Castro et al., 2006; Moraes et al., 
2014). Both of these drugs are reasonably effective against the acute form of the disease but 
have poor tolerability and patient compliance (Field et al., 2017). It has been reported 
elsewhere that once the heart failure develops in chronic Chagas disease, the treatment with 
benznidazole becomes irrelevant (Wang et al., 2012).  Other studies have reported the 
efficacy of benznidazole as a treatment for adults with Chagas disease who havebeen infected 
with the parasite for a long time (Viotti et al., 2006 and de Castro et al., 2006). However, the 
absence of well-structured randomized placebo-controlled studies to assess the specific 
treatment outcomes in different groups has adversely restricted the use of these drugs.  There 
have been some successes however, with antifungal triazoles and protease inhibitors in 
experimental models of infection with T. cruzi (Doyle et al., 2007). 
For visceral leishmaniasis (VL), a liposomal formulation of amphotericin B, AmBisome, was 
shown to be the most effective and well-tolerated treatment, with a single dose of 5 mg/kg 
curing 90% of patients (Singh et al., 2012). However, the use of AmBisome as treatment was 
limited due to the toxicity, requirement for intravenous administration and high costs 
associated with the drug (Bern et al., 2006; Field et al., 2017). Miltefosine is currently the 
only oral treatment for VL (Field et al., 2017). However, its clinical use has been limited due 
to teratogenic effects and increasing reports of treatment failures.  
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The pentavalent antimonials, sodium stibogluconate and meglumine antimoniate have also 
been used to treat both VL and CL. Introducing the generic brands of these drugs helped 
reduce their purchasing costs. However, these drugs are administered parenteral for up to 30 
days, they are cytotoxic, and are now becoming obsolete for treatment due to the emergence 
of drug-resistant parasites (Singh et al., 2012). The emergences of antimonial-resistant 
parasites lead to the introduction of the antibiotic amphotericin B, which was previously a 
second-line drug as a first-line drug for treating leishmaniasis in India. The pentavalent 
antimonials are considered first-line treatment in combination with paromomycin in Africa 
(Field et al., 2017). 
An aminoglycoside Paromomycin has also been reported as a very effective drug in treating 
leishmaniasis in India (Sundar et al., 2007). Despite havingefficacy essentially equivalent to 
that of amphotericin B, Paromomycin is associated with ototoxicity and is intramuscularly 
administered with pain at site of injection (Field et al., 2017). 
 
1.3 Challenges to research on pathogenic kinetoplastids 
Although diseases caused by the kinetoplastids continue to disable and kill hundreds of 
thousands of people in underdeveloped tropical regions, efforts towards identifying effective 
treatment options continue to receive less attention. The pharmaceutical industry and Western 
governments have shown little or no interest in supporting research aimed at developing new 
drugs for kinetoplastid diseases. Perharps this might be because studies on these neglected 
tropical diseases are associated with little or no prospect of generating significant short- or 
long-term financial gain. Another possible reason to the slow pace of research on 
kinetoplastids might be that many fundamental aspects of trypanosome biology have not been 
studied in depth. Research on pathogenic kinetoplastidshas been mostly hindered by the need 
to handle these organisms safely in a laboratory, requiring dedicated containment facilities. 
However, these facilities are very expensive to build, maintain and equip, as experimental 
apparatus cannot be moved in and out of the containment without rigorous decontamination. 
In addition, the expensive serum-containing media and difficulties in cultivating these 
parasites in high yields for different protocols, renders research on kinetoplastids almost 
impractical and unattractive especially to researchers dwelling in resource limited countries 
where  the kinetoplastid diseases are endemic. 
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1.4 C. fasciculata as a model organism to study kinetoplastid biology 
Protists of the genus Crithidia (Kinetoplastida: Trypanosomatidae) are flagellate parasites 
that only infect insects. The genus Crithidia contains a number of species with a wide host 
specificity that are able to parasitize a variety of species grouped into the orders Diptera, 
Hemiptera and Himenoptera. The host specificity of these organisms depends on the species 
of the parasite. In particularly, C. fasciculata successfully infects many species of mosquitoes 
(Wallace, 1966). 
Crithidia parasites exist in many life cycle forms but only two forms are clearly distinguished; 
the Choanomastigotes and the Amastigotes. Choanoamastigotes are free-swimming stumpy 
cells that are round in their posterior part and truncated in the apical pole by the funnel-
shaped flagellar pocket close to the kinetoplast, which is slightly anterior to the nucleus. 
Amastigotes are non-motile round cells with a flagellum non-emerging from the cellular body. 
Although they are extracellular, Crithidia are morphologically similar to amastigotes of the 
genus Leishmania (Olsen, 1974). The development of C. fasciculata starts in the gut of the 
culicid, which becomes infected by ingestion of amastigotes voided with faeces of other hosts. 
In the gut, amastigotes differentiate into choanomastigotes, ensuring proper colonization of 
the gut. Choanomastigotes later differentiate back into non-motile round amastigotes, which 
are attached to the gut epithelium by hemidesmosomes frequently leading to damage (Schaub, 
1994). Infected adult mosquitoes contaminate aquatic environments with amastigotes as well 
as flowers when they feed on nectar, thus providing chances for transmission of the parasite. 
Amastigotes are released within the faeces or the entire body of the dead insect. Eventually, 
the larval and pupal instars of mosquitoes get infected in the aquatic habitat and finally 
amastigotes are transmitted to the adult mosquito through the metamorphosing gut leading to 
completion of the life cycle as shown in Fig 2. 
Since C. fasciculata has such a monogenetic life cycle involving the extracellular 
choanomastigote and amastigote stages, they do not infect mammals. This comparison with 
other species of the same family developing digenetic life cycles responsible for 
leishmaniasis and trypanosomiasis is of outstanding interest in kinetoplastid research.		
Unlike trypanosomes and leishmanial species, C. fasciculata is easy to culture in large 
amounts (>100g wet weight) using inexpensive complex media or fully defined serum-free 
media (Tetaud et al., 2002). These organisms have been used as feeder cells in the monoxenic 
culture of Entamoeba histolytica and Malaria parasites (Diamond, 1903). 
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Figure 2.  The life cycle of C. fasciculata. Amastigotes attached to the culicid gut epithelium 
are voided in faeces and disseminated in the environment. Eventually, the larval and pupal 
instars of mosquitoes get infected in the aquatic habitat and finally amastigotes are 
transmitted to the adult mosquito through the metamorphosing gut. Choanomastigotes are the 
motile stage that allows the colonization of the gut of the host. GE: gut epithelium. (Copied 
from Olsen, 1974) 
 
In addition, C. fasciculata parasites are easily amendable to molecular genetics and 
biochemical analysis and their evolutionary proximity to the pathogenic kinetoplastids makes 
them a very interesting model organism to study biochemical, cellular, and genetic processes 
unique to kinetoplastids.  
The complete genome sequence of C. fasciculate has been determined and is publically 
available at (http://www.ncbi.nlm.nih.gov/nuccore/440789264) to facilitate genome studies 
of these organisms.  Some examples of genetic, biochemical and cellular processes in which 
C. fasciculata has been utilised as a model organisms to study trypanosomes and leishmania 
species are summarised in a Table 2. 
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Table 2. Use of C. fasciculata to study various biological processes. Studies highlighting 
genetic, biochemical and cellular processes in which C. fasciculata has been utilised as a 
model organism to study trypanosomatids cellular and molecular biology. 
 
1.5 Aims of the study 
The main aim of this study was to explore the utilization of C. fasciculata as a convenient 
model organism to study the cell biology and drug discovery vehicle of the pathogenic 
kinetoplastids. 
We specifically aimed to; 
i. Develop and validate an expression vector that can be used to express and isolate PTP 
tagged kinetoplastid proteins in C. fasciculate parasites. 
ii. Develop a Resazurin-reduction cell viability assay with C. fasciculata and utilise the 
developed assay to screen for anti-Crithidial compounds from the Open access 
chemical boxes. 
iii. Investigate the effects of gamma irradiation on the C. fasciculata parasite’s cell 
growth, metabolic viability, motility and morphology. 
Genetic/Biochemical/cellular process studied Ref. 
Effect of tunicamycin on the glucose uptake, growth, and 
cellular adhesion 
Rojas et al., 2014 
Inactivation oftopoisomerase I by Fenton systems Podesta et al., 2003 
Identification and characterization of a kinetoplast-specific 
DNA ligase  
Sinha et al., 2004 
The replication of kinetoplast DNA Liu et al., 2005 
Trypanothione synthesis Comini et al., 2005 
Trypanosomatid flagellum biogenesis Sahin et al., 2004 
Pharmacodynamic screening-medicinal plants Tasanor et al., 2006 
Application of magnetically induced hyperthermia as a 
potential therapy against parasitic infections 
 
Grazu et al., 2012 
kinetoplast DNA organization- The KAP1 protein Lukes et al., 2001 
Lipoarabinogalactan structures Schneider et al.,1996 
Mitochondrial DNA repair- Mitochondrial DNA Polymerase β  Saxowsky et al., 2002 
Genetic manipulation  Hughes and Simpson, 
1986 
Expression vector  Tetaud et al., 2001 
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2. Chapter 2: Developing and validating an expression vector for 
subsequent isolation of PTP tagged kinetoplastids proteins in 
C. fasciculata. 
 
2.1 Introduction 
2.1.1 Kinetoplastids proteins expression systems 
In search for new effective drugs against kinetoplastid diseases, potential drug targets need to 
be identified, characterised and validated. Recent advancements in transformation, protein 
expression, isolation and purification procedures have been a major technical breakthrough in 
identification and characterization of novel proteins as drug targets.  
Highly efficient expression of proteins remain an important alternative to the isolation of 
protein from native sources and is especially useful when the native protein is normally 
produced in limited amounts or by sources that are impossible, expensive and/or dangerous to 
obtain or propagate. In the last few years, gene-transfer systems have been developed 
specifically for pathogenic and medically important kinetoplastids; Leishmania spp, T.brucei 
and T. cruzi. The parasites transformation is usually facilitated by integration, which occurs 
exclusively by homologous recombination, or by episomal shuttle vectors. Moreover, various 
kinetoplatids proteins expression systems are currently available to facilitate relevant studies. 
These included; the pTEX vector for rapid expression of proteins in both T. cruzi and 
Leishmania (Coburn et al., 1991 and Martinez-Calvillo et al., 1997, respectively). Attempts to 
transform C. fasciculata and T.brucei with pTEX vector however, have been unsuccessful 
(Coburn et al., 1991). The pX vector, which has been used for stable transformation of 
Leishmania major and have been successfully applied in studying the parasite’s surface 
antigen genes (LeBowitz et al., 1990). Of recent is the Lexsy, which has been widely used in 
expressing proteins in non-human pathogenic Leishmania tarentolae parasites of gecko. The 
Lexsy system allows not only easy handling like E. coli and yeast, but also full eukaryotic 
protein folding and the mammalian-type posttranslational modifications of target proteins.    
The pTSO-HYG4 vectors in T. brucei, which utilize the PARP promoter and is able to 
replicate extrachromosomally with the aid of minicircle origin of replication have been 
reported (Sommer et al., 1996). Other T.brucei expression systems include the TetR and the 
bacteriophage T7RNAP, which can allow transgenes to be highly transcribed and expressed 
in T.brucei (Wirtz et al., 1999). Mammalian and protozoan signal peptides have also 
observed to function in T. cruzi to target proteins to different cellular compartments (Garg et 
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al., 1997). In addition, bioactive cytokines (IL-2 and IFN-gamma) have been produced in 
both T. cruzi and Leishmania (Tobin et al., 1993), suggesting that mammalian signal peptides 
are recognized and processed by these protozoans. Vectors bearing an rRNA promoter have 
been constructed by Biebinger and colleague (Biebinger and Clayton, 1996), for expressing 
foreign genes in C.fasciculata.  
More recently, the pNUS vectors have been constructed to express biologically active 
proteins in Crithidia and L. amazonensis (Tetaud et al., 2002). Although a number of 
expression systems have proven useful for production of various heterologous proteins, none 
of these systems is universally applicable for the production of all proteins. A protein 
expression system that provides for the efficient expression and isolation of correctly post-
translationally modified heterologous proteins in a non-pathogenic host would therefore 
constitute a highly desired advance in the art. 
 
2.1.2 Multi protein complexes 
Most biological processes in a cell are carried out by proteins and by their ability to form 
multi-protein complexes at an appropriate time. Individual proteins may participate in the 
formation of a variety of different protein complexes (Gavin et al., 2006). Proteins that are in 
the same complex can differ in specific function, but they function in the same overall 
process and hence have a related general function (Panigrahi et al., 2008). Indeed, this protein 
interaction can regulate proteins activities through either post-translational modification or 
conformational-transformation.  
Studies of individual proteins in a multi-protein complex assembly can provide clear 
information of their specific functions in the complex (Cusick et al., 2005). The interactions 
of proteins in a complex to control various significant biological processes for cell viability 
should therefore not be overlooked as a focus of potential drug targets.  
 
2.1.2.1 The replication factor C protein complex 
Eukaryotic replication factor C (RFC) complex previously known as a clamp loader is a 
heteropentamer consisting of five essential subunits referred to as RFC1 through 
RFC5(Bowman et al.,2004). With the exception of the large RFC1 subunit (approximately 
128 kDa in humans), the RFC 2, 3, 4 and 5 subunits are approximately 38–41 kDa each (Yao 
and O'Donnell, 2012). The five subunits contain a region of homology with one another 
(Erzberger and Berger, 2006). This region of homology defines a large family of proteins 
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referred to as AAA+ proteins. The AAA+ homologous region folds into two domains that 
bind ATP: the larger N-terminal domain contains the P-loop and DEAD box ATP site motifs, 
while the smaller C-terminal domain is outside the AAA+ homology region and is mostly 
composed of α-helix. The C terminal domain mediates a strong inter-subunit interaction that 
holds the pentamer tight (Bowman et al., 2004).  The five RFC components are organised in a 
circular form (Fig.3a). The C-terminal domains define a nearly planar circle referred to as a 
“collar domain” as shown in Fig 3a. One component of RFC is shown (Fig. 3c), to illustrate 
the three domains structure of clamp loader subunits. By convention, clamp loaders are 
viewed from the “side” as C-terminal domain on the top, and the N terminal AAA+ domains 
on the bottom. Proceeding counterclockwise around the circle from the subunit at the far right, 
the subunit positions are read as A- E subunits or simply RFC1-RFC5 (Fig. 3b and c). The 
collar C-terminal domain forms a tightly closed circle with no gap and holds the complex 
together. In all eukaryotesclamp loaders, a gap exists in between the AAA+ domains of 
subunits RFC1 and RFC5 as shown in Fig. 3a and c. This is so because RFC1 has a C-
terminal region that extends across the gap and protrudes down toward the N-terminal face of 
the clamp loader and it interacts directly with the Proliferating Cell Nuclear Antigen (PCNA) 
and with DNA (Fig. 3c) (Bowman et al., 2004). 
	
Figure 3. Architecture of the RFC complex: The five subunits of the RFC complex are 
referred to as RFC-A, RFC-B, RFC-C, RFC-D and RFC-E, respectively, moving in a right-
handed sense around the assembly, with the thumb pointing towards the collar (a and b). The 
three domains of RFC and the extensions of C-terminal domain that interact with PCNA (c). 
The yeast and human nomenclature for each subunit is shown in parentheses (copied from 
Bowman et al., 2004). 
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The RFC complex functions are universally conserved in all eukaryotic organisms. As clamp 
loaders, RFC complexes catalyses the process of loading the PCNA on to the 3` ends of 
nascent DNA strands. As described by Hedglin and his colleagues (Hedglin et al., 2013), the 
complex utilizes the ATP and act as a protein topoisomerase to open the ring of PCNA so 
that it can encircle the DNA. The ATP hydrolysis causes release of RFC, with concomitant 
clamp loading onto DNA thus permitting highly processive DNA replication (Fig. 4) 
 
 
 
 
Figure 4. Schematic model of eukaryotic RFC complex as clamp loader.  ATP binding to 
RFC enables RFC to bind and open PCNA. RFC places PCNA onto DNA and then 
hydrolyses ATP to eject itself out of the PCNA-DNA complex (copied from Hedglinet al., 
2013). 
 
The RFC complex have also been reported for switching DNA polymerase enzymes from 
DNA Pol α to Pol δ during initiation of leading strand DNA replication in the Simian virus 40 
origins of replication and as well as synthesizing of Okazaki fragments during lagging strand 
DNA replication (Yao and O’Donnell, 2012). As a structure specific DNA binding protein, 
RFC complex is a primer recognition factor for DNA polymerases especially δ and ɛ, and 
function as accessory proteins for these enzymes	 (Bowman et al., 2004). The complex binds 
primers synthesized by Pol α-primase blocking them for further elongation and increasing 
their affinity to Pol δ. 
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Other studies have reported the requirement of RFC complex in DNA repair mechanisms and 
in replication checkpoints in yeast cells (Schmidt et al., 2001; Chen et al., 2009). When there 
is no DNA replication due to DNA damage, checkpoint regulatory networks are induced by 
RFC complex, which avoid the cells to enter in mitosis (so cells accumulate in the interphase) 
until the DNA damage is restored(Chen et al., 2009). 
 
Alternative forms of RFC protein complexes or RFC-like complexes (RLC) have been 
purified in various organisms such as yeast, plants and mammals. Each RLC is made up of 
the four small subunits of the RFC (RFC2-5), but with a specific large subunit of that 
complex (Fig. 5). One such RLC is Elg1-RFC complex in yeast and humans in which Elg1 
replaces RFC1 (Fig.5a) (Kim and MacNeill, 2003). Cells with Elg1-RLC deletions had 
chromosomal instabilities and showed slow S-phase progression suggesting the role of Elg1-
RFC in genome stability. 
A second form of RFC is Rad24–RLC in which the RFC1 subunit is replaced by Rad24 
(known as Rad17 in humans)  resulting in the formation of the pentameric Rad24–RLC 
(Fig.5b), that specifically loads the heterotrimeric Rad9–Rad1–Hus1 (9-1-1) clamp complex 
onto DNA (Majka and Burgers, 2003). In addition, the 9-1-1 complex comprises of other 
proteins such as Ddc1 and Mec 3 (Kim and MacNeill, 2003). The 9-1-1 clamp complex 
activates the DNA damage checkpoints (G1, G2 and in the intra-S phases) to ensure that cell 
cycle progression is halted until repair is complete (Eichinger and Jentsch, 2011). 
The third form of alternative RFC in eukaryotes is the Ctf18-Dcc1-Ctf8/ Ctf18-RLC complex 
(Fig.5c). Similar to the other two forms, the RFC1 subunit is replaced by Ctf18 to form the 
heteroheptameric Ctf18–RLC complex. The Ctf18 subunit is known to interact strongly with 
two other subunits; the Dcc1, and Ctf8. The Ctf18, Dcc1, and Ctf8 together form a complex 
(Ctf18-Dcc1-Ctf8) with the four small subunits of RFC (Mayer et al., 2001). Unlike other 
RLC, the Ctf18-RLC complex is known to play crucial role in chromosome cohesion, the 
process by which newly replicated sister chromatids remain physically associated until 
mitotic anaphase (Lengronne et al., 2006). Apart from helping the replicated chromosomes 
stay together until mitosis, the Ctf18-RFC complex also enhances genome stability in yeast 
(Ansbach et al., 2008; Gellon et al., 2011). This is achieved by its ability to help the DNA 
replication machinery move through triplet repeats and able to repair any resulting DNA 
damage.  
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Figure 5. Schematic representation of the three RLCs in eukaryotes with their cognate sliding 
clamps. The complexes are defined by their large subunits, as the four small RFC subunits 
designated 2–5 are common to all. Note that the large subunits possess extended amino- and 
carboxy-terminal regions. (a) Elg1-RLC where RFC1 is replaced by Elg1,(b) Rad24-RLC in 
which RFC1 is replaced by Rad 24 (Rad17) and (c) Ctf18-RLC in which RFC1 is replaced by 
Ctf18 but has two additional non-RFC subunits Ctf8 and Dcc1 (Copied fromKim and 
MacNeill, 2003). 
 
 
2.1.2.2 The RNA exosome protein complex 
As described by Makino and Conti,  the core of eukaryotic exosome complex is  made up of 
six RNase PHlike subunits, which assemble into a ring-like structure and three additional 
subunits composed of S1/KH domains (so-called cap proteins),  forming a coaxial ring 
(Makino and Conti, 2013). At the base of the complex are the six RNase PH-like proteins 
(Fig. 6): RRP41, RRP42, RRP43, RRP45, RRP46, and Mtr3, forming a core ring structure 
and central channel of the complex. On top of the complex are the three catalytic “cap” 
subunits; RRP4, RRP40, and Csl4, which have the S1-RNA binding domain (SI) and the K-
homology (KH) domain.  Apart from the nine core exosome components, two extra subunits-
-RRP6 and RRP44/Dis3 have been reported in yeast (Lorentzen et al., 2008a). The 
RRP44/Dis3 is a hydrolytic processive exoribonuclease subunit and is not available in the 
archaeal organisms (Navarro et al., 2008). If RRP44/Dis3 is associated with humans or 
trypanosome exosomes, the interaction is weak because it has never been purified in these 
organisms (Chen et al., 2001; Estevez et al., 2001; Estevez et al., 2003). 
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Figure 6. (a) A simplified architecture of Saccharomyces cerevisiae exosome complex and 
(b) its model interaction with the mRNA fragment (Copied from Navarro et al., 2008). 
 
The exosome complex plays a very significant role in RNA metabolism processes. In the 
nucleus, the exosome complex regulates messenger RNA numbers during their turnover 
processes and participates in various RNA maturation processes (Makino and Conti, 2013). 
The complex degrades the RNA maturation by-products such as 5’ External Transcribed 
Sequences and functions in RNA quality control processes by destroying aberrant products of 
rRNA, tRNA,snRNA and snoRNA in the nucleus (Fig. 7b) (Tomeckiet al., 2010). In 
cytoplasm, the complex participates in RNA surveillance systems (“non-stop decay”, which 
degrades mRNA with a no stop codon, “nonsense-mediated decay”, which degrades products 
possessing immature stop codons and the “no-go decay”, which degrades RNA within stalled 
ribosomes). The exosome complex has also reported to degrade the 5′ intermediate segments 
from the RNA interference processes in the both nucleus and cytoplasm (Tomeckiet al., 
2010). 
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Figure 7. Schematic examples of eukaryotic exosome complex catalytic activities. (a) Single 
stranded substrates with enough long single stranded overhangs are recognised by the 
trimetric cap of RNA-binding proteins and passes through the central channel of the complex 
before accessing the RRP44/Dis3-exoribonuclease active site. (b) RNA substrates with 
secondary structures but of no 3’ single stranded extensions of enough length to pass through 
the central channel, access the RRP44/Dis3 exoribonuclease active site directly after being 
recognized by the OB-fold RNA-binding domains. The PIN domain can endonucleolytically 
cleavage (yellow scissor) single stranded loops of the secondary structure to assist in 3’-5’ 
exoribonucleolytic degradation by RNB domain catalytic activity. (c) In the nucleus, 
transcripts polyadenylated by the TRAMP are trimmed by RRP6 without passing the central 
channel and later get degraded (Copied fromTomeckiet al., 2010) 
 
 
2.1.3 Overview of protein complexes purification methods 
Although several biochemical studies have identified proteins likely to play a role in the 
establishment and maintenance of the pathogenic kinetoplastids’s life cycle, specific 
functions of these proteins has remain unknown in several cases. The process of isolating and 
identifying protein complexes is very useful when the purpose is to gain more understanding 
on the specific functions of individual proteins in the complex as well as to determine their 
importance at a molecular level. Complete genome sequencing of various microorganisms 
has created a chance to analyse roles of various proteins encoded in their genes. More 
knowledge on various cellular processes can be acquired through analysing, characterizing 
and identifying interactions, which exist among proteins in the complex (Schwikowski et al., 
2001).  
The two-hybrid systems were commonly used identity components of specific protein 
complexes. However, these were time consuming, labour intensive and limited to a small-
scale protein analysis. Moreover, the two-hybrid systems have low rates of true positives and 
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true negatives results. More effective and reliable strategies of studying protein-protein 
interactions have been highly needed. 
With the development of the Tandem affinity purification (TAP) coupled to Mass 
spectrometry over the past decades, many proteins complexes have been isolated and the 
interacting partners identified. As long as a specific protein complex of interest is effectively 
and adequately isolated, proteins within the complex can be recognised and characterised by 
TAP-mass spectrometry. Enhanced by the available databases of complete genomic 
sequences of various organisms, though initially designed for yeast cells, this approach has 
been widely employed in various organisms (Puig et al., 2001) to facilitate the identification 
and characterisation of their respective proteins.  
As suggested by Schimanski et al (2005), TAP-mass spectrometry limitations are observed in 
the protein isolation process rather than in the process of identifying them. This is mostly 
because an individual protein may possess different characteristics from other associated 
proteins in the complex. More recently, the tagging of protein of interest with either peptides 
or protein domains has seemed to be a promising strategy of bypassing this limitation during 
purification process. 
The conventional TAP methods required the fusing of a C-terminal TAP tag to a protein of 
interest. The TAP tag composed of two IgG binding units of protein A of S.aureus (ProtA) 
and a Calmodulin binding domain (CBP) with a cleavage site for a Tobacco etch virus (TEV) 
protease inserted between them (Rigaut et al., 1999). Apart from a C-terminal TAP tag, there 
is an N-terminal TAP tag, which is a reverse orientation of the C-terminal TAP tag (Fig. 8a). 
Two TAP steps are required to purify the cell extracts of the tagged protein of interest after 
transformation as shown (Fig.8b). 
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Figure8. A schematic representation of TAP tagging and an outline of the purification 
procedure. (a)Representations of a C- and N-terminal TAP showing orientation of Protein A 
domains and CBP. (b) The TAP purification procedure. In the first step, the protein complex 
containing the tagged protein of interest binds to IgG matrix by the ProtA fraction. The 
protein complex is then eluted using TEV protease under native conditions. In the second 
step, the elution fraction of the first purification step is incubated with beads coated by 
calmodulin in the presence of calcium. Subsequently, contaminants and the remainder of 
TEV protease used in the first step are eliminated through washing. Finally, the protein of 
interest in a complex is obtained by elution using EGTA. (Copied from Rigaut et al., 1999). 
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Compared to the traditional protein purification methods, the TAP method has been observed 
to be a very effective tool for isolating pure proteins in adequate quantities from a small 
volume of cell culture and under native conditions to retain their functions (Rigaut et al. 
(1999). However, although this has been the case, the TAP tool has been unsuccessful in 
various cicumstances. For instance, Gavin and his collegues reported the failure of the 
method to identify and isolate the tagged and associated proteins in yeast	 (Gavin et al., (2001). 
The failure was claimed to be due to the TAP tag which interfered with the function of the 
protein, its location and as well as complex formation.  
Recently, several new TAP tags combinations have been developed to overcome the 
limitations of the conventional TAP tags, including PTP (for ProtC-TEV-ProtA) where CBP 
is replaced by protein C epitope (ProtC) (Fig. 9b), reducing the overall size of the tag from 
184 to 169 amino acids and the molecular mass from 20.6 to 18.9 kDa. After TEV protease 
cleavage, 44 and 29 amino acids accounting for 5.1 and 3.4 kDa, respectively, remain on 
TAP- and PTP tagged proteins. ProtC is derived from human protein C, a vitamin K-
dependent plasma zymogen specifically expressed in hepatocytes. The monoclonal antibody 
HPC4 recognizes this epitope with high affinity and, as a unique property, has a calcium-
binding site that needs to be occupied for its interaction with ProtC. 
 
 
Figure 9. A schematic representation of TAP and PTP tag. (a) TAP tag showing Protein A 
domains, TEV and CBP. (b) PTP tag where CBP is replaced by Prot C (Copied from 
Schimanski et al., 2005). 
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2.2 Materials and methods 
2.2.1 Organisms and reagents 
The C. fasciculata promastigotes clone HS6 were grown at 27°C with gentle agitation in 
serum-free defined media as described in Appendix 1). The media pH was adjusted to 8.0 
with either NaOH or HCl before haemin (10µg/ml) was added. The parasites' genomic DNA 
was extracted according to DNA extraction procedure described by Bernards et al (1981) as 
described in Appendix 2. Conventional DNA manipulation procedures were conducted using 
DH5α competent E.coli cells. All chemicals and reagents used were of the highest grade and 
were purchased from Sigma-Aldrich or Thermo Fisher Scientific. DNA manipulation 
enzymes were purchased from either New England Biolabs, Thermo Fisher Scientific or 
Promega.  
 
2.2.2 General Molecular biology techniques 
2.2.2.1 Designing primers and amplifying ORFs of target proteins 
Reverse and forward primers were designed to amplify the entire ORFs of our target subunits 
(RFC3 and RRP4) from the C. fasciculata genomic DNA. Briefly, 10 random bases 
(GGTGGTGGTG) and 21 consecutive bases of the target gene sequence after a start codon 
were added upstream and downstream NdeI sequence (CATATG) respectively, to create a 5’ 
NdeI (forward) primers. The 3’NotI (Reverse) primers were also designed by adding 10 
random bases (GGTGGTGGTG) and 24 consecutive bases of the target gene sequence before 
a stop codon (in reverse complement) upstream and downstream the NotI sequence 
(GCGGCCGCC), respectively. Oligonucleotides were then ordered from Integrated DNA 
Technologies. All primers had melting temperatures (Tm) between 65°C and 74°C, the GC 
content between 40 and 60%, with balanced distribution of GC-rich and AT-rich domains 
without secondary structures and had no recognisable intra-primer homology or inter-primer 
homology. The designed primers are shown in Appendix 3. A conventional PCR was used to 
amplify the ORFs of the target protein subunits (RFC3 and RRP4) using Q5 High-Fidelity 
DNA polymerase following the manufacturer’s instructions with slight modifications as 
described in Appendix 4a. 
2.2.2.2 Agarose-gel electrophoresis 
The purified DNA products were mixed with 10x loading dye and loaded onto a 1% agarose 
gel (1% agarose in 1x TAE and 0.001% ethidium bromide) alongside 0.5 µg of a 1 kb DNA 
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ladder (Fermentas). Gels were run at 120 V for 45 minutes and the DNA was visualised using 
a UV transilluminator (Syngene U Genius). 
	
2.2.2.3 Preparative restriction digest and Ligations for cloning  
Prior to cloning, the vector pNUS-PTPcH and inserts (RFC3 and RRP4) were digested in 
60µl reactions with restriction enzymes NotI and NdeI (NEB) for 3 hours at 37°C and 
dephosphorylated during the last 60 minutes with Antarctic phosphatase (NEB) according to 
the manufacture’s instruction. The DNA fragments were gel purified using Thermo Scientific 
DNA purification kit following the manufacture’s instruction. 10% of the eluted volume was 
resolved in a 1% agarose gel containing 0.001% ethidium bromide to confirm the presence 
and size of the fragments before ligations. For each ligation reaction, 50ng of the gel-purified 
vectors were combined with 3-fold molar excess of the insert (calculated using 
NEBioCalculator) and the final volume adjusted to 10µl with distilled sterile water. 10µl of 
2x Quick ligation buffer followed by a 1µl of the Quick T4 DNA ligase was then added and 
mixed thoroughly and briefly centrifuged before incubation at room temperature (25°C) for 
20 minutes. The ligation products were directly used for E.coli transformation. Protocols and 
recipes for preparative restriction digests, diagnostic digests, ligations and agarose 
electrophoresis are described in Appendix 5. 
2.2.2.4 E.coli transformation and Isolation of plasmid DNA 
Conventional TSB transformation procedures were used as previously described in Inoue et 
al. (1990). Briefly, 20ml of LB medium was inoculated with 100µl of the over night grown 
E.coli DH5α cells and incubated at 37°C for 4 hours in a shaker incubator. Cell culture 
(optical density ~0.5) was then spun down at 3,000 rpm for 10 minutes to pellet cells. The 
pelleted cells were suspended in 1 ml of TSB (See recipe in Appendix 6) and thawed on ice 
for 30 minutes to make them competent. For each transformation reaction, 100 µl of the 
competent cells were transferred to a chilled microcentrifuge tube on ice. To this, 10µl of the 
plasmid DNA was added and the mixture kept on ice for 30 minutes. After 30 minutes 
incubation on ice, 200µl of LB media was added and the mixture was later incubated at 37°C 
with shaking for 1 hour. Later, 150 µl of cells were plated on LB plates containing 100µg/ml 
ampicillin using glass beads and incubated over night at 37°C. 
2.2.2.5 Colony PCR for transformations and restriction digest 
Transformed cells were analysed by a standard PCR technique by determining the presence 
of the insert DNA in the plasmid construct using MyTaqRedDNA polymerase following a 
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protocol described in Appendix 4b. Briefly, a final reaction mixture (20µl) contained 5µl 
volume of cells (from 100µl colony suspension) to provide DNA template during initial PCR 
heating step, 5µl of the insert specific primers (4µM each) and 10µl MyTaqRed Mix. The 
presence of a PCR amplicon and size of the product were determined by 1% agarose gel 
electrophoresis. A miniprep culture was prepared by inoculating a 50µl of correct 
transformed cells colony suspension in 5ml of LB media containing ampicillin (100µg/ml) 
for isolation and incubated overnight in a shaker incubator. The Plasmid DNA was purified 
using a Thermo scientific Miniprep kit following manufactures instructions. A portion of the 
eluted volume containing plasmids DNA were digested in 20µl reactions with NdeI and NotI 
enzymes according to manufactures instruction and as described in Appendix 5,  to screen 
and confirm if the plasmids contained the correct inserts. The purified plasmids at a 
concentration of 1.2µg DNA in 60µl dH2O and the associated primers (50µl of 3.2 µM) were 
then sent for sequencing at Dundee sequencing services centre to verify the fidelity of cloning 
process. 
2.2.3 Construction of the expression vector (pNUS-PTPcH) 
The expression vector pNUS-PTPcH was constructed by S. MacNeill (personal 
communication).  Briefly, part of pNUS-SPnHc EcoRI fragment (102 bp) encoding a signal 
peptide (Tetaud et al., 2001),  was removed and replaced with sequences derived by PCR 
amplification of the PTP tag-encoding region of plasmid pC-PTP from Schimanski and his 
colleagues (Schimanski et al., 2005). The cloned region lacked the AflII, EcoRI and BamHI 
sites internal to the PTP tag sequence that are found in pC-PTP and includes unique 
restriction sites for NdeI, XhoI, EcoRV and NotI upstream of PTP for fusing target sequences. 
The full sequence of the	pNUS-PTPcH  vector is shown in Appendix 6. 
 
2.2.4 Identification of C. fasciculata and T. brucei homologous proteins 
from yeast RFC and exosome complexes 
Protein sequences of specific known subunits of yeast Saccharomyces cerevisiae’s replication 
factor C and the exosome complexes were used to BLAST search the TriTrypDB database to 
identify putative C. fasciculata and T. brucei homologues. The online BLASTP program was 
used to determine the percentage identity between the protein sequences. 
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2.2.5 Cloning of the target subunits 
Oligonucleotides (Appendix 2) were designed to amplify the entire ORFs of Cf-RFC3 and 
Cf-RRP4 from the C. fasciculata genomic DNA. Using conventional PCR (Appendix 4a), 
fragments of Cf-RFC3 and Cf-RRP4 were cloned in-frame with the PTP tag coding sequence 
of the constructed pNUSPTPcH vector using NdeI and NotI restriction enzymes, to create C-
terminal PTP-tagged versions pNUS-RFC3-PTPcH and pNUS-RRP4-PTPcH. The TSB 
transformation method was used to propagate the plasmids into DH5α E.coli competent cells 
and the plasmids DNA was isolated as previously described. To verify the fidelity of the 
cloning process, the purified plasmid DNA were sequenced using pC-Seq-F and pC-Seq-R 
(Appendix 3) as described in Sanger et al. (1977). 
2.2.6 Parasite transfection and generation of cell lines 
For a successful transfection, C. fasciculata parasites were grown to a log phase at 27°C in a 
shaker incubator and harvested at a density of ~1 x 107 cells/ml by centrifugation at 3000 rpm 
for 5 minutes. The cell pellet (~2 x 107 cells/ml) was suspended in 100µl of human T-cell 
Nucleofactor solution (Lonza) and transferred to a 0.4 cm cuvette containing 15-60µg of 
purified pNUS-RFC3-PTP or pNUS-RRP4-PTP supercoiled plasmids DNA. The mixture 
was then subjected to program X-014 of the Amaxa electroporation system (Burcard et al., 
2007). Electroporation cells were left on ice for 5 minutes and transferred into a culture flask 
containing 5ml of fresh medium and incubated at 27°C to recover. After 24 hours of recovery, 
the cell culture was supplemented with 5 ml of fresh medium followed by hygromycin final 
concentration of 25µg/ml. Hygromycin-resistant cell lines were subsequently grown with at 
least 50 µg/mlof drug and viable clones observed within 5 to 10 days. Resistant cell lines 
were maintained by supplementing the culture with fresh medium containing the antibiotic. 
 
2.2.7 Expression and PTP purification of the proteins 
To confirm if the selected cell lines expressed the PTP fusion proteins, cell lysates were 
prepared from the parasites and analysed by SDS-PAGE and Western blots. Briefly, a sample 
volume of 1ml (~1 x 107 cells) was harvested by centrifugation at 2000 g for 5 minutes. The 
cell pellet was heated to boil in 2 X SDS-PAGE sample buffer at 95oC for 5 minutes. The 
protein extract sample was resolved in a 12 % SDS-PAGE and blotted on a Polyvinylidene 
difluoride (PVDF) membrane. To detect PTP fusion proteins, blots were incubated with PAP 
reagent, which contained primary antibodies raised against Protein A epitopes of the PTP tag, 
diluted 1:2000 using 5% milk-PBS-Tween (0.05%) blocking solution. Blots were developed 
using Goat-Anti-rabbit IgG (H+L DyLightTM 680) conjugated secondary antibody 
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(ThermoFisher Scientific) diluted in 1:10000 according to the manufacturer’s instructions and 
scaned on Odyssey scanner using the 700nm channel. 
Purification of the target proteins and their interacting partners in the complexes was 
conducted according to the generic TAP method described inSchimanski et al. (2005) with 
slight modifications. Recipes for solutions and buffers used in the purification experiments 
are described in Appendix 7. Briefly, a volume of 2.5 litres of culture (~ 2x107 cells/ml) was 
harvested by centrifugation at 800 g for 10 minutes. The cell pellet was washed three times 
with 5 ml PBS to a final packed cell volume of approximately 4 ml. The cell extract had a 
volume of ~6.5 ml and contained 150 mM sucrose, 300 mM potassium chloride, 40 mM 
potassium L-glutamate, 3 mMMgCl2, 20 mM HEPES-KOH (pH 7.7), 2 mM dithiothreitol, 
0.1% Tween 20, and half of a Complete Mini EDTA-free protease inhibitor cocktail tablet 
(Roche, Indianapolis, IN). Cells were Dounced in continuous strokes for 5 minutes in a cold 
room using a 7 ml Dounce homogenizer (Sigma-Aldrich) and centrifuged at 20,500 g for 10 
minutes at 4°C. For IgG affinity chromatography, the resultant lysate was filtered straight 
into a 10 ml Poly-prep chromatography column (Bio-Rad, Hercules, CA) containing a 
volume of 200 µl of PA-150 buffer equilibrated IgG Sepharose beads (GE Healthcare). The 
top and the bottom of the column were sealed with Parafilm and the column rotated for 2 
hours at 4°C allowing the PTP tagged protein to bind to the IgG beads. The beads were later 
washed 2 x with 10 ml PA-150 before equilibrating the column with 8ml TEV buffer. To 
TEV cleave the IgG matrix bound proteins, a 20µl of TEV protease was diluted in to 2 mL 
TEV buffer and added to the column rotating it overnight at 4°C.  
The TEV and column dead-volume were eluted by washing the IgG beads with 4 ml of PC-
150 buffer.  0.5ml of the remaining Mini EDTA-free protease inhibitor tablet (Roche) and 7.5 
µl of 1 M CaCl2 were added to the eluate mixture to avoid any proteolysis in the eluate. The 
mixture was added to a second equilibrated Poly-prep column containing a volume of 200 µl 
anti-ProtC affinity matrix beads (Roche) and was rotated for 2 hrs in the cold room to allow 
the tagged protein to bind to the anti-ProtC affinity matrix. After washing the anti-ProtC 
affinity matrix beads for 6 times with 10 ml PC-150 buffer, the PTP tagged proteins were 
eluted with a 1.8 ml EGTA/EDTA buffer at room temperature. 
To concentrate the eluted proteins, eluates were bound to a volume of 30 µl of StrataClean 
resin beads (Stratagene) and pelleted at 5,000 g for 1 minute. The beads were later re-
suspended in 20 µl 4XNuPAGE LDS sample buffer and boiled at 95°C to release the proteins. 
A 20 µl of the sample was loaded onto a NuPAGE 4-12% Bis-Tris pre-cast gel and the 
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proteins were resolved by SDS-PAGE before stained with SYPRO Ruby stain. The stained 
gels were visualised using a UV transilluminator.  
 
2.2.8 Mass Spectroscopy analysis 
Individual protein bands were excised from the gels and analysed by our in-house Mass 
Spectroscopy and proteomics facility at the University of St Andrews, Biomedical Sciences 
Research Complex. Briefly, proteins were digested overnight with trypsin prior to separation 
by AB Sciex 4800 MALDI (Matrix-Assisted Laser Desorption/Ionisation) TOF/TOFTM 
analyser (AB Sciex, UK). The obtained data were processed with MASCOT and compared 
against the C. fasciculata or NCBI protein databases to unambiguously identify the proteins. 
2.3 Results and Discussion 
2.3.1 Identification of C. fasciculata and T.brucei homologous proteins 
from yeast RFC and exosome complexes 
 
Protein sequences of specific known subunits of yeast S. cerevisiae replication factor C and 
the exosome complexes were used to BLAST search the TriTryp database to identify putative 
C. fasciculata and T. brucei homologues. The S. cerevisiae RFC and exosome complexes 
homologs of C. fasciculata and T. brucei identified are shown in Table 3. The percentage (%) 
identity between the protein sequences were determined using the NCBI online BLASTP 
program. The identified homologs were selected based on their maximum identity and E-
scores in TriTryp database.  
The C. fasciculata RFC and exosome subunits shared around 30-55% and 28-56% sequence 
identity with the yeast counterparts, respectively and also shared 65-73% and 34-60% 
sequence identity with the T.brucei homologs, respectively. As expected, C. fasciculata 
proteins were more homologous to the T.brucei than the yeast counterparts. The RFC 
complex subunits of the C. fasciculata and T.brucei were more identical compared to the 
exosomes subunits (average identity of 70% and 45% for RFC subunits and exosome, 
respectively, between C. fasciculata and T. brucei homologues). This is not surprising as 
ribosomal RNA metabolisms in trypanosomes are unique as observed in various studies (Ullu 
et al., 1996; Hartshorne and Toyofuku 1999; Di Noia et al., 2000). 
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Table 3. C. fasciculata and T.brucei homologs of S. cerevisiae’s RFC and Exosome complex 
subunits. The yeast S. cerevisiae protein sequences were used to BLAST search the 
TriTrypDB database to identify putative C. fasciculata and T. brucei homologs. The 
systematic identities, the molecular masses (Mwt) of the predicted C. fasciculata peptides and 
the percentage of identity are indicated. 
 
2.3.2 Construction of the expression vector 
TAP has been used for many years as a rapid and efficient method of isolating epitope-tagged 
protein complexes from crude extracts under native conditions. Initially established in yeasts, 
the method is now applied to other organisms such as trypanosomes. However, a number of 
studies have reported the inefficiencies of the original TAP method, which is based on fusing 
the proteins of interests to a TAP tag consisting of a duplicate protein A epitope, a tobacco 
etch virus protease cleavage site, and the calmodulin-binding peptide (CBP) (Schimanski et 
al., 2005; Drakes et al., 2005; Palfi et al., 2005). In most cases, the protein yield recovery has 
	 S. cerevisiae  
subunits 
   T. brucei homologs                         C. fasciculata homologs 
 Name  Name  Gene ID Gene ID Mwt (Da) % Identity 
(positives %) 
to S.cerevisiae 
%Identity(pos
itives %) to 
T.brucei R
FC
 com
plex  subunits 
  Exosom
e subunits 
RFC1 TbRFC1 Tb927.11.
5650 
CFAC1_210019
200 
72,644  30 (47) 65 (79) 
RFC2 TbRFC2 Tb927.6.3
890  
CFAC1_260050
500 
38,286  44 (66) 69 (83) 
RFC3 TbRFC3 Tb927.9.1
2300  
CFAC1_300082
900 
39,856  43 (62) 72 (83) 
RFC4 TbRFC4 Tb927.11.
9550 
CFAC1_230046
600 
33,546  55 (74) 69 (81) 
RFC5 TbRFC5 Tb927.10.
7990  
CFAC1_280077
100 
39,086  39 (61) 73 (86) 
                           Exosom
e com
plex  subunits 
 
RRP4p TbRRP4 Tb927.7.4
670  
CFAC1_110005
300 
32,088  37 (56) 51 (67) 
RRP6p TbRRP6 Tb927.4.1
630  
CFAC1_290060
300 
80,085  31(48) 51 (65) 
RRP40p TbRRP40 Tb927.9.7
070  
CFAC1_030007
200 
34,302  28 (38) 46 (59) 
RRP41p TbRRP41
A 
Tb927.10.
7450  
CFAC1_280032
800 
26,798  48(76) 60 (75) 
RRP42p EAP1 Tb927.1.2
580  
CFAC1_170027
500 
43,178  29(61) 41 (53) 
RRP43p EAP2 Tb927.11.
16600  
CFAC1_300052
700 
32,147  26(43) 40 (56) 
RRP45p TbRRP45 Tb927.6.6
70 
CFAC1_240024
400 
39,758  31 (49) 46 (62) 
RRP46p TbRRP41
B 
Tb927.2.2
180 
CFAC1_160013
900 
35,618  22(40) 37(50) 
RRP47 EAP3 Tb927.7.5
460  
CFAC1_180026
700 
23,121  27(50) 34 (48) 
Mtr3 EAP4 Tb927.11.
11030 
CFAC1_280054
900 
23,286  32 (46) 50 (66) 
CSL4p TbCSL4 Tb927.5.1
200 
CFAC1_150031
200 
27,882  30 (44) 41 (53) 
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been very low, an obstacle which has been mainly attributed to the calmodulin affinity 
purification step. To overcome this limitation, CBP has recently been replaced with PTP and 
successful results have been reported (Schimanski et al., 2003; Drakes et al., 2005; Palfi et al., 
2005; Schimanski et al., 2005). Recently, series of shuttle vectors have been developed by 
Tetaud and colleagues to facilitate the expression of histidine tagged proteins in C. 
fasciculata (Tetaud et al., 2002). Extending this work, we modified the initial vector and 
developed a pNUS-PTPcH vector, which can be utilised to facilitate the expression and 
isolation of PTP tagged kinetoplastids proteins in these convenient parasites. Briefly, the 
vector pNUS-PTPcH (Fig. 10c) was constructed by S. MacNeill (personal communication), 
by removing and replacing the EcoRI fragment (102 bp) encoding a signal peptide in pNUS-
SPnHc plasmid (Fig.10a) (from Tetaud et al., 2002) with sequences derived by PCR 
amplification of the PTP tag-encoding region of plasmid pC-PTP (Fig. 10b) (Schimanski et 
al., 2005). The cloned region included unique restriction sites for NdeI, XhoI, EcoRV andNotI 
upstream of PTP for fusing target sequences to the tag (Fig. 10c). 
As in the original vectors, bonafide replication and transcription promoters were maintained 
to facilitate episomal expression of the construct. The 5`- and 3`-untranslated (UTR) 
sequences in the intergenic region of the C. fasciculata phosphoglycerate kinase genes A and 
B (IG-PGKAB) and the C. fasciculata glutathionylspermidine synthetase(GSPS) 3` UTR 
were also maintained as in Tetaud et al. (2002), to allow expression and maturation of the 
target genes and the hygromycin resistant gene. 
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Figure 10. Circular maps of the plasmid constructs. (a) The pNUS-SPnH (copied from 
Tetaud et al.,2002) showing the region encoding signal peptide which was removed and 
replaced by a PTP tag-encoding sequence from pC-PTP-NEO plasmid (b) (Copied from 
Schimanski et al., 2005). (c)The constructed pNUS-PTPcH plasmid showing the IG-PGKAB, 
GSPS and specific restriction sites NdeI and NotI for cloning genes of interest. 
 
2.3.3 Cloning of C. fasciculata RFC3 and RRP4 subunits in pNUS-PTPcH 
plasmid and Transfection. 
	
Using PCR, we successfully cloned the ORF of target subunits RFC3 (CFAC1_300082900) 
and RRP4 (CFAC1_110005300) in frame with the PTP sequence of the constructed pNUS-
PTPcH shuttle vector to create C-terminal PTP-tagged versions pNUS-RFC3-PTPcH (Fig. 
11a) and pNUS-RRP4-PTPcH (Fig. 11b). Unlike the RFC complex, exosome complex have 
previously been TAP isolated using RRP4 subunit as a bait (Estevez et al., 2001). We 
therefore took advantage of this approach and also PTP tagged RRP4 in our constructs for 
validation.  
C. fasciculata parasites were succesfuly transfected with the constructed plasmids using 
Amaxa program X-014 (Burcard et al., 2007), where it conferred hygromycin resistance and 
persisted as circular extrachromosomal DNAs that could be recovered back in E.coli. 
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Figure 11. Circular maps of RFC3 and RRP4 tagged versions. (a) pNUS-RFC3-PTPcH and 
(b) pNUS-RRP4-PTPcH.In each case, fragments of the target genes, the PTP cassette, the C. 
fasciculata IG-PGKAB gene flank, the resistance marker and the 3`flank GSPS are drawn in 
different colours. 
 
2.3.4 Expression and PTP purification of the proteins 
To validate the pNUS-PTPcH plasmid, we first determined if the cloned genes were 
expressed in C. fasciculata cells. Cell lysates were prepared from the resistant cell lines and 
analysed by SDS-PAGE and Western blots. The immunoblot revealed two proteins of sizes 
~51kDa and ~57kDa that were confirmed with the theoretical masses as PTP-tagged RRP4 
and RFC3, respectively (Fig. 12a). When the hygromycin concentration was increased from 
50µg/ml to 200µg/ml, the expression of the tagged proteins also increased though cells grew 
more slowly (data not shown), a similar observation to (Tetaud et al., 2002) and others. 
However, increasing the hygromycin concentration to 200µg/ml did not significantly increase 
the expression of PTP tag protein from empty pNUS-PTPcH cell lines. 
To determine if the tagged proteins and their interacting partners could be isolated from their 
respective complexes, the two consecutive step TAP method was used as previously 
described in the methods and the eluted complexes analysed by SDS-PAGE and SYPRO-
ruby staining. The specificity of the purification method was monitored by generating a cell 
line expressing the empty pNUS-PTPcH. In this case, no bands were detected from the cell 
lysates of cells expressing the empty plasmid (data not shown). 
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Figure 12. Western blot analysis of C. fasciculata expressing the tagged proteins and Sypro 
Ruby stained SDS-PAGE gels of TAP purified proteins. (a) 1 x 107 cells/ml were analysed 
with the PAP reagent directed against the Prot A domains of PTP. Lane 1, C. fasciculata WT; 
Lane 2, C. fasciculata expressing pNUS-RRP4-PTP and Lane 3, C. fasciculata expressing 
pNUS-RFC3-PTPcH. Purified components of C. fasciculata Replication factor C (a) and 
exosome (b) multiprotein complexes, separated by SDS-PAGE and Sypro Ruby stained. The 
probable identities of subunits as determined by mass spectrometry are indicated. The C. 
fasciculata cell line expressing the empty pNUS-PTPcH was used as our purification 
specificity control (TAP-control). 
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Table 4a. Mass spectrometric identification of subunits in pNUS-RFC3-PTPcH 
pull-down 
Protein Gene ID Mascot score Coverage 
RFC1 CFAC1_210019200 586 21% 
RFC2 CFAC1_260050500 1144 59% 
RFC3 CFAC1_300082900 1507 77% 
RFC4 CFAC1_230046600 941 70% 
RFC5 CFAC1_280077100 997 52% 
Rad17 CFAC1_260035800 174 6% 
 
Table 4b. Mass spectrometric identification of subunits in pNUS-RRP4-PTPcH pull-
down 
Protein Gene ID Mascot score Coverage 
RRP41A CFAC1_280032800 988 83% 
RRP41B CFAC1_160013900 326 34% 
RRP6 CFAC1_290060300 1943 62% 
EAP1 CFAC1_170027500 950 34% 
RRP45 CFAC1_240024400 829 31% 
RRP40 CFAC1_030007200 1173 70% 
RRP4 CFAC1_110005300 1330 48% 
CSL4 CFAC1_150031200 573 40% 
EAP2 CFAC1_300052700 585 33% 
EAP4 CFAC1_280054900 691 40% 
 
Five major polypeptide bands were identified in the pNUS-RFC3-PTP pull downs. Mass 
spectrometry identification of these polypeptides revealed RFC complex subunits 1-5 (Fig. 
12b), which were confirmed by comparing their electrophoretic nobilities with the theoretical 
masses. Details of mass spectroscopy analysis of the identified subunits and associated 
protein sequences are shown in the Table 4a and the associated protein sequences are shown 
in Appendix 8a. Two additional proteins Rad17 and tubulin were also detected. Tubulin is 
most abundant protein in cells and is not part of the RFC complex. We therefore conclude 
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that this was most likely a contaminant. RFC1 subunits have been shown to be replaced by 
Rad17 in fission yeast, which forms a pentameric alternative RFC complex derivative Rad17-
RFC (Al-Khodairy et al., 1994 and Griffiths et al., 1995), which plays a role in the DNA-
damage replication checkpoint response, specifically by loading the 9-1-1 complex onto the 
DNA. The co-purification of Rad17 in these experiments may suggest that such alternative 
complexes exist in kinetoplastids as previously (MacNeill, 2014). 
To analyse whether we could express and isolate exosome complex subunits in C. fasciculata 
using the constructed pNUS-PTPcH plasmid, we fused the PTP sequence to the C-terminus 
of RRP4, which is known to be present in the 11S exosome complex and previously CBP-
TAP purified in T.brucei parasites. However, unlike the conventional TAP-RRP4 purification 
in which only four exosome components in T.brucei were purified (Estevez et al., 2001), we 
purified all exosome components in C. fasciculata by PTP tagging. Ten subunits were 
detected after MASCOT peptides mass analysis, which were unambiguously identified as 
RRP6, EAP1, RRP45, RRP40, RRP4 (Tagged), RRP41B, CSL4, EAP2, RRP41A and EAP4 
(Fig. 12c). Details of mass spectroscopy analysis of the identified subunits and associated 
protein sequences are shown in the Table 4b and the associated protein sequences are shown 
in Appendix 8b. The observed different sizes of bands corresponding to RRP6 could be due 
to proteolysis or partial post-translational modification of the protein. We did not find EAP3 
subunit in our experiments. Estevez and colleagues also did not TAP purified EAP3 in the 
cytosolic extracts of T.brucei (Estevez et al., 2001).  Perhaps this could be due to the weak 
interaction of EAP3 with the core exosome complex subunits (EAP3 interacts with the core 
complex through RRP6) or it was degraded. However, the fact that EAP3 has been isolated in 
L.tarentolae (Cristodero et al., 2008), further optimizations on extract preparation, and using 
antisera to confirm this finding should be considered. For wider applicability, further 
experiments are needed to determine if the purified components are functional. It will be also 
worthwhile to find out if T.brucei and perhaps Leishmania could also be transformed with 
this particular construct. 
Efficient and high-level heterologous expression of proteins is a crucial step in protein from 
native sources and is especially useful when the native protein is normally produced in 
limited amounts or by sources, which are impossible, expensive and/or dangerous to obtain or 
propagate. We are considering optimising our purification experiments with the anticipation 
to isolate other novel interacting subunits, which will be validated as potential drug targets in 
other pathogenic kinetoplastids.  
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To conclude, we report the application of tandem affinity purification to C. fasciculata for the 
first time, demonstrating the effectiveness of the technique by purifying both the intact 
exosome and replication factor C complexes. Adding tandem affinity purification to the C. 
fasciculata toolbox significantly enhances the utility of this excellent model system. The 
present protein expression vector can therefore be used in place of or as an adjunct to other 
protein expression systems for production of proteins needed for the discovery, evaluation, or 
production of diagnostics, vaccines, therapeutics or medical treatments of kinetoplastid 
pathogens. 
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3. Chapter 3: Developing a Resazurin-viability assay in Crithidia 
fasciculata allowing subsequent screening for Anti-Crithidial 
Compounds from the GSK Open Access Pathogen Boxes 
 
3.1 Introduction 
 
Compounded by massive global food, water shortages and climate change, kinetoplastid 
diseases continue to have a devastating, long-term impact on both human and animal health 
and the general welfare in the world, and therefore represent a major global challenge. 
Although there have been some successes in drug discovery against kinetoplastid diseases for 
example; the SCYX-7158, Fexinidazole and Diamidine series for HAT (Drugs for 
Neglected Diseases, 2012b); the K777 and triazoles for treating Chagas disease (Barr et 
al., 2005; Urbina, 2010); the 8-aminoquinoline NPC1161,  bis-quinolines series, DB766, 
rhodacyanine dyes and amiodarone for Leishmaniasis (Richard and Werbovetz, 2010) and 
the more recent GNF6702 drug candidate against all the three kinetoplastids (Khare et al., 
2016), progress in discovering new and effective drugs against the three pathogenic 
kinetoplatids has been very slow,  mostly due to reasons previously discussed (see Chapter 1). 
One approach in accelerating the discovery of novel leads for the treatment of pathogenic 
kinetoplastids has been the use of simple, robust and inexpensive cell-based systems to serve 
as tools for high throughput screening (HTS) of large sets of chemical libraries.  
However, very few reports are available on HTS assays for the kinetoplastids. A non-human 
infective kinetoplastid parasite C. fasciculata could enhance HTS and speed up the process of 
searching for new drugs to treat the diseases caused by the pathogenic kinetoplastids. As 
previously discussed, C. fasciculata parasites are lower non-humans infective 
trypanosomatids, which can be handled in a standard laboratory without specific biosafety 
issues. The parasites can be easily and quickly grown to high densities in less expensive 
liquid media or fully defined serum-free media and therefore could shortern the long turn 
around time associated with the pathogenic kinetoplastids screening assays. 
In this chapter, we report the development and the application of a resazurin reduction--- C. 
fasciculata cell assay for primary screening and predicting compounds with potential 
activities against the pathogenic kinetoplastids. In particular, we utilized the developed assay 
to query the Open Access Chemical boxes for compounds with inhibitory activities against C. 
fasciculata parasites, which will be followed up against the actual pathogenic kinetoplastids. 
36 
  
3.1.1 Open access chemical boxes 
Some few decades ago, an innovative collaboration model for research and development for 
neglected diseases emerged in the form of public-private partnerships (PPPs), which later 
came to be known as product development partnerships (PDPs). A notable example of such 
PDPs are the Medicines for Malaria Venture (MMV) and the Glaxo Smith Kline (GSK) Tres 
Cantos which were formed with the aim of catalysing the discovery, development and the 
delivery of new medicines against tropical diseases.  
Almost seven million compounds have been tested in phenotypic assays against malaria over 
the last decade, which has resulted in a solid pipeline of new preclinical and clinical 
candidates (Preston et al., 2016). Moreover, an open science initiative has made many of 
these structures available online and a collection of 400 key malaria phenotypic ‘hits’, called 
the ‘Malaria Box’, was launched in 2013. Building on this model, in December 2015, MMV 
took this a stage further with an initiative to stimulate the drug discovery for neglected 
parasitic diseases by introducing a Pathogen box. The ‘Pathogen Box’ (www. Pathogen 
box.org), contains 400 diverse drug-like molecules, which is provided at no cost to research 
groups. Each of the 400 compounds in the ‘Pathogen Box’ has confirmed activity against one 
or more key pathogens that cause some of the most socioeconomically important diseases 
worldwide such as tuberculosis, malaria, sleeping sickness, leishmaniasis, schistosomiasis, 
hookworm disease, toxoplasmosis and cryptosporidiosis. All the 400 compounds were tested 
for cytotoxicity with compounds included in the library being at least 5-fold more selective 
for the pathogen than its mammalian host. 
Between October 2012 and May 2014, a diverse set of 1.8 million compounds were screened 
by the GSK Tres Cantos against the three pathogenic kinetoplastids i.e. L. donovani, T. cruzi 
and T. brucei (Peña et al., 2016). Secondary confirmatory and orthogonal intracellular anti-
parasitic assays were conducted, and the potential for non-specific cytotoxicity determined. 
From this high through put screening, three anti-kinetoplastid chemical boxes were 
assembled. The selection of representative chemical boxes for the three kinetoplastids 
started from the most potent, specific, and non-cytotoxic compounds in the dose–response 
outputs of each screen after having filtered for lead-like properties as described in Pena et 
al. (2016). In order to generate representative boxes with high chemical diversity and 
potency, compounds were clustered initially by similarity using a complete-linkage 
algorithm (Leach et al., 2007) and a threshold of 0.55. Secondly, they were sorted by 
decreasing potency (i.e. pIC50). The hypothetical biological target space covered by these 
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diversity sets was also investigated through bioinformatics methodologies. The analysis 
suggested that most of the compounds are new chemical entities with potential novel 
mechanisms of action that have not been previously exploited against these parasites. 
Clusters of compound were represented by only two members in the final ranked boxes. 
The final boxes contained 592 compound entries; 192 were active against L. 
donovani (Leish-Box), 222 against T. cruzi (Chagas-Box) and 192 against T. brucei (HAT-
Box). The three anti-kinetoplastid chemical boxes showed little overlap, pointing to 
specific mechanisms of growth inhibition or structural divergence across molecular targets 
in each parasite. Three compounds were in both the Leish-Box and Chagas-Box, nine in 
both the Chagas-Box and HAT-Box and one compound was present in all three chemical 
boxes (Peña et al., 2016). 
Both the Pathogen and the GSK kineto boxes containing compounds are provided free to 
researchers upon request and the data of all these chemical boxes is publically available with 
the aim of facilitating and stimulating the drug discovery for these diseases. We therefore 
took advantage of these boxes to identify compounds with anticrithidial activitivies that will 
be followed up against the actual pathogenic kinetoplastids. 
 
3.1.2 High throughput phenotypic screening assays 
Different assays have been developed and investigated to identify new active starting points 
for drug development against kinetoplastid pathogens. Most of these assays are based on the 
selection of compound collections and evaluating them in either target-based or phenotypic 
(whole cell) screening (Pink et al., 2005). Most of the new drug candidates that were 
approved by the FDA between 1999 and 2008 were identified through phenotypic screening 
(37% versus 23% discovered by target-based approaches) (Lee et al., 2012).  However, the 
target-based approaches have out numbered phenotypic screening and the success of 
phenotypic screening has been underrated.  
Unlike target-based screens, which rely upon known therapeutic pathways, phenotypic 
screening has the advantage of identifying new other targets. A compound may affect two or 
more proteins or pathways in the organism, which would not be identified in a high-
throughput target-based screen. Unfortunately, lack of membrane permeability can lead to 
inactivity being reported for a particular compound that initially demonstrated target activity 
when assessed in a phenotypic screen. This can be a double-edged sword as a target specific 
molecule with inactivity in a phenotypic screen would be lost. However, given the costs and 
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frequent failure to suitably optimize and progress molecules for drug discovery, this loss is 
usually considered acceptable in phenotypic screens (Sykes and Avery, 2013).  
In the process of searching for new drugs against kinetoplastid diseases in which very few 
validated targets exist, a non-reductionist approach such as the phenotypic screening 
therefore holds significant advantages. Phenotypic screening is considered a cost-effective 
method of identifying activities of unknown compounds and provide a wider view of the 
antiparasitic activity that can be hitting either single or multiple targets (De Muylder et al., 
2011). Reliable and reproducible phenotypic assays are of great benefits 
to kinetoplastids drug discovery where assay cost becomes an issue because of the low 
funding schemes dedicated to kinetoplastid diseases research and the lack of interest in these 
diseases by large pharmaceutical companies. Recent developments in various platforms for 
phenotypic screening especially the high throughput screening (HTS) assays has opened new 
doors of investigation and has allowed the evaluation of significantly larger compound 
collections (10,000 to several million) representative of a much broader chemical diversity 
such as those provided by the MMV and GSK Tres Cantos.  A number of such whole cell 
phenotypic screening assays have used succesfully in identifying some novel 
antikinetoplastid candidates for example; the hydrazine CA272 and a quinolone derivative 
CH872 for leishmaniasis  (Siqueira-Neto et al., 2010), azole antifungals---ianoconazole, 
bifonazole, and oxiconazole nitrate for T. cruzi, the five new scaffolds--phenylthiazol-4-
ylethylamide, phenoxymethylbenzamide, 6-aryl-3-aminopyrazine-2-carboxamide, pyrido-
isoxazol-2-ylanilide and aminoethyl benzoylarylguanidine (Sykes and Avery,2013) and the 
quinolones (Hiltensperger et al., 2012; Fotie et al., 2010) for T. brucei. 
3.1.3 Resazurin-reduction cell-based HTS assay 
The establishment of a simple in vitro cell culture systems for axenic growth of kinetoplastids 
has led to the exploration of a various whole cell assay formats to serve as tools for HTS, 
with the aim of assessing large sets of chemical libraries and prioritize those for further 
synthesis of analogues in hit-to-lead and lead optimisation phases of the drug discovery 
process (Muskavitch et al., 2008). For evaluating the cell viability following exposure to test 
compounds, the resazurin (Alamar Blue™)  (Räz et al., 1997; Sykes and Avery, 2009) and 
Cell-Titer-Glo™ luminescent cell viability assay (Mackey et al., 2006) methods have 
emerged as those most amenable to HTS because of their high signal-to-background ratio and 
reproducibility.  Generally, these assays are performed in "automation-friendly" microtiter 
plates with either a 96, 384 or 1536 well format. 
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The resazurin-based assay is preferred due to its simplicity, low cost, lack of radioactive 
materials and non-toxic and transferability to the field if necessary. It has been extensively 
used for screening of drug susceptibility in whole cell cultures of trypanosomes and other cell 
lines for so many years (Bowling et al., 2012;  Sykes and Avery, 2009, Räz et al., 1997; 
Shimony and Jaffe, 2008; Nare et al., 2010 ), Leishmania ( Fumarola et al., 2004b) human 
cells (Ahmed et al., 1994; O’Brien et al., 2000), fungi (Tiballi et al., 1995), bacteria (Baker 
and Tenover, 1996; Franzblau et al., 1998).  
Resazurin is an active ingredient of alamar blue. Resazurin dye is a water-soluble, non-toxic, 
permeable through cell membranes and is stable in culture medium. It is highly dichromatic 
based on Kreft's dichromaticity index (Kreft and Kreft, 2009). The dye acts as an 
intermediate electron acceptor in the electron transport chain without interference of the 
normal transfer of electrons (Page et al., 1993). The oxidation-reduction potential of resazurin 
is +380 mV at pH 7.0, 25 °C. It can therefore be reduced by NADPH (Eo = 320 mV), FADH 
(Eo = 220 mV), FMNH (Eo = 210 mV), NADH (Eo = 320 mV), as well as the cytochromes 
(Eo = 290 mV to +80 mV) (Rampersad, 2012). Resazurin can be converted from its oxidized, 
non-fluorescent, blue colour to the reduced, highly fluorescent, pink coloured resorufin that 
can further be reduced to nonfluorescent uncoloured dihydroresorufin (Page et al., 1993) (Fig. 
13). Mitochondrial reductases and other enzymes such as the diaphorases (EC 1.8.1.4, 
dihydrolipoamine dehydrogenase) (Matsumoto et al., 1990), NAD (P) H: quinone 
oxidoreductase (EC 1.6.99.2) (Belinsky and Jaiswal, 1993) and flavin reductase (EC 1.6.99.1) 
(Chikuba et al., 1994) located in the cytoplasm and the mitochondria may be able to reduce 
resazurin. Therefore, resazurin reduction may signify an impairment of cellular metabolism 
and is not necessarily specific to interruption of electron transport and mitochondrial 
dysfunction (Mood and Mommsen, 2005). This change from oxidized to reduced state allows 
flexibility of detection where measurements can be quantitative as colorimetric and/or 
fluorometric readings (the latter being more sensitive) or qualitative as a visible change in 
colour indicating presence or absence of viable cells. These properties of resazurin have been 
exploited to provide a quantitative measurement of parasite proliferation and viability to 
identify a variety of inhibitor compounds. 
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Figure 13. Schematic of Resazurin reduction reaction. Reducing environment in viable cells 
continuously converts the essentially non-fluorescent resazurin to a highly fluorescent 
resorufin, increasing the overall fluorescence and colour of the media surrounding cells. The 
resorufin is further reduced to uncoloured and no fluorescent dihydroresorufin. 
 
Indeed, utilizing these robust and reliable assays with convenient organisms like C 
fasciculata and taking advantage of the available open access chemical boxes in drug 
discovery screening cascades could play a very crucial role in speeding up the process of 
searching for new drugs against kinetoplastids. 
 
3.2 Materials and methods 
3.2.1 Parasites and cell culture 
The C. fasciculata promastigotes clone HS6 was used in all assays and parasites were grown 
at 27oC with a gentle agitation in axenic serum-free defined culture media containing Yeast 
extract, Tryptone, Sucrose, Triethanolamine, Tween 80 and supplemented with haemin as 
described in Appendix 2. All chemicals and reagents used in the experiments were of highest 
grade and were purchased from Sigma-Aldrich. The parasites were sub-cultured every 2-3 
days to ensure log growth phase for subsequent experiments. 
3.2.2 Compounds libraries 
Chemical boxes were kindly provided by MMV and GKS Tres cartos following a request. 
The Pathogen Boxes contained 400 chemicals representing compounds that were active 
against one or more of 12 distinct pathogens (http://www.pathogenbox.org/about-pathogen-
box/supportinginformation). Individual compounds had only been tested to confirm activity 
against the pathogen for which the compounds were first reported to be active, and have not 
been tested against the other pathogens represented in the Pathogen Box. All compounds 
have been tested for cytotoxicity; typically, they were five-fold less potent against a human 
fibroblast cell line (MRC-5) than the pathogen (www. pathogenbox.org/about-pathogen-
box/supporting-information). 
41 
  
 
The three GKS kineto chemical boxes (Leish-box), (Chagas-box) and HAT box) with each 
box containing ~200 compounds assembled by Pena and his colleagues (Pena et al., 2016) 
as previously discussed, were donated by GSK Tres-Cartos. These compounds included 
details on the pathogen against which the compound was shown activity, their cytotoxicity as 
well as other useful data such compound ID, batch ID, trivial name, molecular weight, salt, 
and cLogP. More information about these compounds can also be accessed online via 
ChEMBL-NTD (https://www.ebi.ac.uk/chemblntd). 
 
Both the MMV and the GSK compounds were supplied in 96-well plates, containing 10 µL 
of 10 mM dimethyl sulfoxide (DMSO) solution of each compound. Each compound was then 
diluted with PBS to a working concentration of 2.5 mM (DMSO 25%) working and aliquoted 
into multiple plates. The compounds were stored at -80°C and thawed at room temperature 
prior to use. Each of the 400 compounds was screened in quadruplicate at a concentration of 
100 µM (DMSO 0.5% final concentration) in 96-well plates.  
Subsequent pure compounds were repurchased from Sigma-Aldrich for structure-activity 
relationships (SARs). Similary, these compounds were prepared in stock concentration of 10 
mM with DMSO and screened at 100 µM (DMSO 0.5% final concentration). 
The Alamar Blue solution was prepared by dissolving 12.5 mg Resazurin sodium salt 
(Sigma-Aldrich) in 100 ml of Phosphate Buffered Saline (PBS). The solution was then 
sterilized by filtration with a 0.22 µm Millipore Express PLUS membrane filter and used 
immediately. All fluorescence measurements in this study were performed with the Spectra 
Max Gemini XPS Microplate reader (Gemini XPS, Molecular devices) with excitation 
wavelength of 530 nm and 560 nm. 
3.2.3 Resazurin-reduction C. fasciculata cell-based assay optimization 
Although resazurin-reduction assay has been extensively used for screening drug 
susceptibility of various cell types, none has tempted to apply this assay in Crithidia. 
Therefore, a number of conditions such as; the growth kinetics of cells, maximum cell 
densities, the incubation period, the resazurin concentration and the DMSO concentrations 
had to be considered and optimised for the resazurin-reduction assay to work as a screening 
tool in this system. 
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3.2.3.1 The multiplicative kinetics of C. fasciculata 
Cell densities of three replicate cultures starting at 1x103, 1x104 and 3x104 cells/ml were    
microscopically monitored and counted using a haemocytometer at 24 hour intervals, over 5 
days. A growth curve was plotted to estimate the doubling time and the maximum number of 
cells attainable in a 25-cm2   before stationary phase and possible cell death occur.  
3.2.3.2 Determining the effect of incubation period and the volume of 
resazurin on fluorescence development  
In order to determine the fluorescent development at different volumes of the dye and the 
incubation period, C. fasciculata choanoamastigotes (5x104cells/ml) were incubated in the 
presence of various resazurin dye volumes (5, 10, 15 and 20 µl) and monitored after every 1 
hour for a period of 4 hours. The experiment was performed twice and the results were 
averaged over eight replicate wells. 
3.2.3.3 Determining the relationship between cell density and the Resazurin 
fluorescence 
To determine the relationship between cell density and the fluorescence signal, the parasites 
in the logarithmic phase of a stock suspension of 80x106cells /ml were serially diluted (100 µl) 
into 96-well plates followed by addition of 10 µl of resazurin. Plates were incubated at 27°C 
and fluorescence measured after every 1 hour for a period of 4 hours. The experiment was 
performed twice and the results were averaged over eight replicate wells. 
3.2.3.4 Determining the effect of DMSO concentrations on the assay signal 
A 90µl of medium containing C. fasciculata choanoamastigotes (5x103cells/ml) was 
inoculated into a 96-well plate and incubated for 24-hours. Ten microliters of various (0.5-9% 
final) concentrations of DMSO diluted in the medium were then added to the plates and 
further incubated for 24 hours. The experiments were performed twice and the results were 
averaged over eight replicate wells. 
3.2.4 Compound sensitivity assays 
3.2.4.1 Primary screening assays 
C. fasciculata choanoamastigotes in the log phase of growth were diluted 1:20 in the growth 
media, and 20µl was counted using a hemocytometer. For anti-crithidial activity, compounds 
were added to the test plates with medium containing the parasites (density: 5x103cells/ml) to 
achieve a final compound and DMSO concentration of 100 µM and 0.5%, respectively. The 
controls on each plate included wells containing growth media--0.5% DMSO without cells 
(Positive control) and growth media--0.5% DMSO with cells only (Negative control). The 
activities of test compounds were normalized against controls from the same plate according 
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to the following formula: Activity (%) = [1 − (FCpd − FPos) / (FNeg − FPos)] ×100, where FCpd 
corresponds to the emitted fluorescent signal expressed in arbitrary fluorescence units for the 
test compound; and FNeg and FPos correspond to the mean fluorescent signal of the negative 
and the positive control wells, respectively. For estimation of the hit confirmation rate, 
compounds were considered “confirmed” when the normalized anti-parasitic activity was 
equal to or greater than 80% (≥80%) at 100 µM concentration. 
3.2.4.2 Dose-response assessments of active compounds 
Compounds which showed ≥80% inhibition when tested at 100 µM concentration in at least 
one biological replicate were re-tested in 10-point dose response, two-fold dilution 
experiments starting at various compound concentrations with the parasites seeding density 
of 5x103cells/ml.  Wells containing the 0.5% DMSO growth media with no cells and 0.5% 
DMSO growth media with cells but no drug served as 100% inhibition and 100% growth 
controls, respectively. Pentamidine and suramin were used as reference compounds. A 10 µl 
of Resazurin® was added after 44 hours incubation and fluorescence development was 
determined after a total drug exposure time of 48 hours. The obtained fluorescence data was 
analysed with the graphic data analysis software “GraFit” which calculated EC50 values by 
linear regression from the sigmoidal dose inhibition curves.  
Compounds which did and did not yield an EC50 value within the confines of the analysis 
parameters were simply expressed as the “true active” and “false active” compounds, 
respectively. A few compounds of interests, which had comparably low EC50 values were 
cherry picked from the top ten lists, purchased from commercial sources (Sigma-Aldrich) and 
screened to finally confirm their activities.   
EC50 was defined as the amount of a compound required to decrease the C. fasciculata 
viability by 50% compared to those grown in the absence of the test compound.  All 
experiments were performed twice, with each drug concentration in quadruplet. For 
standardisation, of EC50 values were converted to pIC50 using a converter found at 
www.sanjeevslab.org/tools.html. According to the FDA, pIC50 is the recommended way of 
measuring/reporting the effectiveness of a substance in inhibiting a specific biological or 
biochemical function. The pIC50 represents the concentration of a drug that is required for 50% 
inhibition in vitrowhile EC50 mainly represents the plasma concentration required for 
obtaining 50% of a maximum effect in vivo. 
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3.3 Results and Discussion 
3.3.1 Resazurin-reduction C. fasciculata cell-based assay optimization 
In order to determine the maximum cell numbers that could be used for developing the 
screening assay, the growth kinetics of C. fasciculata parasites growing in our formulated 
serum free medium was analysed using the growth curve as shown (Fig.14). The parasites 
grew quite robustly under axenic conditions in vitro and reached the stationary phase after 3 
days. Similar C. fasciculata choanoamastigotes growth kinetics in in vitro culture systems 
have been reported elsewhere (Calderón-Arguedas et al., 2006 and Scolaro et al., 2005).  An 
average generation time was determined according to Popp and Lattorff (2011) equations and 
gave an estimation of approximately 4.5 hours. The doubling time observed is shorter than 
the doubling time (6.8 hours) reported for T. brucei brucei blood foams when grown in HMI-
9 supplemented with 10% fetal calf serum (Skyes and Avery, 2009) and 7 hours for 
Leishmania species (personally communicated by Menzies S, Terry Smith’s laboratory). 
 
 
Figure 14. Growth curve of C. fasciculata choanoamastigotes. Cultures starting at 1000, 
10000 and 30000 cells/ml were microscopically monitored and counted using a 
haemocytometer at 24 hours intervals for 5 days. Average counts were obtained from two 
biological replicates and the experiment was repeated twice. 
 
A linear relationship was observed between the incubation time and the fluorescent 
development of Resazurin reduction (Figure 15). However, low dye concentrations gave 
relatively higher fluorescent signal as compared to high concentrations.  Skyes and Avery 
(2009) and Raz et al. (1997) also observed a similar independent relationship between 
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resazurin concentration and the fluorescent signal in their assay development. Obviously, this 
is due to quick reduction of small volumes of the dye by the cells or perhaps high 
concentrations of resazurin salts had inhibitory effect on cell growth and metabolism. For 
higher cell inoculums, the fluorescent signal easily reached saturation within some few 
minutes when a 5% (5 µl) dye concentration was used but we were able to get strong 
fluorescent signal after 4 hours incubation with a 10% (10 µl) resazurin. We therefore 
considered using the 10% resazurin as an ideal dye concentration for all of our assays. 
The fluorenscence signal correlated with cell numbers (Fig.16). However, for high cell 
densities such as 80x106/ml and 40x106/ml the fluorescence signal reached saturation after 1 
hour and 2 hours incubation, respectively. We were able to obtain a very strong signal with 
20x106 cells/ml giving the best maximum fluorescence to background signal ratio of 9:1. The 
reported signal to background ratio (S/B) is much higher than the 3:1 obtained on T. b. 
gambiense and but lower than on T. b. rhodesience (15:1) in similar assays (Raz et al., 1997). 
These differences could be attributed to variations in the dehydrogenase activity responsible 
for metabolizing resazurin or reduced uptake of the dye substrate among the parasites. 
Differences in the fluorescence analysers, concentrations of the dye used as well as the 
composition of media used to culture these parasites could potentially also account for some 
of the variations observed.  
Future studies should however, aim to accurately determine the linearity between the 
fluorenscence signal and the cell density. For example, carrying out the experiment at much 
lower parasite density than 80 x106 cells/ml or perharps using direct transfer (inoculation) of 
known cell densities (starting at very lower densities) from the culture to the wells according 
to  Sykes and Every (2009) and  Raz et al (1997). 
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Figure 15. The effect of incubation period and the volume of resazurin on fluorescence 
development. The fluorescence was monitored by incubating C. fasciculata 
choanoamastigotes (5x104cells/ml) in the presence of various resazurin volumes (5, 10, 15 
and 20 µl) at 1 hour interval for 4 hours period. All experiments were performed twice and 
average signals plotted. 
 
 
Figure 16. Relationship between the C. fasciculata choanoamastigotes density and resazurin 
fluorescent signal. Serial two-fold dilutions of parasites starting at 80 x106 cells/ml were 
prepared in 100 µl followed by addition of resazurin and fluorescence measurement to 
determine parasite viability. All experiments were performed twice and average signals 
plotted. 
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Since compounds library collections were diluted in DMSO, which is known to be toxic to 
various cells, we exposed the parasites to various DMSO concentrations to determine wether 
it had any effect on the cells viability. The C. fasciculata parasites were able to tolerate 
maximum DMSO concentrations of up to 0.5% with no significant decrease in fluorescent 
signal (Fig. 17).  This DMSO sensitivity is a bit higher than 0.42% reported for blood forms 
T. b. brucei by Skyes and Avery (2009) but comparably lower than that reported on blood 
stream forms of T. brucei and T.brucei congolense (Merschjohann and Steverding, 2006). 
Since C. fasciculata parasites grows almost everywhere including the harsh environments and 
unprotected from the UV from the sun, we expected the parasites to more resistant to DMSO 
than the blood stream forms trypanosomes.  The fact that the blood stream forms 
trypanosomes also endure a harsh host immune system should also not be ruled out as a 
possibility of their advantage to with stand such toxic concentrations of DMSO. Nevertheless, 
one other possible factor that may have resulted to such different observations of DMSO 
sensitivities might be due to the nature of the medium used in each of the protocols. Different 
culture medium may have different constitutes which may positively or negatively react with 
the DMSO effecting the viability and consequently the doubling times of the parasites. 
Moreover, the use of water to dilute compounds have been observed to possess significant 
effects on the cell viability and EC50 value of the compounds possibly due to osmotic effect 
of water on cells and changes in buffering capacity of the medium as reported somewhere 
(Sykes and Avery, 2009). 
 
After optimizing conditions such as cell concentrations, incubation times, resazurin 
concentration and the DMSO concentration, the assay performance and its capabilities to 
discriminate the activities of different compounds was determined by calculating the Z` factor, 
a statistical parameter for use in evaluation and validation of high throughput screening 
assays (Zang et al.,1999). Statistically, the assay performed well according to the Z` factor 
criteria (cut off=0.5, but closest to 1 as possible) by obtaining an average Z` factor of 0.7 (a 
maximum plating cell density of 5x103cells/ml, 48 hours incubation, 10% v/v resazurin and 
max 0.5% DMSO). The distribution Z` factor in a total of 100 randomly selected plates 
(Fig.18) also confirmed that the assay was able to discriminate compounds with different 
levels of inhibition in C. fasciculata viability assay during the screening process. 
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Figure 17. Dimethyl sulfoxide (DMSO) concentration and fluorescent signal. A cell density 
of 5x103cells/ml was incubated for 48 hr in various DMSO concentrations and resazurin 
(10%) florescent signal measured. The experiment was performed twice with signal at each 
DMSO dose averaged from quadruplicate samples 
 
 
 
Figure 18. Distribution of   Z` factors in a total of 100 plates randomly selected from the 
MMV (25 plates) and; GSK T. brucei (25 plates), T. cruzi (25 plates) and Leishmania (25 
plates) boxes. 
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3.3.2 Screening GSK pathogen boxes for anti-crithidial compounds with a 
resazurin-reduction assay. 
 
Utilizing the conditions established during optimization, the Resazurin reduction--C. 
fasciculata assay was used to screen for anti-crithidial compounds in the Open Access 
Chemical boxes (MMV pathogen box and GKS chemical boxes) to identify a workable 
number of potential compounds for follow up testing against the actual pathogenic 
kinetoplastids. 
Using an inhibition cut-off of ≥80%, the primary screening of MMV pathogen box led to the 
identification of 91 (23%) compounds with inhibitory activities against C. fasciculate (Fig. 
19) (Appendix 9). The potency of the 91 compounds was further evaluated through dose-
response experiments to determine their IC50 values. This led into the identification of 72 
(79%) true active compounds and 19 false active compounds thus representing 18% hit rate. 
 
 
Figure 19. The workflow used to identify and progress hits of the open access pathogen 
boxes including key criteria considered in the decision-making process. In this case, all the 
compounds that had inhibition of ≥80% were progressed to dose-response experiments to 
determine their IC50 values. True active compounds are those that had a ≥80% inhibition and 
showed an IC50 in dose-response experiments. 
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Ten compounds (top ten) were then cherry picked from the 72 true active compounds in the 
MMV boxes and the profiles of these top ten hits are shown in Table 5.  
Strikingly, three compounds (1, 6 and 9) shared a pyrimidin-4-amine chemical fragment. 
Pyrimidin-4-amine derivatives are well-known kinase and cytochrome P450s inhibitors in 
various organisms (Pena et al., 2016 and Gunatilleke et al., 2012).  One compound (5) had a 
quinazoline-2, 4-diamine series well referenced in the literature as inhibitors of folate 
synthase pathways in Leishmania, Trypanosoma and Plasmodium (Pez et al., 2003; 
Khabnadideh et al., 2005; Muller and Hyde, 2013). 
 
From the GSK boxes, the primary screening of a T. brucei box identified a total of 66 
compounds (35%) with inhibitory activities against C. fasciculata (Appendix 10), of which 
only 42 (64%) were true active representing a hit rate of 22%. Screening the T. cruzi and 
Leishmania boxes identified 101(46%) and 122(67%) compounds with inhibitory activities 
against C. fasciculata (see Appendix 11 and 12, respectively), of which 68 (67%) and 
89(73%) were true active, respectively (Fig. 19), representing the hit of 31% and 49% for T. 
cruzi and Leishmania box, respectively. The enriched hits rates observed among the GSK 
boxes suggest the commonality of the targets shared between C. fasciculata and the T. brucei, 
T. cruzi, and to the large extent the leishmania species. Since all the GSK compounds were 
previously shown to be active against each of the respective kinetoplastids in vitro (Pena et 
al., 2016), this might suggest that the hits have favourable properties to reach their active 
biological targets shared between C. fasciculata and the pathogenic kinetoplastids in these 
assays.  
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Table 5. Profiles of the top ten hits identified from screening of the MMV pathogen box. 
Compounds with pyrimidin-4-amine scaffold are highlighted in red.The cytotoxicity of all 
these compounds are at least 5-fold more selective for the pathogens than their mammalian 
hosts. The cLogP, cytotoxicity data and other relevant information of these compounds are 
found at (http://www.pathogenbox.org/about-pathogen-box/supportinginformation). 
 
 
 
 
	
Compound 
ID 
pIC50 cLogP  
 
Compound name  Mwt 
 
Structure of the 
compound 
1 MMV0
21013 
7.4 ± 
0.004 
3.55 
 
N-cyclohexyl-6-cyclopropyl-2-
(pyridin-2-yl)pyrimidin-4-
amine 
294.40 
 
 
2 MMV2
72144 
7.7 ± 
0.03 
-0.27 
 
1-(3-methoxyphenyl)-5-
(methylsulfonyl)-1H-tetrazole 
254.27 
 
 
3 MMV6
88755 
8 ± 0.001 2.81 
 
(S)-2-nitro-6-((4-
(trifluoromethoxy)benzyl)oxy)-
6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine 
359.26 
 
 
4 MMV6
89243 
8 ± 0.003 4.26 
 
N-(4-(trifluoromethyl)phenyl)-
N-(1-(5-
(trifluoromethyl)pyridin-2-
yl)piperidin-4-yl)pyridin-3-
amine 
466.42 
 
 
5 MMV6
75968 
8 ± 0.005 2.31 
 
5-chloro-6-(((2,5-
dimethoxyphenyl)amino)methyl
)quinazoline-2,4-diamine 
359.81 
 
 
6 MMV6
58988 
6.1± 0.01 3.93 
 
5-chloro-N,6-dimethyl-N-
phenethyl-2-(pyridin-2-
yl)pyrimidin-4-amine 
338.84 
 
 
7 MMV5
53002 
6.3 ± 0.1 -0.31 
 
3-((methylsulfonyl)methyl)-2H-
benzo[b][1,4]oxazin-2-one 
239.25 
 
 
8 MMV6
88262 
 
7±0.04 5.04 
 
2-methyl-6-nitro-2-((4-(4-(4-
(trifluoromethoxy)phenoxy)pipe
ridin-1-yl)phenoxy)methyl)-2,3-
dihydroimidazo[2,1-b]oxazole 
534.48 
 
 
9 MMV6
88470 
 
6.1±0.02 3.12 
 
1-(2-(1-
(methylsulfonyl)piperidin-4-
yl)ethyl)-3-(naphthalen-1-
ylmethyl)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine 
464.58 
 
 
10 MMV6
76445 
 
6.1±0.01 2.71 
 
2-(((1-propyl-1H-
benzo[d]imidazol-2-
yl)methyl)amino)phenol 
281.35 
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Ten compounds (top ten) were then cherry picked from the list of the true active compounds 
in each of the T. brucei, T. cruzi and Leishmania box and the profiles of the top ten hits are 
shown in Table 6, 7 and 8, respectively.  
 
From the T. brucei GSK box (Table 6), two compounds (4 and 8) also had a pyridine-4-
amine chemical fragment while three compounds (1, 5 and 10) shared a 5-nitrofuran-2-yl 
fragment and the other compounds had distinct structures. The nitro-substituted aryl group 
derivatives are substrates of type I nitroreductases of various parasites which are metabolized 
into toxic nitrile products harmful to the parasites (Hall et al., 2011). Nevertheless, the 5-
nitrofuran-2-yl derivatives also inhibitors of Myco-bacterium tuberculosis H37RV 
(Doreswamy and Chanabasayya, 2013).  
The fact that there are no mammalian homologues to the 5-nitrofuran-2-yl targets place their 
derivatives as potential drug candidates against various pathogens. The increasing interest in 
treating kinetoplastids diseases with nitro drugs such as nifurtimox and benznidazole 
(Patterson and Wyllie, 2014), and the nitro-aromatic chemicals present in these sets calls for 
further studies on their substrate selectivities. 
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Table 6. Profile of ten top hit compounds identified in the GSK T.brucei box. Compounds 
with pyrimidin-4-amine scaffold are highlighted in red and those with 5-nitrofuran-2-yl 
scaffold are in blue. Data on cytotoxicity and cLogP and other information about these 
compounds is  found on (https://www.ebi.ac.uk/chemblntd). 
	
Compound 
ID 
pIC50 Cytotoxi
city  
cLogP 
 
Compound name  Mwt 
 
Structure of the 
compound 
1 TCMDC
-143074 
 
5.5±0.3 <4.0 
 
3.422 
 
2-(4-chlorophenyl)-
5-(5-nitrofuran-2-
yl)-2H-tetrazole 
291.65 
 
 
2 TCMDC
-143457 
 
5.4±0.0
1 
<4.0 
 
1.21 
 
2-(3-(4-
(difluoromethoxy)-3-
methoxyphenyl)-
1,2,4-oxadiazol-5-
yl)acetonitrile 
281.22
1 
 
 
3 TCMDC
-143609 
 
5.4±0.2 4.7 
 
1.881 
 
4-bromo-2-
nitrobenzonitrile 
227.01
8 
 
 
4 TCMDC
-143363 
 
5.3±0.0
3 
4.5 
 
2.772 
 
N-(5-cyclopropyl-
1H-pyrazol-3-yl)-6-
methyl-2-
(pyrrolidin-1-
yl)pyrimidin-4-
amine 
284.36
7 
 
 
5 TCMDC
-143112 
 
5.3±0.1 4.8 
 
2.654 
 
(2-
(diethylamino)thiaz
ol-5-yl)(5-
nitrofuran-2-
yl)methanone 
295.31
9 
 
 
6 TCMDC
-143316 
 
5.1±0.5 4.5 
 
3.74 
 
5-methyl-7-(2,4,5-
trichlorophenoxy)-
[1,2,4]triazolo[1,5-
a]pyrimidine 
329.57
5 
 
 
7 TCMDC
-143172 
 
5.0±1.0 <4.0 
 
4.29 
 
3-chloro-N-(5-
chlorobenzo[d]oxazol
-2-yl)benzamide 
307.13
2 
 
 
8 TCMDC
-143460 
 
5.0±0.7 <4.0 
 
2.383 
 
N-(4,5-dimethyl-1H-
pyrazol-3-yl)-1H-
pyrrolo[2,3-
b]pyridin-4-amine 
227.26
5 
 
 
9 TCMDC
-143079 
 
5.0±0.0
4 
<4.0 
 
1.358 
 
4-(benzylcarbamoyl)-
1,2-phenylene 
bis(methylcarbamate) 
357.36
1 
 
 
10 TCMDC
-143073 
 
5.0±0.3 <4.0 
 
1.212 
 
3-(5-(5-nitrofuran-2-
yl)-2H-tetrazol-2-
yl)pyridine 
258.19
8 
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No compounds with common scaffolds were identified in the T. cruzi box (Table 7). 
However, of particular interest, we identified one compound (3) with a quinolin-8-ol 
chemical scaffold previously reported for their antifungal properties but of which their mode 
of action is not yet known (Musiol et al., 2006). We also identified one compound (8) in the T. 
cruzi box, which shared a common 2, 2, 2-trifluoroacetate moiety with two compounds (2 
and 10) in Leishmania box (Tables 7 and 8). 
The Leishmania box also revealed two more compounds (1 and 2) with pyrimidin-4-amine 
based structure (Table 8). The increased number of active compounds sharing a pyrimidin-4-
amine structural class identified in both the MMV and GSK boxes strongly suggest the need 
for follow up testing of their analogues against the pathogenic kinetoplastids.  
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Table 7.  Profile of ten top hit compounds identified in the GSK T. cruzi box. Compound 
with quinolin-8-ol and 2, 2, 2-trifluoroacetate scaffolds are highlighted in green and yellow, 
respectively.  Data on cytotoxicity, cLogP and other information about these compounds is 
found on (https://www.ebi.ac.uk/chemblntd). 
	
Compound 
ID 
pIC50 Cytoto
xicity  
cLogP 
 
Compound name  Mwt 
 
Structure of the 
compound 
1 TCMD
C-
143149 
 
5.9±0.0
5 
<4.0 
 
-0.242 
 
5-((allyloxy)methyl)-2-
nitro-5,6-
dihydrooxazolo[3,2-
b][1,2,4]triazole 
226.18
9 
 
 
2 TCMD
C-
143088 
 
5.6±0.1 <4 0.432 
 
1-(1-methyl-3-nitro-1H-
1,2,4-triazol-5-
yl)piperidine 
211.22
1 
 
 
3 TCMD
C-
143308 
 
5.7±0.0
1 
4.7 
 
2.799 
 
2-methyl-7-((pyridin-2-
ylamino)(pyridin-3-
yl)methyl)quinolin-8-ol 
342.39
4 
 
 
4 TCMD
C-
143593 
 
5.8±0.0
3 
<4.0 
 
3.005 
 
((1S,2S)-2-((bis(pyridin-
3-
ylmethyl)amino)methyl)
cyclopropyl)(3-
methoxyphenyl)methano
ne 
387.47
4 
 
 
5 TCMD
C-
143590 
 
5.7±0.0
7 
4.3 
 
3.947 
 
1-(4-(4-bromo-2-
chlorophenoxy)butyl)-
1H-imidazole oxalate 
419.65
5 
 
 
6 TCMD
C-
143606 
 
5.6±0.0
1 
4.7 
 
2.666 
 
6-ethyl-7-
propylpyrido[2,3-
d]pyrimidine-2,4-
diamine 
231.29
7 
 
 
7 TCMD
C-
143622 
 
6.5±0.0
2 
4.3 
 
4.109 
 
2-(4-(4-((4-
chlorophenyl)sulfonyl)pi
perazin-1-yl)phenoxy)-
N,N-dimethylethan-1-
amine 
423.95
7 
 
 
8 TCMD
C-
143422 
 
6.2±0.0
5 
<4.0 
 
3.173 
 
(3aS,7aS)-2-(2-
fluorophenyl)-5-(pyridin-
3-yl)octahydro-1H-
pyrrolo[3,4-c]pyridine 
2,2,2-trifluoroacetate 
411.393 
 
 
9 TCMD
C-
143612 
 
6.3±0.0
03 
4.4 
 
1.913 
 
N-(cyclohexylmethyl)-
1,2,3-thiadiazole-5-
carboxamide 
225.311 
 
 
10 TCMD
C-
143127 
 
5.7±0.0
1 
<4.0 
 
2.525 
 
(2-chloro-4-(pyrrolidin-1-
yl)phenyl)(4-methyl-1,4-
diazepan-1-yl)methanone 
321.845 
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Table 8.  Profile of ten top hit compounds identified in the GSK Leish box. Compounds with 
pyrimidin-4-amine and 2, 2, 2-trifluoroacetate scaffolds are highlighted in red and yellow, 
respectively. Data on cytotoxicity, cLogP and other information about these compounds is 
found on (https://www.ebi.ac.uk/chemblntd). 
 
 
	
Compound 
ID 
pIC50 Cytoto
xicity  
cLogP 
 
 
Compound name  Mwt 
 
Compound structure 
1 TCMD
C-
143621 
6.9±0.0
1 
4.3 
 
3.7 
 
N-(3-methoxyphenyl)-
6-methyl-2-(pyridin-2-
yl)pyrimidin-4-amine 
292.3
43	
	 	
2 TCMD
C-
143487 
6.8±0.0
03 
4.8 3.597 
 
6-cyclopropyl-2-(1-
methyl-1H-imidazol-2-
yl)-N-(2methyl 
benzyl)pyrimidin-4-
amine2,2,2-
trifluoroacetate 
433.4
37	
	
	
3 TCMD
C-
143239 
6.0±0.2 <4.0 
 
3.648 
 
N-(6 ethyl 
benzo[d]thiazol-2-yl)-4 
morpholinopicolinamid
e 
368.4
61	
	
	
4 TCMD
C-
143586 
6.0±0.0
2 
4.0 
 
3.005 
 
((1S,2S)-2-
((bis(pyridin-2-
ylmethyl)amino)methyl
)cyclopropyl)(3methox
yphenyl)methanone 
387.4
74	
	
	
5 TCMD
C-
143375 
5.9±0.1 <4.0 
 
4.188 
 
5-ethyl-N-(1-phenyl-
1H-imidazol-2-
yl)thiophene-3-
carboxamide 
297.3
81	
	
	
6 TCMD
C-
143315 
 
5.6±0.0
6 
<4.0 
 
3.07 
 
2-(((1-butyl-1H-
tetrazol-5-
yl)methyl)thio)-4,6-
dimethylnicotinonitrile 
302.4
04	
	
	
7 TCMD
C-
143113 
 
5.5±0.2 4.4 
 
3.856 
 
N-(4-(pyridin-2-
yl)thiazol-2-yl)-1,2,3,4-
tetrahydronaphthalene-
2-carboxamide 
335.4
31	
	 	
8 TCMD
C-
143358 
 
5.4±0.0
1 
<4.0 
 
3.349 
 
N-benzyl-2-((1-phenyl-
1H-pyrazolo[3,4-
b]pyridin-3-
yl)oxy)acetamide 
358.3
93	
	
	
9 TCMD
C-
143252 
 
5.5±0.5 <4.0 
 
4.289 
 
N-butyl-4-
isobutyramido-N-
phenylbenzamide 
338.4
43	
	 	
10 TCMD
C-
143218 
 
5.5±0.3 5.0 
 
1.55 
 
4-(5-amino-3-phenyl-
1H-pyrazol-1-yl)-6-
(pyridin-2-yl)-1,3,5-
triazin-2-amine octakis 
(2,2,2-
trifluoroacetate) 
1242.
549	
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A total of eight chemical fragments were chosen from the top ten lists of active compounds 
from the respective chemical boxes and their near neighbors purchased from commercial 
sources. These fragments were prioritised based on: (i) existing in vitro or in vivo data 
regarding their potency and efficacy in other applications (ii) evaluation of their chemical 
structure for drug-like potential and metabolic liabilities; and (iii) the availability of near 
neighbors for SAR studies. The purchased near neighbors were then analysed in dose-
response experiments to confirm their potency.  
Unfortunately, no significant improvement in the in vitro activities was observed in the pure 
near neighbour compounds of the chosen fragments. This could be possibly due to the 
general physicochemical properties of these pure compounds. However, compounds 1, 2 and 
4 harbouring an uncumbered 2-pyridinyl moety were observed to be more potent compared to 
other near neighbors (Table 9). 
 
 
 
Table 9. Profiles and pIC50s of near neighbour compounds based on the more potent 
compounds in the top ten lists of the chemical boxes. Compound number 8 (N-
(cyclohexylmethyl)-4-oxo-4H-chromene-2-carboxamide) have structural similarity to 
compound number 7(Cyclohexanemethyl-amine) all of them showing comparably low 
potency. 
	
	 Name of the compound  pIC50 Mwt Structure  
1	 4,5-dichloro-6-methyl-2-(2-
pyridyl)pyrimidine 
	
5.0±0.6	 240.09	
	
2	 2-(2-pyridinyl)-6-(trifluoromethyl)-4-
pyrimidinol 
	
5.3±1.0	 241.17	
	
3	 2-(4,6-Dimethyl-pyrimidin-2-yl)-5-
methyl-2H-pyrazol-3-ylamine 
	
4.0±0.2	 203.24	
	
4	 5-(isopropylsulfonyl)-2-(2-
pyridyl)pyrimidin-4-amine 
	
5.4±0.7	 278.33	
	
5	 Ethyl 4-methyl-1,2,3-thiadiazole-5-
carboxylate 
 
4.2±0.7	 172.21	
	
6	 1,2,3-thiadiazole-4-carboxylic acid 
 
4.1±1.0	 130.12	
	
7	 Cyclohexanemethyl-amine 
 
4.4±0.4	 113.20	
	
8	 N-(cyclohexylmethyl)-4-oxo-4H-
chromene-2-carboxamide 
3.9±0.6	 285.34	
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The potency of near neighbors harbouring a 2-pyridyl ring provided confidence in the anti-
crithidial activities of compounds harbouring this moety.  Derivatives of 2-pyridyl are well 
reported as CYP51 inhibitors, previously shown to enhance the anti-Mycobacterium 
tuberculosis and anti-trypanosome activity of 2-aminothiazoles (Meissner et al., 2013 and 
Kaiser et al., 2015). Nevertheless, two pyridinyl derivatives, (S)-(4-chlorophenyl)-1-(4-(4-
(trifluoromethyl) phenyl)-piperazin-1-yl) -2-(pyridin-3-yl) ethanone and the  N-[4-
(trifluoromethyl)phenyl]-N-[1-[5-(trifluoromethyl)-2-pyridyl]-4-piperi-dyl]pyridin-3-amine 
have also been identified as promising drug candidates in animal models of Chagas 
disease(Hargrove et al., 2013).  
The reasons to the failure to retain potency observed in the other near neighbors might be 
because of inefficient pin transfer or perharps due to other physicochemical properties of 
these pure solid compounds. However, as is crucial for any screening approach, our hit 
definition was set to identify a workable number of compounds for follow-up, and despite the 
relatively modest sensitivity of our assay, it enabled the identification of compounds with a 
high likelihood of confirmed activity when cherry-picked for follow-up testing. 
 
In conclusion, we have developed a simple drug screening system with C. fasciculata that can 
be used to predict compounds with potential activities against the pathogenic kinetoplatids. 
Using the developed assay, we repurposed the open access chemical boxes for anti-crithidial 
compounds and we have identified attractive chemical scaffolds, which will be considered in 
follow up testing against the actual pathogenic kinetoplastids. 
The utilization of C. fasciculata to predict compounds with potential activities against the 
pathogenic kinetoplastids could therefore provide a less expensive but easy and faster 
altenative approach in search of potential drug candidates against these pathogens. 
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4. Chapter 4: The effects of ionizing gamma radiation on the 
kinetoplastid Crithidia fasciculata 
 
4.1 Introduction 
4.1.1 Gamma ionizing irradiation and its effects on cells 
Gamma irradiation is described as electromagnetic radiation of short wavelength emitted by 
radioactive isotopes with unstable nuclei that break up and decay to reach a more stable form. 
It has been widely used for sterilization of medical devices, food preservation and processing 
of tissue allografts and blood components avoiding the need for high temperatures that can 
damage such products (Hansen and Shaffer, 2001; Kainer et al., 2004; Mendonca et al., 2004; 
Osterholm and Norgan, 2004). For the past few decades, studies on the effects of ionizing 
irradiation stress have been an important issue in different areas of interest, from 
environmental safety and industrial monitoring to aerospace and currently in biology.  
The absorption of ionizing radiation by living organisms may directly disrupt atomic 
structures and produce chemical and biological changes in their cells (Azzam et al., 2012). 
Radiation may also act indirectly through radiolysis of water, thereby generating reactive 
chemical species that may damage nucleic acids, proteins and lipids (Eric and Amato, 2006) 
(Fig. 20).  
The combined direct and indirect effects of radiation may initiate series of biochemical and 
molecular signalling events that may repair the damage or progress into permanent 
physiological changes that may consequently lead to cell death (Sharma et al., 2012). The 
oxidative biochemical changes may continue to arise for days and sometimes months after 
the initial exposure possibly because of continuous generation of reactive oxygen (ROS) and 
nitrogen (RNS) species in the cells (Petkau, 1987). Surprisingly, these processes occur not 
only in the irradiated cells but also in their progeny (Spitz et al., 2004; Kryston et al., 2011; 
Sharma et al., 2012).  
The radiation-induced oxidative stress may spread from targeted cells to non-targeted 
bystander cells through intercellular communication mechanisms (Azzam et al., 2012; 
Seymour and Mothersill, 2004; Prise and O'Sullivan 2009) (Fig. 21). The progeny of these 
bystander cells also experience changes in their oxidative metabolism and may exhibit a wide 
range of oxidative damages such as protein carboxylation, lipid peroxidation, and enhanced 
rates of spontaneous gene mutations and neoplastic transformations (Buonanno et al., 2011). 
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Figure 20. Direct and indirect effects of ionizing gamma radiation on a cell. Absorption of 
ionizing radiation directly disrupts atomic structures and producesbiochemical changes in the 
cells. Indirectly, the radiation may generate ROS and RNS through radiolysis of cellular 
water that contribute to persistent alterations in lipids, proteins, nuclear DNA (nDNA) and 
mitochondrial DNA (mtDNA) (Copied from Azzam et al., 2012). 
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In humans, the persistence of such stressful effects in progeny cells has profound implications 
for long-term health risks such as emergence of a second malignancy after radiotherapy 
treatments (Cucinotta and Chappell, 2010).  Increasing evidence also supports the role of 
chronic oxidative stress in the progression of degenerative diseases and radiation-induced late 
tissue injury (Azzam et al., 2012 and Sharma et al., 2012). 
 
 
Figure 21. Ionizing radiation (IR) induces targeted and non-targeted (bystander) effects. 
Communication of stress-inducing molecules from cells exposed to IR propagates stressful 
effects, including oxidative stress, to the bystander cells and their progeny. The induced 
effects may be similar in nature to those observed in progeny of irradiated cells.(Copied from 
Azzam et al., 2012). 
 
Although there are many common mechanisms of response of organism and cells to 
irradiation and other stresses they encounter, the main difference is the extent of DNA 
damage (Ravanat et al., 2001).  However, these differences are mostly attributed to high dose 
rates. In cases of low dose radiation, direct effects of irradiation such as clustered DNA 
damage and DNA double strand breaks are minimal while the indirect DNA damages caused 
by the induction of ROS and RNS becomes major problem (Ravanat et al., 2001). For high 
doses, adverse effects accumulate in the cells in a deterministic manner that depends directly 
on the amount of the dose. However, for low doses the effects are stochastic, non-linear on 
the amount of the dose, and depend mainly on the efficiency of the stress response’s 
protective mechanisms (Moskalev et al., 2011).  
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4.1.2 Effects of gamma irradiation stress on Kinetoplastids 
Similar to other organisms, the oxidative stress induced by gamma ionizing irradiation has 
profound effects on kinetoplastids.  Single and double-strand breaks and base damage may 
occur in the kDNA after subjected to a large amount of gamma radiation-induced oxidative 
stress (Takeda et al., 1986 and Regis-da-Silva et al., 2006). Since kDNA replication always 
takes place earlier than mitosis, cell reproduction and proliferation is hindered once the DNA 
is damaged, suggesting that a viable kDNA is needed for cell division (Achim et al., 2002). 
Nevertheless, the oxidative stress induced by the ionising gamma radiation is observed to 
alter kinetoplastid gene expression in the first 96 hours after gamma radiation, when DNA 
repair has already been completed (Grynberg et al., 2012).  Among the genes that are highly 
expressed, categories of members of the retrotransposon hot spot gene family and kDNA are 
the most up-regulated genes (Grynberg et al., 2012). However, functional gene categories 
related to basal metabolism, translation and protein degradation processes tend to be 
repressed during this time. Other researchers have reported the increased expression of Rad51 
mRNA in T. cruzi after irradiation and have associated it with the resistance to ionising 
radiation observed in these organisms (Regis-da-Silva et al., 2006). 
 
Apart from the inhibition of proliferation and decrease in the infectivity, gamma irradiation 
was also been observed to cause fragmentation of chromosomes in L. major and consequently 
produce changes in the karyotypes of these organisms (Seo et al., 1993). The inhibition of 
proliferation and decrease in the infectivity might be because of destruction of the parasite’s 
chromosomes. Certain doses of gamma irradiation are able to destroy the infectivity of the 
parasites but not their viability. Mice and chicken-embryos repeatedly inoculated with the 
irradiated T. cruzi parasites could not get infected (Brener, 1962 and Chiari et al., 1968).  
 
Resistance to the ionizing gamma radiation varies within the pathogenic kinetoplastids as 
between other organisms. Irradiation doses of higher than 1000 Gy have shown to inhibit the 
mobility and reproductively of culture forms of T. cruzi (Silva et al., 1967 and Chiari et al., 
1968). Blood forms of T.brucei gambeinse are sensitive to gamma radiation doses higher than 
120Gy (Halberstaedter, 1938) while L.major culture forms can endure gamma radiation doses 
up to 500 Gy (Seo et al., 1993). It is possible that the mechanisms behind these parasites 
radiation resistance maybe part of the responses against the stresses the organisms face such 
as changes in temperature, pH and osmolarity in the insect’s saliva and gut (Kollien and 
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Schaub, 2000). Inaddition, blood digestion by the vector may be sources of heme molecules 
required for the Fenton’s chemical reaction that produce reactive chemical species and 
consequently causing oxidative stress (Kollien and Schaub, 2000).  
 
Although C. fasciculata parasites have been used previously as a model organisms to study 
kDNA replication and repair mechanisms of the pathogenic kinetoplastids (Saxowsky et al., 
2002, Shapiro and Englund, 1995), no any study has investigated the responses of these 
parasites to gamma irradiation and that it is still unclear to wether the parasites are 
Trypanosomes or Leishimania—like, in terms of their DNA replication and repair 
mechanisms after stress. We therefore initiated studies to investigate theresponses of C. 
fasciculata parasites to gamma radiation. We particularly investigated the effect of the 
irradiation on the cell growth, metabolic viability, motility and morphology as parameters of 
our investigation. In the long term, this will provide basis in understanding the post-
irradiation DNA damage and repair mechanisms in C. fasciculata as a model for the 
corresponding systems in the pathogenic kinetoplastids. 
 
4.2 Experimental procedures 
4.2.1 Parasites strain and cell culture 
The C. fasciculata promastigotes clone HS6 was used in this experiment and maintained in a 
culture media as previously described in methods section of chapter 2. The parasites were 
sub-cultured every 2-3 days to ensure log growth phase for subsequent experiments. 
4.2.2 Irradiation of parasites 
C.fasciculatalog phase choanoamastigotes in tissue culture plastic flasks were irradiated with 
ionising gamma rays from a Cobalt-60 irradiator at the University of St-Andrews, School of 
Medicine Radiation facility. This apparatus has a dose rate of 2.51 Grays per minute (Co-60 
half-life is 11.833 years). 
4.2.3 Growth experiments 
A total of 200ml medium was inoculated with log phase C. fasciculata choanoamastigotes to 
a final density of 2x106 cells/ml. The medium containing cells was then divided into five cell 
flasks each containing 40 ml. The four flasks were irradiated at room temperature with 
varying gamma dosages (250, 500, 750 and 1000 Gy); the non-irradiated control flask (0 Gy) 
was left at room temperature the same length of time as the irradiated flasks. Cells were 
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counted using a haemocytometer immediately after irradiation and at 24 hours interval for 5 
days post-irradiation to generate the growth curve. 
4.2.4 Parasites Viability experiments 
Two techniques – the Trypan blue exclusion and the Resazurin (Alamar blue) reduction 
methods were employed to determine the viability cells after exposure to the radiation. For 
the Trypan blue exclusion test, 100 µl of cells was suspended in an equal volume of 0.4% 
Trypan blue solution. A 20µl cell suspension was thenloaded into a haemocytometer and 
examined immediately under a microscope at low magnification. The blue stained cells were 
counted and compared against the total number of cells counted to determine the structural 
viability using the equation: % viable cells = [1 – (Number of blue cells counted ÷ Number of 
total cells counted)] × 100. 
For the Alamar blue reduction assay, aliquots of 25% (10 ml) of the medium containing the 
irradiated cells, control cells (100% viability) and the cell-free medium were inoculated in the 
96 well plates (200 µl/well) and incubated at 27oC in a shaker incubator for 68 hours.After 68 
hours, 20 µl of Alamar blue (0.125 mg/ml) was added to the wells and the plates further 
incubated for 4 hours.  Fluorescence measurements were performed with the Spectra Max 
Gemini XPS Microplate reader (Gemini XPS, Molecular devices) at excitation wavelength of 
530nm and 590 nm emission wavelength of 530 nm. The experiments were performed in 
duplicate and the results were averaged over eight replicate wells and normalised using an 
equation: Activity (%) = [1 − (FUntreated– FTreated) / (FUntreated– FCell free)] ×100, where Ftreated 
corresponds to the emitted fluorescent signal expressed in arbitrary fluorescence units for the 
treated; and FUntreated andFCell free correspond to the mean fluorescent signal of the untreated 
and the cell free wells, respectively. 
4.2.5 Parasites motility estimates 
A conventional wet mount technique was used to estimate a fraction of the parasites that were 
motile after exposed to ionising gamma radiation stress. Briefly, a 20 µl of cell suspension 
was pipetted onto a clean microscope slide and a coverslip gently lowered onto the sample. 
The slide was immediately examined using a microscope with a 20X objective. At least ten 
widely spaced fields were examined to provide estimates of percentage motile cells. 
4.2.6 Parasites morphology 
To assess the parasites morphology after irradiation, cells were stained with Giemsa solution 
(Sigma-Aldrich) using a standard Giemsa staining protocol and visualised on a microscope. 
Briefly, slides containing cells were fixed in methanol for 5 minute and stained with Giemsa 
solution for 30 minutes. The slides were then washed gently with deionised water and air-
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dried prior to microscopy. At least 10 widely spaced fields were examined per sample and 5 
images were taken for morphology evaluation. 
4.3 Results and Discussion 
In order to ascertain the response of C. fasciculata choanoamastigotes to the ionising gamma 
radiation, the cells were exposed to varying gamma dosages with all finishing at the same 
time experimental set-up. The non-irradiated control flaskwas left at room temperature the 
same time duration as the irradiated flasks to generate the growth curve as shown in Fig. 22. 
A clear correlation was observed between gamma raadiation doses and the decrease in the 
cell growth. The control non-irradiated cells reached early stationary stage of growth within 
48 hours, more quickly than the irradiated cells. Remarkably, we found that a gamma dose of 
1000 Gy was able to arrest the growth of C. fasciculata the first 24 hour of post-irradiation 
(Fig. 22). Culture forms of T. cruzi were observed to endure gamma radiation doses as high 
as 1000 Gy while their blood stream forms could only tolerate doses not more than 300 Gy 
(Silva et al., 1967 and Chiari et al., 1968). In contrast, bloodstream forms of T.brucei 
gambiense and cultured forms of L.major can only endure gamma doses of up to 120 and 500 
Gy (Halberstaedter, 1938 and Seo et al., 1993), respectively. Surprisingly, a gamma ray dose 
of 500 Gy was able to arrest the growth of T. cruzi for 96 hours (Vieiraet al., 2014), longer 
than what have been currently observed with C. fasciculata parasites, which are able to 
resume normal growth just after 24 hours post-irradiation with as much as 1000 Gy. The C. 
fasciculata postirradiation growth kinetics might therefore be similar to the observed post-
irradiation growth kinetics of a radiation resistant bacterium D. Radiodurans, which is also 
able to resume normal growth within 9-24 hours due to its robust DNA repair machinery (Liu 
et al., 2003). This observation may suggest that C. fasciculata parasites posses active post-
irradiation recovery machinery compared to T. cruzi parasites. One might agree that since C. 
fasciculata parasites grows almost everywhere mostly in the harsh environments and 
unprotected from the UV from the sun, the parasites have developed rapid recovery 
mechanisms to cope up with the oxidative stresses in their environments. A comparative and 
systematic genome-wide investigation of the genes and pathways involved in these unique 
parasites post-stress recovery mechanisms would therefore be useful for further 
understanding of how other kinetoplastids respond to and recover from such similar stress. 
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Figure 22. Growth curve of C. fasciculata choanoamastigotes after exposed to varying 
ionising gamma doses. Cultures were microscopically monitored and counted using a 
haemocytometer at 0 hour post-irradiation and 24 hours intervals for 5 days. Average count 
was obtained from two measurements per sample. 
 
To determine the viability of the parasites at 0 hours and at 72 hours of post-irradiation, two 
techniques; the Trypan blue dye exclusion and the Alamar blue (Resazurin) reduction 
methods were employed, respectively.  
The Trypan blue dye exclusion test has been widely used to determine the number of viable 
cells present in a cell suspension (Strober, 2001). It is based on the assumption that live cells 
possess intact cell membranes that exclude certain dyes such as Trypan blue whereas dead 
cells do not. Viable cells therefore, have a clear cytoplasm whereas a non-viable cell has a 
blue cytoplasm (Strober, 2001). In our experiments, no significant differences in cell viability 
after exposure to different radiation doses were observed at 0 hours (p≥0.05) (Fig. 23a). This 
observation is consistent with Emmet. (1950)  and Chiari et al. (1968), who reported that 
some gamma dosages can only destroy the parasites infectivity but not their viability. This 
may suggest that unlike the DNA, which is a well-known primary target of irradiation 
damage, cell membranes are perhaps not altered with the gamma radiation induced oxidative 
stress. However, the decrease in the cell permeability due to the irradiation itself should not 
be ignored as a possible cause of this observation. Perhaps the irradiation itself rendered cells 
less permeable to the dye as demonstrated by Khale and his colleagues (Khare et al., 1982), 
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where the uptake of several amino acids was reduced in Candida albicans following 
exposure to various gamma dosages.  The cell viability or rather the cell membrane integrity 
of post-irradiation when assessed with Trypan blue or any other dye exclusion method should 
therefore be interpreted with caution unless assessed in parallel with other specific parameters 
of membrane damage such as sulfhydryl content, potassium ion permeability, sodium ion and 
many more.  
Alamar blue reagent has been widely used over the past 50 years in studies on cell viability 
and cytotoxicity in a range of biological and environmental systems (Rampersad, 2012). Live 
cells maintain a reducing environment within the cytosol of the cell. Resazurin, the active 
ingredient of alamar blue reagent, is a non-toxic, cell permeable compound that is blue in 
colour and virtually non-fluorescent. Upon entering cells, resazurin is reduced to resorufin, a 
compound that is red in colour and highly fluorescent. Live cells are able to convert resazurin 
to resorufin in proportional to the cell density, and thus increasing the overall fluorescence 
and colour of the media surrounding cells while dead cells. In our experiments, a clear 
correlation was observed between gamma dosages and the decrease in the cell viability after 
72 hours of post-irradiation when assessed with alamar blue reduction assay (Fig. 23b). The 
dose dependent decrease in the viability of C. fasciculata parasites currently observed is 
consistent with other studies on the pathogenic kinetoplastids (Chiari et al., 1968and Regis-
da-Silva et al., 2006). 
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Figure 23. Viability of C. fasciculata choanoamastigotes post-irradiation. (a) Viability at 0 
hours assessed with Trypan blue exclusion test. (b) Viability after 72 hours of irradiation 
assessed with Alamar blue reduction assay. Values represent the mean±SE of two 
experiments each performed with eight replicate wells. 
 
The motility of the parasites was not significally affected with gamma radiation doses (up to 
1000 Gys) (Fig. 24). Intriguingly, the parasites were very motile irrespective of their gamma 
irradiation doses when observed under the microscope immediately after irradiation. 
However, similar studies on T. cruzi have reported that the mobility of the parasites were 
rapidly affected with gamma dose of 4660 Gys; employing doses of 3500, 2450 and 1550Gys, 
the mobility could be observed up to 72 hours post-irradiation, after which it gradually 
decreased (Chiari et al., 1968). We can therefore speculate that doses less than 1550 Gys 
could perhaps have little or no effect on the motility of either T. cruzi or C.fasciculata. 
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Figure 24. Motility of C. fasciculata choanoamastigotes at 0 hours of post-irradiation. A wet 
mount was prepared for each sample immediately after irradiation to determine cells motility. 
Motility was calculated as percentages of mobile cells out of all cells counted.Values 
represent the mean±SE of three counts. 
 
We also did not observed significant morphological changes of the C. fasciculata parasites 
after exposure to gamma doses up to 1000Gy, contraly to T. cruzi parasites that are able to 
maintain their morphologies when exposed to gamma doses not exceeding 600 Gy.   
However, at 0 hours post-irradition, cells subjected to 250 Gy and 1000Gy were long and 
slender and stained less dense than the controls (Fig. 25). Structures such as the nucleus, 
kinetoplast and flagillum could be observed after 120 hrs of post-irraditon indicating a 
recovery. Future studies should aim to use more sensitive stains and powerful tools like 
electron microscopy to precisely assess morphological changes of individual ultrastructural 
features of the parasites after irradiation.  
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Figure 25. Morphology of C. fasciculata at 0 hours and 120 hours of post-irradiation. Cells 
were stained with 10% Giemsa solution.  At least 10 widely spaced fields were examined per 
sample and 5 images were taken for morphology evaluation. 
 
In general, although it was also not possible to conduct a side-by-side comparative study of 
the susceptibility of C. fasciculata and the pathogenic kinetoplastids to gamma irradition, C. 
fasciculata appears to be more like T. cruzi in respect to the resistant to gamma radiation and  
suggests that these parasites may perharps posses an enhanced postirradiation recovery 
mechanism as compared to the pathogenic kinetoplastids. 
C. fasciculata may therefore be a suitable organism fundamental for studies aimed at 
understanding the rapid kDNA repair mechanisms and protein expression profiles in the 
kinetoplastid pathogens when exposed to harmful environments. 
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5. Chapter 5: General discussion and principal conclusions 
 
5.1 General Discussion 
This project aimed at exploring the utilization of C. fasciculata as a convenient model 
organism to study the biology of the pathogenic kinetoplastids and its suitability as a drug 
discovery vehicle.We specifically aimed to; (i) Develop and validate an expression system 
that can be used to purify protein complexes from C.fasciculata. (ii) Develop C. fasciculata 
as a non-pathogenic compound screening model for kinetoplastid diseases. (iii) Study the 
effects of ionizing Gamma radiation on the model kinetoplastid C.fasciculata. 
One may argue on the significance of conducting these studies in C. fasciculata parasites, 
given that many tools are currently available to do such studies directly in trypanosomes or 
leishmania species. Nevertheless, C. fasciculata is a monogenic parasite of insects and 
therefore may not have some important biological pathways found in the digenic 
kinetoplastid pathogens. For example, the biological payways that help the pathogenic 
kinetoplastids to survive in stressful environments found in the veterbrate hosts. This may 
make C.fasculata limited in the number of pathways representing potentially druggable 
targets shared with the pathogenic kinetoplastids. In addition, conducting studies in C. 
fasciculata and then validating them in the actual pathogenic kinetoplastids seem to be a very 
long process than conducting these studies direct on the kinetoplastid pathogens. However, 
although this might be the case, studies on the pathogenic kinetoplastids have for been 
hampered by the need to culture these highly infectious organisms safely in the laboratory. 
The dedicated containment level 3 (cat 3) facilities are needed for this purpose but these are 
very expensive to build, maintain and equip as experimental apparatus cannot be moved in 
and out of the cat 3 lab without rigorous decontamination. The trypanosomes T. brucei brucei, 
the causative organism of liverstock trypanosomiasis and leishmania tarentolae, a protozoan 
parasite of Gecko has been widely used in studies as safer altenatives of their human 
pathogenic couterparts. However, unlike these models, C. fasciculata have a shorter 
generation time and can beeasily grown to high densities using comparably less expensive 
media in a standard laboratory, thus reducing the time required to harvest adequate numbers 
of parasites for some large-scale applications. Nevertheless, Crithidia is an excellent example 
of a parasite that can easily be isolated and cultured outside of its normal host organism. It is 
an ideal model to study the biology of not only a single kinetoplastid but rather three 
pathogenic kinetoplastid (T.brucei, T. cruzi and leishmania species). It is also important to 
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notice that the T. brucei brucei, which was traditionaly known to be human non-infectious 
organism, has been reported to cause disease in humans (Deborggraeve et al., 2008). 
Moreover, unlike the trypanomes models, C. fasciculata is easly amenable to molecular 
genetic and biochemical analysis and itscomplete genome has already been determined and is 
publically available online to facilitate these studies. 
 
In this study, we have confirmed that C. fasciculata can be cultivated in high yields (to high 
cell densities) using our inexpensive serum-free media and can be handled in a standard 
laboratory without specific bio-safety precautions. By modifying an existing plasmid from 
Tetaud and his colleagues (Tetaud et al., 2002), we have successfully constructed plasmid 
pNUS-PTPcH, which can be utilised for expressing and purifying kinetoplastids protein 
complexes. Protein expressed from pNUS-PTPcH has the PTP tag, a variant of the TAP tag 
(but with CBP in TAP is replaced by the protein C peptide). The PTP tag overcomes some of 
the limitations of the conventional TAP method as described elsewhere (Schimanski et al. 
2005; Schimanski et al., 2003; Drakes et al., 2005; Palfi et al., 2005). We have shown that C. 
fasciculata can be efficiently transfected with pNUS-PTPcH by electroporation with Amaxa 
program X-014 (Burcard et al., 2007), and that the encoded PTP tagged proteins can be 
readily detected by Western blotting. The pNUS-PTPcH plasmid was maintained as a circular 
extrachromosomal DNA and conferred a hygromycin resistance on C.fasciculate parasites. 
As a proof of concept, we have successfully cloned, expressed and isolated C. fasciculata 
proteins and their interacting partners though TAP. PTP purification from cell lysates 
expressing RFC3-PTPcH identifies its interacting proteins RFC1, RFC2, RFC4, RFC5 and 
RAD17, while PTP purification from cell lysates expressing RRP4-PTPcH identifies RRP6, 
EAP1, RRP45, RRP40, RRP41B, CSL4, EAP2, RRP41A and EAP4 that have been 
previously isolated in T.brucei exosome complex (Estevez et al., 2001).  
Since RFC complex has not been characterised in any kinetoplastid organism, the 
identification of its associated subunits in C. fasciculate will provide a basis for future studies 
on these complexes in other kinetoplastid pathogens. In particular, the identification of 
Rad17-RFC as the only alternative complex in our immunoprecipitation experiments may 
suggest that this complex co-exist with the RFC complex in C. fasciculata contraly to what 
have been observed in other organisms such as S.cerevisiae (Green et al., 2000). Nevertheless, 
although Rad 17 and other large RLC subunits Ctf18 and Elg1 have similar sequence to 
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RFC1 but are considered non-essential genes (reviewed in Kim and MacNeill, 2003), the 
identification of Rad17 as only RLC subunit in our experiments may also suggest that 
perharps Rad17 have some essential roles in these specific parasites and should be properly 
explored as a potential target for new drugs. 
Despite the conserved features and components, the exosomes of different eukaryotes are 
generally not identical. The genes of the six Rnase PH in human exosome complex do not 
reveal any orthologous in yeast or trypanosomes and there are no homologs for Rrp43p or 
Mtr3 in T. brucei (Estevez et al., 2001). Moreover, the T. brucei and yeast exosome complex 
have the RRP44 that is not present in human exosomes (Estevez et al., 2001). We also did not 
find C. fasciculata homologs of T. brucei RRP44 in both our database searches and 
immunoprecipitation experiments and never has itbeen identified in Leishmania species 
(Cristodero et al., 2008). This may suggest that kinetoplastid organisms, RRP44 is perharps 
conserved in T. brucei.  All components of the yeast and human exosome except Rrp6p are 
essential for viability. Contraly, depleting RRP6 in trypanosomes caused a loss of both 
RRP45 and RRP4, suggesting that unlike in yeast or human cells, RRP6 may have an 
important role in the trypanosomes (Estevez and Clayton, 2010). Depletion of the Rnase PH 
domain proteins RRP41 and EAP1 disassembled the T.brucei exosome complex but had no 
effect on the humun exosome complex (Estevez and Clayton, 2010).  Functionally, the T. 
brucei RRP4 exosome subunit has a processive exonucleolytic activity while its yeast 
counterpart has a distributative mode of action (Mitchell et al., 1997). The observed 
uniqueness in the composition and functions of trypanosomes exosomes as compared to yeast 
and more importantly human’s exosomes makes them ideal drug targets.  In particular, 
utilising the RRP44 as a target protein in human trypanosome infection implies that the drug 
will specifically inhibit the activity of RRP44 in the trypanosomes. Using the trypanosomes 
exosomes subunits that have homologues in the host (humans) as drug target will result into a 
drug cross attacking the host essential exosome subunits causing disastrous effects. More 
studies are therefore, needed to characterise the molecular mechanism of RRP44 subunit to 
be considered as a drug target and perhaps a potential biomarker to aid in diagnosis of 
trypanosomes. 
Although we have shown that the pNUS-PTPcH plasmid can be utilized to express and 
isolate kinetoplastids proteins in C. fasciculata, a few points need to be critically looked at 
for its wider utility. For example, western blots of extracts from cell lines expressing the 
empty pNUS-PTPcH revealed a very weak protein band for a PTP tag. However, the fact that 
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a protein band though still weak was observed in the immunoblots of its extract after 4 weeks 
make us speculate that perhaps a few copy numbers of pNUS-PTPcH plasmid are maintained 
in the parasites. Future work should therefore consider quantifying copies of pNUS-PTPcH 
maintained in the parasites. Epitope tags and stringency conditions applied in the purification 
process might interfere with functions of the proteins as shown in different studies elsewhere. 
Whether the protein subunits we purified in this study are functional or not is still unknown. 
It is also imperative to point out that although we have demonstrated the successful PTP 
purification of replication factor C and exosome complexes proteins, we did not quantify the 
yield of the proteins purified neither did we manage to pull down other novel proteins as 
initially anticipated. Future work should therefore consider monitoring the purification 
efficiency by quantifying the yield of the proteins at each step of the purification process.  In 
addition, it will be important to consider optimizing purification conditions such as buffers 
used for preparation of cell-free extracts for efficient extraction and purification.  Since we 
used a dounce homogenisation to lyse the cells, other cell lysis methods such as sonication 
should be considered in the future for comparisons. Nonetheless, while a C-terminal tag has 
the inherent advantage that only fully synthesized proteins carry the tag, some proteins are 
inactivated by a C-terminal tag. These proteins may accept a tag fusion at the N-terminal and 
may improve the purification efficiency (Schimanski et al., 2005). Future studies should 
therefore consider altenative-tagging ways to compare the efficiency of each tagging on 
purification. 
We also did not control our purification experiments to avoid the co-purification of 
contaminating proteins such as the major cytoskeletal proteins α and β tubulin that bind to the 
resins non-specifically. Although we used the C. fasciculata cell line expressing the empty 
pNUS-PTPcH as a specificity control, the ideal control experiment was to generate a cell 
lines which expressed the PTP fused to an unrelated protein, which is preferentially expressed 
in the same cellular compartment as the protein of interest and then prepare the extract and 
perform TAP purifications and protein analyses in parallel. In this case, we would have 
excluded proteins that potentially interact with the TAP tag itself. Since we have cell lines for 
pNUS-DCC1-PTP construct (DCC1 is a subunit of the alternative Ctf18-Dcc1-Ctf8 
replication factor C complex) and pNUS-Tfb4-PTP construct (Tfb4 is a subunit of theTFIIH 
complex), we plan to make further optimisations in our purification process and conduct 
more TAP experiments with these cell lines with an anticipation to pull down some novel 
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proteins which will be further characterised and validated as potential drug targets in the 
actual pathogenic kinetoplastids. 
 
One promising approach for identifying new compounds for the drug development pipeline 
for treatment of patients with diseases caused by kinetoplastids is by HTS of compound 
collections.  Simple in vitro cell culture systems for axenic growth of pathogenic 
kinetoplastids has led to the exploration of a various cost effective whole cell assay formats 
to serve as tools for HTS with the aim of assessing a large set of chemical libraries and 
prioritize newly synthesised analogues in hit-to-lead and ultimately lead optimisation phases 
of the drug discovery process (Muskavitch et al., 2008).  Considering that C. fasciculata 
shares a variety of biochemical mechanisms such as polyamine synthesis and methionin 
salvage with the medically and veterinary important pathogenic kinetoplastids, Tanasor and 
collegues initiated work of utilising a non-pathigenic kinetoplastid C. fasciculata to screen 
medicinal plants that could posses cross activities against the pathogenic kinetoplastids 
(Tanasor et al., 2006). Extending this work, we have currently developed a simple, robust and 
reproducible alamar blue reduction--C. fasciculata based phenotypic screening assay that can 
facilitate the process of predicting potential anti-kinetoplastid compounds, which can be later 
followed up against the pathogenic kinetoplastids. We have shown that the developed assay 
fulfils the necessary and desirable criteria for a HTS. Although this assay has been developed 
in a 96-well format, it may be amenable to automated liquid handler and used in the 384-well 
formats. Utilising the developed assay, we have identified attractive chemical scaffolds in the 
Open access chemical boxes that will be considered for follow up testing in the actual 
pathogenic kinetoplastids. In particular, we have identified a Pyrimidin-4-amine chemical 
scaffold which has derivatives with well known kinase and cytochrome P450 inhibitors 
(Gunatilleke et al., 2012 and Pena et al., 2016), the quinazoline-2,4-diamine scaffold which 
are also well referenced in the literature as folate synthase pathway inhibitors in  
Leishmania,Ttrypanosoma and Plasmodium (Pez et al.,2003; Khabnadideh et al.,2005; 
Muller et al.,2013) and the  5-nitrofuran-2-yl derivatives which are substrates for type I 
nitroreductases of various parasites that metabolise them into nitrile toxic products (Hall et al., 
2011) and are also inhibitors of Mycobacterium tuberculosis H37RV (Doreswamy and 
Chanabasayya, 2013). Nevertheless, our screening revealed the potency of compounds 
harbouring Quinolin-8-ol and 2-pyridinyl moieties previously reported for their antifungal 
properties (Musiol et al., 2006) and CYP51 inhibitors (Meissner et al., 2013 and Kaiser et al., 
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2015), respectively. Weather these compounds are hitting same targets shared betweenC. 
fasciculata and the pathogenic kinetoplastids remains an open question. However, 
considering the evolutionary proximity and the number of conserved cellurar pathways 
between C. fasciculata and the pathogenic kinetoplastids, one may agree that these 
compounds are likely to target the same pathways and therefore compounds with anti-
Crithidial activities should be more likely to work against the pathogenic kinetoplastids. 
To our knowledge, no any fluorochrome viability assay protocol for C. fasciculata parasites 
has been reported. Therefore, it is impossible to make direct comparisons and conclusions 
that this assay is ideal than any other alternative viability detection methods currently 
available unless this assay was developed and evaluated in parallel with a similar viability 
detection method. However, the fact that C. fasciculata can be used to predict potential 
compounds against not only one specific pathogenic kinetoplastids is of high importance.  
Since the 96-well method may not be suitable for undertaking HTS of larger libraries because 
of intensive labour requirement and expenses, it will be of value to upgrade the Alamar blue 
reduction-Crithidia assay into a 384-well format. 
Although we managed to identify such attractive chemical scaffolds, it attempts to conduct 
further comprehensive optimisations and analysis of the near neighbour compounds was not 
successful, mainly due to the cost of purchasing the related compounds and time factors.  
Future work should therefore consider further structural optimisation and investigation of the 
identified chemical scaffolds prior to testing them against T. brucei, T. cruzi, Leishmania and 
mammalian cell lines. However, additional assays such as serum shift, time to kill and 
reversibility of compound effect of the structurally optimised compounds should be 
considered to provide further criteria for advancing them through hit-to-lead phase of the 
project.  
 
 
Responses to the ionizing gamma radiation-induced oxidative stress varies form one 
organism to another and within the kinetoplastids. Generally, the primary target of gamma 
radiation in kinetoplastids is the kDNA (Genois et al., 2014).  Although the effect of gamma 
ionising radiation on the kDNA damage and associated repair mechanisms in pathogenic 
kinetoplastids have been extensively studied, little is known on howC. fasciculata responds to 
such radiations. More importantly, despite being used as model organism to study kDNA 
replication and repair mechanisms in the pathogenic kinetoplastids previously (Saxowsky et 
al., 2002; Shapiro and Englund, 1995, Ryan et al., 1988), it is still unclear to wether C. 
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fasciculataparasitesbehave more like trypanosomes or leishmania when it comes to 
theirresponses to irradiation.In this study, we have demonstrated that compared to culture 
forms of T. cruzi, which undergoes growth arrest for 96 hours after exposed to 500 Gy 
(Vieira et al., 2014), C. fasciculata is able to recover and resume normal growth within 24 
hours after being subjected to gamma ray dose as high as 1000 Gy.  It is important to notice 
that theC. fasciculata observed post-irradiation growth kinetics might be similar to the 
observed post-irradiation growth kinetics of a radiation resistant bacterium D. radiodurans, 
which has also a shorter (9-24 hours) post-irradiation cell growth arrestattributed to its robust 
DNA repair machinery (Liu et al., 2003). This observation may suggest that Crithidia posses 
very active post-irradiation recovery mechanisms as compared to other kinetoplastids.  
However, the effects of gamma irradiation on C. fasciculata currently reported should be 
interpreted with caution mainly because of the weakness of our experimental design. Our 
main aim was to investigate the response of C. fasciculata to ionizing gamma radiation as 
compared to the other kinetoplastids. Therefore, the ideal experimental design would have to 
conduct the experiments in parallel with the other kinetoplastids of interests to avoid bias. 
Future work should therefore aim to conduct a well-designed comparative study of the 
susceptibility of these organisms to gamma irradiation to provide undoubted data on the 
responses of these organisms to irradiation. Nevertheless, for detailed assessment of 
morphological changes, the extent of DNA damage and the repair kinetics at the level of a 
single cell, future studies should consider utilising more powerful tools like electron 
microscopy and assays like comet assay aspreviously described in Lolenzo et al. (2013). 
 
5.2 Principal conclusions 
The overall aim of this study was to explore the utilization of C. fasciculata as a convenient 
model organism to study the cell biology of the pathogenic kinetoplastidsand its suitability as 
a drug discovery vehicle. This study has confirmed that C. fasciculata parasites can facilitate 
various important aspects aimed at studying the biology of different pathogenic kinetoplastids, 
an imperative step towards the discovery of their respective new drugs, new diagnostic 
approaches as well as preventive mechanisms.  
 
The current study reports the construction of plasmid pNUS-PTPcH that can be utilised to 
express PTP tagged kinetoplastids proteins in C. fasciculata for subsequent purification. As a 
proof of concept, we have shown that C. fasciculata can be efficiently transfected with this 
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plasmid to facilitate the isolation of two protein complexes: replication factor C and the 
exosome.  We have demonstrated that the expressed PTP tagged-replication factor C subunit 
3 (PTP-RFC3) co-purifies with RFC1, RFC2, RFC4, RFC5 and RAD17, and that the PTP 
tagged exosome subunit RRP4 co-purifies with RRP6, EAP1, RRP45, RRP40, RRP41B, 
CSL4, EAP2, RRP41A and EAP4. RFC complex has never been characterised in any 
kinetoplastid organism. Therefore, the identification of its associated subunits in C. 
Fasciculate may provide basis for future studies on these complexes in other kinetoplastid 
pathogens. In particular, the identification of Rad17-RFC as the only alternative complex in 
our immunoprecipitation experiments may suggest that this complex co-exist with the RFC 
complex in C. fasciculata contraly to what have been previously observed in other organisms. 
As a continuation of this project, we are planning to conduct further TAP experiments on 
various PTP-tagged kinetoplastid proteins with an anticipation to pull down some novel 
proteins that will be further characterised and validated as potential drug targets in the actual 
pathogenic kinetoplastids.  
This study also reports the development of a simple and robust resazurin-reduction cell 
viability-screening assay with C. fasciculata that can be used to predict compounds with 
potential activities against the pathogenic kinetoplastids. The developed assay fulfils the 
necessary and desirable criteria for a HTS and therefore could speed up the process of hit-to-
lead and ultimately lead optimisation phases in the drug discovery cascade. Utilising the 
current developed assay, we repurposed the open access chemical boxes for anti-crithidial 
compounds that have revealed attractive chemical scaffolds that will be followed up against 
the actual pathogenic kinetoplastids. We are considering developing a C. fasciculata cell line 
resistant to some of the identified scaffolds and use the whole genome sequencing and 
recombineering techniques to identify specific drug targets in C. fasciculata. Plans are also 
on the way to upgrade the 96-well format Resazurin reduction-Crithidia based assay into a 
384-well format compatible for large compound libraries. 
Nevertheless, the current study has revealed that C. fasciculata parasites behave more like T. 
cruzi than T.brucei or leishmania in terms of their responses to irradiation. However, 
compared to cultured forms of T. cruzi that undergo growth arrest for 96 hours after exposure 
to 500 Gy of gamma radiation, C. fasciculata is able to recover and resume normal growth 
within 24 hours after being subjected to doses as high as 1000 Gy.  These findings form basis 
in understanding the kDNA repair mechanisms in the kinetoplastid pathogens when exposed 
to such stressful conditions. Moreover, since work have already been initiated to determine 
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changes in gene expression during DNA repair and cell recovery mechanisms following 
ionizing irradiation in T. cruzi, it might be very interesting to extend this work to C. 
fasciculata to find out if there is any overlap in the genes up-regulated or down-regulated 
following exposure to gamma radiation. 
 
In general, we have shown that C. fasciculata can be utilised as a covinient and ideal model 
organism to study the biology and speed up the drug discovery cascade of the pathogenic 
kinetoplastids.  In particular, the constructed protein expression vector, the developed 
screening assay and the observed responses of C. fasciculata to gamma irradiation will form 
basis for future studies aimed to discover novel drugs, new diagnostic approaches and 
preventive mechanisms for kinetoplastid diseases. 
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7. Appendices 
 
7.1 Appendix 1. The C. fasciculata serum free defined growth media recipe. 
 
 
The pH of the media was adjusted to 8.0 with either NaOH or HCl before adding Haemin 
(final concentration of 10µg/ml). The media was filter sterilised using 0.22µm stericups 
vacuum filters (Merck Millipore) and stored in the cold room. 
 
 
7.2 Appendix 2. Extraction of  C. fasciculata genomic DNA. 
 
Ingredients Stock concentration In 1000 µl Final 
concentratio 
Tris-HCl 1 M 10 µl 10 mM 
NaCl 5 M 20 µl 100 mM 
EDTA pH 8.0 0.5 M 50 µl 25 mM 
SDS 10% 50 µl 0.5% 
Proteinase K 20 mg/ml 5 µl 0.1 mg/ml 
Distilled water  865 µl  
 
A 1ml of media containing C. fasciculata cells in log phase was centrifuged at 2000g for 5 
minutes. The cell pellet was then suspended in lysis buffer (see table below) to the final 
volume of 1000 µl. Cells were lysed and incubated at 56oC for at least 3 hours and the gDNA 
was precipitated with 500 µl of absolute ethanol. The DNA was then spooled on a sterile 
pipette tip and washed 2 times with 500 µl of 70% ethanol. The ethanol was allowed to air 
dry off the spooled gDNA and the gDNA was dissolved into 100 µl elution buffer pH 8.5 
(from PCR clean up Kit) before storage in a +4oC fridge. 
	
	
	
	
	
Ingredient In 1 Litre distilled water  
Yeast Extract 5 g 
Tryptone 4 g 
Sucrose 15 g 
Triethanolamine 4.37 g 
Tween 80  4.72 mL 
Haemin (2.5mg in 1 ml of 50 mM NaOH) 4 mL 
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7.3 Appendix 3. The designed forward and reverse primers that were used to 
amplify the ORFs of target subunits. 
 
Protein 
subunit 
Primers Sequences Descriptions 
RFC3 
 
CfRFC3-5Nde GGTGGTGGTGCATATGGCA
ACTTCGAAG 
To PCR amplify the 
RFC3 insert sequence. 
CfRFC3-3Not GGTGGTGGTGGCGGCCGCC
AGCGCTGC 
To PCR amplify the 
RFC3 insert sequence. 
RRP4 CfRRP4-5Nde GGTGGTGGTGCATATGTCG
TCAGGAGTC 
To PCR amplify the 
RRP4 insert sequence. 
CfRRP4-3Not GGTGGTGGTGGCGGCCGCC
CTGGCGGC 
To PCR amplify the 
RRP4 insert sequence. 
 
Vector 
pC-Seq-F GCAAGGCGATTAAGTTGGG
TAAC 
To sequence inserts 
within PTP vector 
pC-Seq-R TGTTGTCCACGGCTTCATCG
TG 
To sequence inserts 
within PTP vector 
 
The first 10 are random bases followed by a NdeI or NotI sequence (in yellow) and ORF 
sequence of a target subunit gene. The primers pC-Seq-F and pC-Seq-R were used to confirm 
the fidelity of cloning process. Oligonucleotides were ordered from Integrated DNA 
Technologies (IDT). 
 
7.4 Appendix 4(a).  A conventional  PCR reaction recipe and cycling 
conditions using Q5 High-fidelity DNA polymerase enzyme. 
	
Reaction recipe of PCR using Q5 High-fidelity DNA Polymerase 
Component 50 µl reaction Final concentration 
Template DNA 5 µl 500 ng 
5xQ5 Reaction buffer 10 µl 1x 
10 mM dNTPs 1 µl 200 uM 
Forward primer(100 µM) 0.5 µl 1 mM 
Reverse primer (100 µM) 0.5 µl 1 mM 
Q5 High fidelity DNA polymerase 0.5 µl 0.02 U/µl 
5xQ5 High GC enhancer(optional) 10 µl 1x 
Nuclease free water 22.5 µl  
Final reaction volume 50 µl  
                               Thermocycling conditions for PCR 
Step Temperature (0C) Time  
Initial Denaturation  98 30 sec 
 
30 Cycles 
Denaturation 98 10 sec 
Annealing  70 20 sec 
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Extension 72 45 sec 
Final extension 72 2 min 
All reaction components were assembled on ice and the reaction mixture was quickly 
transferred to a thermocycler preheated to the denaturation temperature (98oC). 
	
7.5 Appendix 4(b). PCR reaction recipe and cycling conditions for a standard 
My Taq Red MIX. 
 
Component 20 µl Reaction 
Template 5 µl  
Primers (4 µM each) 5 µl 
My Taq Red Mix,2x 10 µl 
Final reaction volume 20 µl 
Step  Temperature  Time  Cycles  
Initial denaturation  95oC 1 min 1 
Denaturation  95oC 15 sec  
30 Annealing  65 oC 15 sec 
Extension  72 oC 10 sec 
 
All reaction components were assembled on ice and the reaction mixture was quickly 
transferred to a thermocycler preheated to the denaturation temperature (95oC). 
7.6 Appendix 5.  Preparative restriction/diagnostic digest and ligation 
experimental set up. 
	
Component  Reaction (20 µl) 
                                      Analytical/Preparative digest 
DNA 2 µl (1-20 µg) 
Buffer x2 10 µl 
Restriction enzymes (NdeI and NotI) 2 µl (1 µl each) 
Sterile water  6 µl 
 Dephosphorisation 
Antarctic Phosphatase Rxn Buffer (10X) 4 µl  
Antarctic Phosphatase 5 µl 
Sterile water  11 µl 
Ligations (20 µl reaction) 
10 X T4 DNA Ligase Buffer 2 µl 
Vector DNA(~4 kb) 50 ng 
Insert DNA (~1 kb) 37.5ng 
Nuclease-free water upto 20 µl 
T4 DNA Ligase 1 µl  
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7.7 Appendix 6. Recipes for solution and buffers used for PTP purification 
experiments. 
	
Lysis buffer   
10 ml  
150 mM sucrose 
300 mM potassium chloride 
40 mM potassium L-glutamate 
3 mM MgCl2 
20 mM HEPES-KOH (pH 7.7) 
2 mM dithiothreitol 
0.1% Tween 20 
TST buffer  50 ml  50 mM Tris-HCL (pH7.7) 
150 mM NaCl 
0.05% TWEEN 
0.5 M glacial acetic acid 50 ml 1.43 mL Acetic acid in 50 mL d H20 
PA-150 buffer  50 ml  20 mM Tris-HCl (pH7.7) 
150 mM KCl 
3 mM MgCl 
0.1% TWEEN 
1 mM DTT 
TEV buffer 20 ml 150 mM KCl 
20 mM Tris-HCl (pH7.7) 
3 mM MgCl 
0.5 mM EDTA pH8.0 
0.1% TWEEN 
1 mM DTT  
PC-150 buffer  150 ml  150 mM KCl 
20 mM Tris-HCl (pH7.7) 
3 mM MgCl 
1 mM CaCl2 
0.1% Tween 
EGTA/EDTA elution 
buffer 
2 ml  5 mM Tris-HCl (pH7.7) 
10 M EGTA 
5 mM EDTA 
Fix 200 ml 50% methanol 
7% acetic acid 
Wash 100 ml 10% methanol 
7% acetic acid 
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7.8 Appendix 7 (a). Protein sequences of RFC complex subunits identified by 
Mass spectroscopic analysis. 
The residues that were found to be identical with the protein residues on database are 
highlighted in red. 
 
RFC1 
 1 MSTLSFSTGI EAMTPVNTQS SATAAPRLSE LWADKYKPRS IAEMCYPSYA 
51 NKLKAWLENF TPVGSPGDDP NKHHGVLLSG SPGVGKTTTV YVVARELGRT 
101 VIEYNASDFR SRKSLRENVL DLISNRAFAA QATSYTRAVL LMDEVDGCDI 
151 GGVGEVVKML FITKIPILCT CNDRWHPKLQ TLVKYVEDMR FSHPPCNIVA 
201 NYLCERVLAR EGITLSKPLL QDIIKKSGSD IRNMLNNLQL WCLNRRSLEQ 
251 RQLAECAAQA TKDGDAGLFD SAEYFLLQGT SRGERHSIAE MQACYYNSDL 
301 IDMFVQENYL HYNPEPVDGR DWMTAVAQAA SSISRADAAQ RIMYYEQNWS 
351 VSRFHVLSSS IAPCVYTRGK YETFMTGQQK FFDLQRPVKF PQWLGHNSTA 
401 GKNRRLLRCV AMQASHPTRG ISGNQEDVAA DYMPNGWERP LTQPLAEKEK 
451 DGIAEVIALM DQYNLMRDDW DLVQTLPHFR HMETPRQQPP VSITTAVKAA 
501 FTREFNKTHR FDSFAKTTLK RTDKADEDDG IDEEEGESQK EGAGAKAGTK 
551 GRVIADGVTA VTITGSDAAK PKAKTSAARK PRAKKSAANA AAAADDSGET 
601 KPARKRAASA STRKPAKPAG KASKAAAGGK ARKRARVESS SESEVEISSD 
651 SSSDSSDSE 
    
	
RFC2 
 
1 MSLSSQPVTK KAKTEAAASP AAAATPWIEK YRPRTLDEVE AQDEAVSALR 
51 ACLKEGANMP HFLFHGPPGT GKTTSILAVA HELFGPDYIR SRVRELNASD 
101 DRGINVVREK IKVFAQGAVS SGGSSVTQSD GKVYPVPGFK LIILDEADAL 
151 LPDAQGALRR MMEDFSDVTR FCILCNYVSR IIDPIASRCA KYRFKPLVKT 
201 ALYNRIQFVA NAEGIELSDA SLQALDSVSG GDLRLAIMHL QSAHKASGSD 
251 LTREDFVSVS GSVPADAMQT YVAALVSRRL EDVIAVSRQL VAQGYAAAQV 
301 LVQLQRYLVS AECPLNSAQR GRMMLKLCQT ERRLADGGDD YLQLLDMGSS 
351 VCAS 
    
      
RFC3      
      
 
1 MATSKQAEDA KAGGSHLPWV EKYRPDNLDS VVAHEDILST LRHLMNSGNM 
51 PHLLLYGPPG TGKTTTIKAC AYYLYGKDRV RANVLEMNAS DDRGIDVVRQ 
101 QIREFSSTSS IFSMMGPSSS SGGGGNGGSG PLASFKLVIL DEADQMSHDA 
151 QAALRRVIEK YTKNVRFCIL CNHINKVIPA LQSRCTRFRF APVKKSAMMP 
201 RLKYVAEQEK VKYTTEGLAA AFRLSHGDLR RCMNTMQSSA LSADEITEES 
251 VYRVTGNPTP AEVTAIVSDM LSGDFATSWA KVEVAVTQKG ISIADLAREI 
301 HPIMMAMDLP QDCKCFLLMK LSDMEYYAAG GAREAAGLGG LLGAFQLVKE 
351 AVTQRKPIKA VAGDCSA 
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RFC4 
 
      
1 MLCLARDLLL QNTDAATGAD KAGGKDILKD AVLELNASDD RGLDVVREKI 
51 KLFAQTKKTL PKKFFTTGEG AETMEQVVHL HKIVLLDEAD SMTPAAQQAL 
101 RRTMELHSST TRFAFACNNS SKIIEPIQSR CAVVRFKKLS DADILRRLVF 
151 VIQQEKVSYT DDGLEALLYL AEGDLRQAMN SLQATHTGYG LVNADNVFKV 
201 CDQPHPVLVE NIITACVTKR NIEEAHKEMN RLLNRGYAPA DVIATFFKVV 
251 QTNARLFRSE LQQLEVLKVV GETTMRIAEG VGTSLQLAAM LARMIAAVEN 
301 NQS 
    
     
      
      
RFC5      
 
1 MLWVDRYRPK TLKEVELYPE LNDVLGRLAK AQDLPHLLFY GPSGSGKKTR 
51 AMAVLHEIYG PSVYSVRLEH KSVQVSDSKV VDIATLSSPH HIDINPSDAG 
101 NYDRVIVMQM IREIAQTVPL HTTASSAKAV PYKVVVLNEV DKMSRSAQHA 
151 LRRTMEKYMK TCRLVLICNS TSRLIPPLRS RCLGIRVAAH SKDNLALAVQ 
201 HVCEGESRPM PSPAFLNSLA LRSDGNLRRG LLMLEASAMT KVDWSGNGAA 
251 IPQADWKLFL DEISHDILAE QTPKKLHEVR LKFYDLLAQC ISGETILKTL 
301 LDSLLLAVPP KHQAALIQLA ATYDHNMKLG TKPILHLEAF VAGVMKLIKQ 
351 Q 
    
     
      
Rad17 
 1 MLNEVYAPTT VADLAWSRQK IVALSTLVRS TRSGAQNPRI LLLYGPPGCG 
51 KLESLKVLLR EAPPAAASTT SKSKTPAPAP QVIEPPTTVS VFHTCEASST 
101 AYSQFLQHVL SLCSGQLVGS ALMLTPKDMH GGRDTPSAPS DVQHAHIIKL 
151 YGEPATHVLH RATVAFLRQY EALRLQAIRE EEQQQHQRRY LAKVLASPAS 
201 PSTTLMDHLR RNLIFFVHTT HDSHNDKVDL GSALPAAVLQ SAAVELFHCT 
251 PVTEINLKKR LRHILDTEAR RRANRSAQQR RADVAEATDV DDLFGIAPAL 
301 SGSSAAPRRV AARGGAGSSR GKKGKENAKH APVTALHIPD AADVLDSLAL 
351 DAIAAGSQGD IRQALLQVQW AALVPPGSST AASLVETVAD SSDVVWARLQ 
401 HRRALAQAFA SGSSKADESS LVLSTKSVAP LAEACAAPQQ QDSTVAEDDD 
451 GVVLLISSSS SEFDAPLPLS AAEVTRRQHL PSRSHEAATR KRSRSSENDV 
501 VDVDDVGTTS KAAPPSAQAR ATDMLSLLDS QMNGAGESRA AAAASRGAAK 
551 KLLRAAPVRR DGLAAKNNTD ADDGAAVLPD HRTVLPTTRD EYLGLSHATG 
601 RLLSQKYSVD AVLDILNVPP RKMLDYLTNN QVRYFSDAQL PQYLVCAAAA 
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7.9 Appendix 7 (b). Protein sequences of exosome complex subunits 
identified by Mass spectroscopic analysis. 
The residues that were found to be identical with the protein residues on database are 
highlighted in red. 
	
RRP 41 
1 MSRQKEYVSP AGLRLDGRRP LEARRMDIAF STLSGCDGSC DITLGRSKVC 
51 ASVFGPRESV HRQEAKHDEV IITCEVAVAA FAGEVRRNPQ RRGRLSEDIS 
101 AAVVQVARSV VLLPQYPNSQ IHIYLEVLQQ DGNEKIACIN AACLALVDAN 
151 VAMRDAVCCT NVGLLDEHVL VDLTNEELRS QCPVIAAAFT GHDTRNIIWL 
201 ETTSRLLPEA AIRLLKAAGQ SAKELFEGTV RGALVEHATQ ILALQS 
	
RRP41B 
	
1 MSSALSGQSA VTLSSSSSSS HPTAAATAGA SYTRRDGRTA LEIRGKEMRL 
51 SEMADFDGSS WYAQGQTAVL VTLHGPTLAK NEEYDTCLVR VRVQHAHGLT 
101 PSAGGAERAV YEEMKLEMLT RTDALELESL LESTIDAVVM RDRFPRCVLV 
151 VDVVVVQDDG SLAAVALNAV MCALLDAGVP CRTTMAAVCV AAVTRAEDAA 
201 AGDASRAVGS SLELLLDPTT AEETLGAGNT AAATAAGGEK ARSTVDATMA 
251 EKGDLSGAAA AKLSLLRPDA LQGHYRCVST GVFVFSNPAC GGGVLAQLVR 
301 RRSGGDSGTG ANTVSVEVYG QMMTLAERAA VVLFDFFRQC NVAE 
	
RRP6 
1 MPPKSAEASL PATKAVVSAV FGAVKDYSKL SAQIPADDFE YHLAFAGFRK 
51 HIRDDSVGLV EVMDACCQML PKRRRTNLVA EEDPHSGAVH LAETQRNAVM 
101 EAIDSLLENV DSLLDEVKGR KLDAQDQLSV TFGSELAVSA HHDASRGGSS 
151 ASNAAGVVRL AHVRRPQLSF ETPVDNSAAP FTPTYRDASG VQHTGVAGEH 
201 PFHDAIRAFS VPEAQMMPKA EIPPVPLETC PLSFVDTPDA MQAMVAKLLS 
251 ASEIAVDLEH HDFYSYQGFT CLMQISTREE DFIVDCLQLR ASMGALAPVF 
301 LNPSILKVFH GAREDVRWLQ KDFALYLVNF FDTGVALQTL HMPYSLAFAV 
351 DHFCQVKLNK KYQTADWRVR PLPADMVHYA RQDTHFLLYV YDRLKALLLN 
401 SEGRASVGNL LVHVYNESKQ LALQVYAKPN VDPAETYKLA LGRSLGGLTA 
651 SEVDALRTAE FDGGYGGSAA ALRERRQLAD RTTAGESVGN VARLLDVIAL 
701 QTFHRRYLVE QTAVQAPPGF TPQEPPPFLR SAYPRVRDVG STTNTTGPYM 
751 TQRGEAVLEL LAGVSEHEWM EQFLLRLDSA VSASGAITSF SSIGRRRMPP 
801 AASVVSSDAI FSQPALGLTS PSIRLDEVDI LREGLPDLLY RCGCTESVVM 
851 DHYALAPYIV LNLPASSQPS AAAVASQPSP AVTPAGISSA ASGDSADAGG 
901 APLSVARPRR TVFKFAASTP PPPPPTQLHS QPAPLSLRET HAARLSARRP 
951 CTSLQLKILQ RGRDSAAATL RGDHFVLVAT ENIAEEGSMS EKGGVEERPW 
1001 MPEGDDIEDD 
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451 VQEEVAREIF NWRESAARDV DDSPTAVLHL SSVLAIASKL PTTAKDLLRC 
501 CSPATAVLRA NVAHLVELVK KAVASSSEDF ENGVSGSGAG RHGKEEGSRH 
551 HNYLDGAAEG SLEWAVYRSR CPTGVHRPMT GTLPSLASVV KTVTPAAVSV 
601 SEQAALLSHT MPSSWFSAMS ALSRVLASRQ QHHVELPGAD VRAARQAAAA 
651 KSLAGTADAA AAAAVAAEEE TAKAEVESVS SASGEGEQKD EEATGDLPAE 
701 ADVAEASSVI ALDKKAFSIK QEYGVGAKSR FKKGEKGGAA KKKK 
	
EAP1 
1 MSVSAASISL AEVRAVQDGV ANDVREDGRT LLQRRPVYIT PRSSPSAVAA 
51 VVGGSDGGDA AGVAQQSYSG SYVEVRASGT VVLAAATPTV VDGCATAAPS 
101 PVSAADNADG AKEAAAAAPH DAGRGQLHIT IDAVPHVLDA YAGTVGGRNT 
151 HRYRRDYLAF LAATIRAVFG AAQVQVQEQQ GVAEAEVVPE EREGAEDEVG 
201 AGTVSSSAVA PAGSGRGDGE TSLASGFPAA DLYIGEGFGF RVHVDVHVLQ 
251 CAGGNLFTAI AYAVHAALRS LQLPAVTLHR APGDGAGVSV EVDRSQPYRR 
301 PVQWSQLPLL CVLLVSPTGH YVVDPTLREE WALPQQVHVA AGASGQVFYF 
351 RYQQLPSRRG NRYQLQEARK ADAEACAAYV APPMALNLLD CWAVLSDAVY 
401 VCQAMIHDCE VALQG 
   
	
RRP45 
1 MLLRSAAPVP ADALVQRNVE FARTAWRAGL RPDQREAHQL RMIEIEFPLL 
51 ARDTVQVKCG NTIATASVTC DLVEPMPFRP KHGFFEVHAR QLLHERDPLD 
101 QPKAVKQLSM YLTRLLSGSV VETEGLCVIP GRRVWSIAAE VLILNNDGNL 
151 HDVAQWAVMA ALQHVRRPEL TIRGDDVVVH PPHERDPVPL SLHHIPLSFT 
201 FAVCANPQQV QLAARAAALR RASPVSAGAA GQGSSDNAGE KEDGADASAW 
251 SDDALQIVAD PSLEEAAAAA CTVSVAVNAE GHVCSLEKAD GCDVSLEHLE 
301 QCMQVALQLT PPLLTQMQEA MAAHDVKRKA AVRSQFLWAQ KRLGIQAAGG 
351 AGASQTQEEQ AAKKSKTE 
   
	
RRP40 
 1 MSTHSPTLKS VSELVPLKGH VCLPGEPVLM VQSSAVVAVG GGLRLLAQPS 
51 TATDASQDVA DVFLAEYCAP LQRSSHHLHT HVPRYTVATP ASRRYTPRHA 
101 DPVIAVIARK VSQHYYYCYI GGSSLAYLEA IAFDGATKVS RPRLAEGDVV 
151 YCYVKPRAAA SYVDGAAASS AAATAAAVSS GGEVELACTA AEVGLPPKDW 
201 TSGEAVFGPL LGGRLLTLPL AYVRRLLAPL PATLSGEGPA VKRARVEGGG 
251 GEAEEVPASY LLHLLGQRVP FEVAVGMNGL VWVKGLTSEA DATAAARRTV 
301 AVSACISEAQ YDATRAEMEA RVESYFPS 
  
	
	
	
100 
  
	
RRP4 
 
 
1 MSSGVVIVGD SICGGERIQK LNTSNDEVYL RGFNTFAGNN PSDIALVHEG 
51 AGEIVAAING HIEVTDRVVS VKGLLPRYQP EIGDVVVGRI LEVTGNKWQV 
101 DVNSTQTAIM LLSNVTEPGG MLRRRGRGDE LGMRQLFDQE DLVAAEVQRI 
151 SPDGVVSLHT RAAEKYGRIG GFGVLVSVRP SLVKRAKHQF VELAEHHVRL 
201 TIGMNGNIWV SRKEETADGT EDKEREAEAR QNVARVANCV KALGVAHIQI 
251 HPATIEAAVA ASVEAGFSAF HVSLEKNRDA LLVSVHDAIG VKRRRQ 
    
      
      
CSL4 
1 MPVLVHTGAR VAPGDALFSS AAHVPTGTDA SAATAGDTVS DSDVIPGEGC 
51 VVHYVEVPSE STGDSSRVRR HIVATRQGVA QWDGRLVSVF AAGATGTTAQ 
101 LQGASTAVRS AVTGPRPGDT VHVRITRLSR LFAFGEITAV NWQWCSHRSA 
151 AGASVSGVFK GVLRLEDIRP FRPTRDQLQP PPPTMAFALG DVVLAEVISQ 
201 SDAHQYQLST VGEGFGVVES YVSTAEEHYS GRERVKLQHL PGRRDAMLVP 
251 ATGAVVPRWC PLLP 
   
	
EAP2 
1 MSLPPNTGSI ELTAFRAHTS QLLARGERLD KRDFTTCRVP TVVREERAAE 
51 APSSSSSGVV QTGINMANSG NLAAVMYTDS YGACMQCTVQ GLLGPPRPDR 
101 PAAGRLNIHV EAPFVEQLGG GAATNYKSFQ YIISNGNADL PLRQLEGYIG 
151 SVVDGCFDPT QLSIYDGEAC WVLNVTVTLL SFDGGLRAAS LHAVLAALHQ 
201 LRLPRTRLPN GDVIESRRVR LSCLPTACTF GFLAGAQVRL LADTTAIEEY 
251 VADGLLTIAV SESGEVVGVH QVGRCPLLAQ ALTAAVQQWT EQSASVRKAL 
301 YG 
    
	
EAP4 
1 MTRLDGRQST EAVRAIHVAT NVLANCHSSA CVEIGQTRVL CGVRPPQQLV 
51 QEYRGTRGRI SCQLHRSSAS SAAATVADNS ADRDMALALE GVAEQAVVLE 
101 RIPQLLVEVL IEVLHDDGAV WDAAATALSA ALTAGGVEVY DTFTACSAAV 
151 RPDGAIVVDL TQEEEAAATA RVVVCGGVSL GGVYYMCHLG ACEAATMAQL 
201 VQAATKGMQV RKALLLEQIR NQ 
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7.10 Appendix 8. The full sequence of the constructed pNUS-PTPcH plasmid 
 
AAGCTTACCGACAAGACCAGAATAGCGCTTATGTGTGTGTGTTTGTGTGTGGGTGTGTGTGCCCATGTGTGACAAAGAG
GCCAGTGCTTTCTCTAAAGCAAGAGCGCGAGGTTGCTGGCTAAGGACTCTAAGTCCCTCACAGTGATGGCGTGTTGCAT
TTTCTAAACCGTCAATCCAACACGTCGGTAGCATATCGGTTTTGTAGGCTCTTCTGGATACCTTCCCCAGTAAGACCGC
CACTGCTTCGTGACTGAAGCACTGTAAATATCACTGAAACCGTCGCGTTGCTTTGTCTAATTATCACCGCCTTTGCCAG
CTATCGCCTCAGGCTGCGCTCTTTGACTAATCCACTCACCACTTCTCTGCCTTCTTCCTCCGGTTGTTGTTGTGTCCTG
CGTGTACATGGCGCGTGTCCTTTTCGAGCAAACAGCTGTCTTTTCTTTCACGATAACACACTCATATTAAACGCGAGTA
TTACTCATCAGTCAACGTCACATTCCGCTCTGTCCACTTCGACCTTACACCTCTACTTGTCCAACTATCTTCCACTTGT
CAAGCGAATTCCATATGCTCGAGGATATCGGCGGCCGCGAAGATCAGGTCGATCCTCGTCTTATTGATGGGAAATATGA
TATTCCAACTACTGCTAGCGAGAATTTGTATTTTCAGGGTGAGCTCAAAACCGCGGCTCTTGCGCAACACGATGAAGCC
GTGGACAACAAATTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAACTTAAACGAAGAACAAC
GAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTAACCTTTTAGCAGAAGCTAAAAAGCTAAATGA
TGCTCAGGCGCCGAAAGTAGACAACAAATTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAAC
TTAAACGAAGAACAACGAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTAACCTTTTAGCAGAAG
CTAAAAAGCTAAATGATGCTCAGGCGCCGAAAGTAGACGCGAACTCCGCGGGGAAGTCAACCTGATAATAGGAATTCTG
TATTACGCCGTTTTAAGAGCTCCTTCGACGCCTTTTTGTCCTTCAGCTGCTCCACGGTGACTCGCTTCTCTCTCTTTCC
ACAGTGTCTCTTTTTTCTTTTCACTCTCTATACAAATGTGAGCGACCTCCTTTTCTGTACAACGGCCTTCCGGCGTGTG
CTTTTCTCATCGACCTCTCCTCGCTTCTTGGGCACTCCTTCATCGAGCAAACAAGACGAGGGAGGTGACGCGATTGGTG
AGACCACTACGAGTATGGACGGAGCTGTCTGATACCCCCTGTTTTTTATCTTGTACCCCGCTCTGCAGTGACGGTAGCC
CGCTGCTGTGCTTCGGTATCGCCGCTTCATACGCTTCTCTCTTTTTTCAACGTGCGGCGCTGATTCAAAGGTTACCTCA
ACGCGACCCGCCGCTGCATCCTTTGTTGCTCCTCTTGTCGCAAACAAACAAAAAACGTGCTGTGCTTTTTCCTTTATCG
TGTCTTTTTGCAAAGTCTAGAGTTTACCGACAAGACCAGAATAGCGCTTATGTGTGTGTGTTTGTGTGTGGGTGTGTGT
GCCCATGTGTGACAAAGAGGCCAGTGCTTTCTCTAAAGCAAGAGCGCGAGGTTGCTGGCTAAGGACTCTAAGTCCCTCA
CAGTGATGGCGTGTTGCATTTTCTAAACCGTCAATCCAACACGTCGGTAGCATATCGGTTTTGTAGGCTCTTCTGGATA
CCTTCCCCAGTAAGACCGCCACTGCTTCGTGACTGAAGCACTGTAAATATCACTGAAACCGTCGCGTTGCTTTGTCTAA
TTATCACCGCCTTTGCCAGCTATCGCCTCAGGCTGCGCTCTTTGACTAATCCACTCACCACTTCTCTGCCTTCTTCCTC
CGGTTGTTGTTGTGTCCTGCGTGTACATGGCGCGTGTCCTTTTCGAGCAAACAGCTGTCTTTTCTTTCACGATAACACA
CTCATATTAAACGCGAGTATTACTCATCAGTCAACGTCACATTCCGCTCTGTCCACTTCGACCTTACACCTCTACTTGT
CCAACTATCTTCCACTTGTCAAGCGTCGACATGAAAAAGCCTGAACTCACCGCGACGTCTGTCGAGAAGTTTCTGATCG
GAAAGTTCGACAGCGTCTCCGACCTGATGCAGCTCTCGGAGGGCGAAGAATCTCGTGCTTTCAGCTTCGATGTAGGAGG
GCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTCTACAAAGATCGTTATGTTTATCGGCACTTTGCATCG
GCCGCGCTCCCGATTCCGGAAGTGCTTGACATTGGGGAGTTCAGCGAGAGCCTGACCTATTGCATCTCCCGCCGTGCAC
AGGGTGTCACGTTGCAAGACCTGCCTGAAACCGAACTGCCCGCTGTTCTTCAGCCGGTCGCGGAGGCCATGGATGCGAT
CGCTGCGGCCGATCTTAGCCAGACGAGCGGGTTCGGCCCATTCGGACCGCAAGGAATCGGTCAATACACTACATGGCGT
GATTTCATTTGCGCGATTGCTGATCCCCATGTGTATCACTGGCAAACTGTGATGGACGACACCGTCAGTGCGTCCGTCG
CGCAGGCTCTCGATGAGCTGATGCTTTGGGCCGAGGACTGCCCCGAAGTCCGGCACCTCGTGCACGCGGATTTCGGCTC
CAACAATGTCCTGACGGACAATGGCCGCATAACAGCGGTCATTGACTGGAGCGAGGCGATGTTCGGGGATTCCCAATAC
GAGGTCGCCAACATCTTCTTCTGGAGGCCGTGGTTGGCTTGTATGGAGCAGCAGACGCGCTACTTCGAGCGGAGGCATC
CGGAGCTTGCAGGATCGCCGCGGCTCCGGGCGTATATGCTCCGCATTGGTCTTGACCAACTCTATCAGAGCTTGGTTGA
CGGCAATTTCGATGATGCAGCTTGGGCGCAGGGTCGATGCGACGCAATCGTCCGATCCGGAGCCGGGACTGTCGGGCGT
ACACAAATCGCCCGCAGAAGCGCGGCCGTCTGGACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAAACCGACGCC
TCAGCACTCGTCCGAGGGCAAAGGAATAGGGATCCAGCAGGCGGAGAAAGAGGGAAGTATAAGGCGGACGCATAGGTCG
GAGTATCGAGAAAAAGAGGCAGAGATGGGTGGTGGCGGAGCGCCCCTCTCTGCCCTTCTCTGTTTTACTGTTCCCGCCA
CGTCGCCAACTCCTCTTTTTGTTTGCTCTAATGTCGGTGCTATCCTCTTCCTCTTTTTACTCTCCGTTTTTCTTCCTTC
CGTTTTGTCTTGTTATCACCGTTATTTTTCTTCTTCTTTCTTAGCCGATTTGGGTCTCCTGCCTACGGCAGCGGTGATG
AGTCGCACTTCCGTCCCCCTTTCCTCTCCGTAAGTACTCCCTCGATGCCTCAGGCGCTTCTATTTTGCGGCACTGTGCT
GACCACCTCCCACGTGTGCAGTGAGAGCGCCAGAGACATTCAGGAGAAGAGGGAAGAGGGGAAGTAAATACCAAAGCGA
GGAAGATGTCTTTCTCGCTGCTTCTCATCCTGTTGACCGGTGTGCACGGCGGTGTGTCCTCTCGGCTTCCCTCCTCCTT
CCCTCGCTCCCCTTTTTCTGTGTTTTTTCTTTCTAACATGATTGCGCCTGCTCTTTTTGCCCCGCAGCGTCGCAGTGGG
TGTCACCTGCGACCGCCGTACGTTTTACTATATACATATTTGTTTCTGTGCTGATGCCATTTGTCCGCTACTCCATATC
GTGCGTGTTTGTTTTCCAGTGGTGACGCCTTCCGCATCATTTTAATCAATTCGAGGCGAAAAGGGTGATTTGAGTGTTG
GAGTGGGCTTTTTTATTTATTTGACTCCAAACATCTTTTCTTTTCCCGGTATCTTCGGGTCCGTCACGCAGGTCGGTGG
GTGTGTCCGAGTGCGCTTCTTTACTCACGTGCCGCTGCGCACATACACAGATTTTAAAAGCACGCATACACGATCTGTG
CCTTCAAAACTAATCAACAAAAACAAAAATACAAAAAAGACAAGAATAAGAGGTCAGCAACGCACCCACGGCTCCTTTC
TTCCTGATCCACGTCGTGGCCGCTGTACGCTCTCAAACACGCTTTGGCGCTGATGCGTGCCTTTATACAAAGAACAAAG
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AAGAAGCGAAAAACGGGAGCGTGTTGCTTTGGGGATGTATGCGTGCCACAGTTCTGCGGTACAATTCGTAATCATGGTC
ATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCC
TGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGT
GCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCAC
TGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAA
TCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG
CGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGG
ACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATAC
CTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGA
GTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGC
GGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGT
TTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAG
TGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAA
AATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC
TATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGC
TTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGC
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCG
TTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGG
TTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCA
TAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAG
TGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGC
TCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCAC
TCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCC
GCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATC
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCC
CCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCC
TTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGT
AAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGC
GGCATCAGAGCAGATTGTACTGAGAGTGCACGATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGC
ATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGC
TGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGAC
GGCCAGTGCC 
 
7.11 Appendix 9. Profiles and percentage anticrithidial activities of compounds 
in the MMV pathogen box 
	
Plate barcode Position Compound ID Inhibition (%) at 
100µM concentration 
PathogenBox_PlateA A02 MMV010764 92 
PathogenBox_PlateA A03 MMV688472 67 
PathogenBox_PlateA A04 MMV688416 59 
PathogenBox_PlateA A05 MMV689758 87 
PathogenBox_PlateA A06 MMV688796 79 
PathogenBox_PlateA A07 MMV676526 19 
PathogenBox_PlateA A08 MMV688553 28 
PathogenBox_PlateA A09 MMV676501 73 
PathogenBox_PlateA A10 MMV676449 87 
PathogenBox_PlateA A11 MMV676412 94 
PathogenBox_PlateA B02 MMV1110498 90 
PathogenBox_PlateA B03 MMV000907 95 
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PathogenBox_PlateA B04 MMV688889 20 
PathogenBox_PlateA B05 MMV688776 75 
PathogenBox_PlateA B06 MMV688934 68 
PathogenBox_PlateA B07 MMV676389 82 
PathogenBox_PlateA B08 MMV676603 70 
PathogenBox_PlateA B09 MMV676401 86 
PathogenBox_PlateA B10 MMV102872 94 
PathogenBox_PlateA B11 MMV676477 72 
PathogenBox_PlateA C02 MMV084603 91 
PathogenBox_PlateA C03 MMV688548 95 
PathogenBox_PlateA C04 MMV688888 90 
PathogenBox_PlateA C05 MMV690028 73 
PathogenBox_PlateA C06 MMV688943 95 
PathogenBox_PlateA C07 MMV053220 73 
PathogenBox_PlateA C08 MMV676584 88 
PathogenBox_PlateA C09 MMV676439 84 
PathogenBox_PlateA C10 MMV676395 70 
PathogenBox_PlateA C11 MMV676379 82 
PathogenBox_PlateA D02 MMV687762 88 
PathogenBox_PlateA D03 MMV1028806 94 
PathogenBox_PlateA D04 MMV661713 17 
PathogenBox_PlateA D05 MMV688793 90 
PathogenBox_PlateA D06 MMV688942 95 
PathogenBox_PlateA D07 MMV688554 72 
PathogenBox_PlateA D08 MMV676555 85 
PathogenBox_PlateA D09 MMV676383 86 
PathogenBox_PlateA D10 MMV676444 77 
PathogenBox_PlateA D11 MMV676409 95 
PathogenBox_PlateA E02 MMV688514 87 
PathogenBox_PlateA E03 MMV676350 72 
PathogenBox_PlateA E04 MMV553002 94 
PathogenBox_PlateA E05 MMV688797 88 
PathogenBox_PlateA E06 MMV688756 70 
PathogenBox_PlateA E07 MMV090930 88 
PathogenBox_PlateA E08 MMV676431 42 
PathogenBox_PlateA E09 MMV676571 76 
PathogenBox_PlateA E10 MMV676445 94 
PathogenBox_PlateA E11 MMV676589 80 
PathogenBox_PlateA F02 MMV026020 91 
PathogenBox_PlateA F03 MMV688471 88 
PathogenBox_PlateA F04 MMV676388 95 
PathogenBox_PlateA F05 MMV202553 76 
PathogenBox_PlateA F06 MMV688936 92 
PathogenBox_PlateA F07 MMV676476 64 
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PathogenBox_PlateA F08 MMV676377 95 
PathogenBox_PlateA F09 MMV676406 75 
PathogenBox_PlateA F10 MMV676461 84 
PathogenBox_PlateA F11 MMV676509 76 
PathogenBox_PlateA G02 MMV688470 93 
PathogenBox_PlateA G03 MMV688704 90 
PathogenBox_PlateA G04 MMV188296 60 
PathogenBox_PlateA G05 MMV688958 89 
PathogenBox_PlateA G06 MMV063404 87 
PathogenBox_PlateA G07 MMV676558 73 
PathogenBox_PlateA G08 MMV688555 64 
PathogenBox_PlateA G09 MMV676597 95 
PathogenBox_PlateA G10 MMV676588 96 
PathogenBox_PlateA G11 MMV676554 70 
PathogenBox_PlateA H02 MMV688350 94 
PathogenBox_PlateA H03 MMV688360 95 
PathogenBox_PlateA H04 MMV099637 95 
PathogenBox_PlateA H05 MMV688798 93 
PathogenBox_PlateA H06 MMV676539 95 
PathogenBox_PlateA H07 MMV202458 95 
PathogenBox_PlateA H08 MMV676474 92 
PathogenBox_PlateA H09 MMV461553 94 
PathogenBox_PlateA H10 MMV676520 95 
PathogenBox_PlateA H11 MMV676512 95 
PathogenBox_PlateB A02 MMV676480 52 
PathogenBox_PlateB A03 MMV652003 64 
PathogenBox_PlateB A04 MMV000062 72 
PathogenBox_PlateB A05 MMV006372 40 
PathogenBox_PlateB A06 MMV688854 71 
PathogenBox_PlateB A07 MMV011903 70 
PathogenBox_PlateB A08 MMV020591 46 
PathogenBox_PlateB A09 MMV020623 71 
PathogenBox_PlateB A10 MMV020512 70 
PathogenBox_PlateB A11 MMV688761 75 
PathogenBox_PlateB B02 MMV012074 66 
PathogenBox_PlateB B03 MMV676604 52 
PathogenBox_PlateB B04 MMV002529 68 
PathogenBox_PlateB B05 MMV687776 80 
PathogenBox_PlateB B06 MMV687800 40 
PathogenBox_PlateB B07 MMV020982 60 
PathogenBox_PlateB B08 MMV020120 56 
PathogenBox_PlateB B09 MMV676605 66 
PathogenBox_PlateB B10 MMV007638 56 
PathogenBox_PlateB B11 MMV021057 74 
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PathogenBox_PlateB C02 MMV690027 68 
PathogenBox_PlateB C03 MMV676600 63 
PathogenBox_PlateB C04 MMV676382 62 
PathogenBox_PlateB C05 MMV001625 70 
PathogenBox_PlateB C06 MMV001493 41 
PathogenBox_PlateB C07 MMV020136 17 
PathogenBox_PlateB C08 MMV020710 40 
PathogenBox_PlateB C09 MMV020517 52 
PathogenBox_PlateB C10 MMV019721 63 
PathogenBox_PlateB C11 MMV688763 80 
PathogenBox_PlateB D02 MMV020537 50 
PathogenBox_PlateB D03 MMV637953 69 
PathogenBox_PlateB D04 MMV676536 67 
PathogenBox_PlateB D05 MMV000063 54 
PathogenBox_PlateB D06 MMV689255 56 
PathogenBox_PlateB D07 MMV019838 68 
PathogenBox_PlateB D08 MMV020520 51 
PathogenBox_PlateB D09 MMV019234 23 
PathogenBox_PlateB D10 MMV016136 28 
PathogenBox_PlateB D11 MMV688762 29 
PathogenBox_PlateB E02 MMV676386 64 
PathogenBox_PlateB E03 MMV688773 64 
PathogenBox_PlateB E04 MMV000011 59 
PathogenBox_PlateB E05 MMV687775 76 
PathogenBox_PlateB E06 MMV002817 76 
PathogenBox_PlateB E07 MMV676442 40 
PathogenBox_PlateB E08 MMV020152 50 
PathogenBox_PlateB E09 MMV024397 20 
PathogenBox_PlateB E10 MMV019807 65 
PathogenBox_PlateB E11 MMV560185 25 
PathogenBox_PlateB F02 MMV019189 46 
PathogenBox_PlateB F03 MMV688774 78 
PathogenBox_PlateB F04 MMV003270  14 
PathogenBox_PlateB F05 MMV637229 76 
PathogenBox_PlateB F06 MMV688853 82 
PathogenBox_PlateB F07 MMV020321 62 
PathogenBox_PlateB F08 MMV019087 8 
PathogenBox_PlateB F09 MMV676528 62 
PathogenBox_PlateB F10 MMV020320 34 
PathogenBox_PlateB F11 MMV085210 73 
PathogenBox_PlateB G02 MMV069458 68 
PathogenBox_PlateB G03 MMV688991 51 
PathogenBox_PlateB G04 MMV687801 58 
PathogenBox_PlateB G05 MMV689480 78 
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PathogenBox_PlateB G06 MMV003152 78 
PathogenBox_PlateB G07 MMV006239 70 
PathogenBox_PlateB G08 MMV000858 21 
PathogenBox_PlateB G09 MMV006741  20 
PathogenBox_PlateB G10 MMV688768 81 
PathogenBox_PlateB G11 MMV000023 70 
PathogenBox_PlateB H02 MMV676602 78 
PathogenBox_PlateB H03 MMV000014 82 
PathogenBox_PlateB H04 MMV687803 14 
PathogenBox_PlateB H05 MMV668727 75 
PathogenBox_PlateB H06 MMV019742 27 
PathogenBox_PlateB H07 MMV009054 73 
PathogenBox_PlateB H08 MMV006901 8 
PathogenBox_PlateB H09 MMV020391 74 
PathogenBox_PlateB H10 MMV676380 76 
PathogenBox_PlateB H11 MMV688994 84 
PathogenBox_PlateC A02 MMV675997 95 
PathogenBox_PlateC A03 MMV676204 95 
PathogenBox_PlateC A04 MMV687239 23 
PathogenBox_PlateC A05 MMV688122 96 
PathogenBox_PlateC A06 MMV688852 95 
PathogenBox_PlateC A07 MMV687145 95 
PathogenBox_PlateC A08 MMV688327 94 
PathogenBox_PlateC A09 MMV008439 96 
PathogenBox_PlateC A10 MMV595321 96 
PathogenBox_PlateC A11 MMV687747 96 
PathogenBox_PlateC B02 MMV020388 89 
PathogenBox_PlateC B03 MMV688547 96 
PathogenBox_PlateC B04 MMV688466 89 
PathogenBox_PlateC B05 MMV687749 94 
PathogenBox_PlateC B06 MMV688846 85 
PathogenBox_PlateC B07 MMV054312 97 
PathogenBox_PlateC B08 MMV689060 74 
PathogenBox_PlateC B09 MMV689061 23 
PathogenBox_PlateC B10 MMV689028 84 
PathogenBox_PlateC B11 MMV688371 95 
PathogenBox_PlateC C02 MMV688508 13 
PathogenBox_PlateC C03 MMV688283 71 
PathogenBox_PlateC C04 MMV687243 91 
PathogenBox_PlateC C05 MMV687730 96 
PathogenBox_PlateC C06 MMV687251 96 
PathogenBox_PlateC C07 MMV687254 96 
PathogenBox_PlateC C08 MMV688509 47 
PathogenBox_PlateC C09 MMV688361 93 
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PathogenBox_PlateC C10 MMV689029 62 
PathogenBox_PlateC C11 MMV022236 95 
PathogenBox_PlateC D02 MMV688410 68 
PathogenBox_PlateC D03 MMV676048 96 
PathogenBox_PlateC D04 MMV687703 96 
PathogenBox_PlateC D05 MMV687248 87 
PathogenBox_PlateC D06 MMV688125 89 
PathogenBox_PlateC D07 MMV687188 95 
PathogenBox_PlateC D08 MMV690103 95 
PathogenBox_PlateC D09 MMV688124 16 
PathogenBox_PlateC D10 MMV688845 68 
PathogenBox_PlateC D11 MMV1030799 96 
PathogenBox_PlateC E02 MMV675994 23 
PathogenBox_PlateC E03 MMV676057 37 
PathogenBox_PlateC E04 MMV687699 95 
PathogenBox_PlateC E05 MMV687146 96 
PathogenBox_PlateC E06 MMV687696 50 
PathogenBox_PlateC E07 MMV687170 92 
PathogenBox_PlateC E08 MMV690102 96 
PathogenBox_PlateC E09 MMV689709 96 
PathogenBox_PlateC E10 MMV021375 91 
PathogenBox_PlateC E11 MMV1029203 90 
PathogenBox_PlateC F02 MMV676053 60 
PathogenBox_PlateC F03 MMV688179 96 
PathogenBox_PlateC F04 MMV023969  96 
PathogenBox_PlateC F05 MMV687138 52 
PathogenBox_PlateC F06 MMV688262 96 
PathogenBox_PlateC F07 MMV687189 89 
PathogenBox_PlateC F08 MMV687807 48 
PathogenBox_PlateC F09 MMV676478 87 
PathogenBox_PlateC F10 MMV062221 96 
PathogenBox_PlateC F11 MMV688921 72 
PathogenBox_PlateC G02 MMV676191 45 
PathogenBox_PlateC G03 MMV675993 91 
PathogenBox_PlateC G04 MMV021660 89 
PathogenBox_PlateC G05 MMV688417 91 
PathogenBox_PlateC G06 MMV687273 96 
PathogenBox_PlateC G07 MMV687180 76 
PathogenBox_PlateC G08 MMV1088520 95 
PathogenBox_PlateC G09 MMV688891 28 
PathogenBox_PlateC G10 MMV023370 46 
PathogenBox_PlateC G11 MMV688703 94 
PathogenBox_PlateC H02 MMV675969 80 
PathogenBox_PlateC H03 MMV688313 92 
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PathogenBox_PlateC H04 MMV687172 92 
PathogenBox_PlateC H05 MMV688844 85 
PathogenBox_PlateC H06 MMV1198433 40 
PathogenBox_PlateC H07 MMV024311 93 
PathogenBox_PlateC H08 MMV1019989 52 
PathogenBox_PlateC H09 MMV1037162 83 
PathogenBox_PlateC H10 MMV689437 93 
PathogenBox_PlateC H11 MMV688955 67 
PathogenBox_PlateD A02 MMV026468 28 
PathogenBox_PlateD A03 MMV020670 90 
PathogenBox_PlateD A04 MMV023953 67 
PathogenBox_PlateD A05 MMV010576 69 
PathogenBox_PlateD A06 MMV032967 76 
PathogenBox_PlateD A07 MMV031011 79 
PathogenBox_PlateD A08 MMV688178 70 
PathogenBox_PlateD A09 MMV688362 93 
PathogenBox_PlateD A10 MMV687706 68 
PathogenBox_PlateD A11 MMV026356 93 
PathogenBox_PlateD B02 MMV011511 92 
PathogenBox_PlateD B03 MMV007625 64 
PathogenBox_PlateD B04 MMV007471 87 
PathogenBox_PlateD B05 MMV024829 88 
PathogenBox_PlateD B06 MMV045105 73 
PathogenBox_PlateD B07 MMV022029 66 
PathogenBox_PlateD B08 MMV676064 87 
PathogenBox_PlateD B09 MMV688180 92 
PathogenBox_PlateD B10 MMV024035 92 
PathogenBox_PlateD B11 MMV688941 82 
PathogenBox_PlateD C02 MMV020291 64 
PathogenBox_PlateD C03 MMV006833 84 
PathogenBox_PlateD C04 MMV026490 80 
PathogenBox_PlateD C05 MMV687246 67 
PathogenBox_PlateD C06 MMV676162 73 
PathogenBox_PlateD C07 MMV024114 67 
PathogenBox_PlateD C08 MMV688467 46 
PathogenBox_PlateD C09 MMV675998 93 
PathogenBox_PlateD C10 MMV659010 86 
PathogenBox_PlateD C11 MMV676008 64 
PathogenBox_PlateD D02 MMV676269 60 
PathogenBox_PlateD D03 MMV020081 71 
PathogenBox_PlateD D04 MMV026550 62 
PathogenBox_PlateD D05 MMV675995 82 
PathogenBox_PlateD D06 MMV688274 71 
PathogenBox_PlateD D07 MMV023860 75 
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PathogenBox_PlateD D08 MMV688407 93 
PathogenBox_PlateD D09 MMV023949 76 
PathogenBox_PlateD D10 MMV676050 78 
PathogenBox_PlateD D11 MMV024406 46 
PathogenBox_PlateD E02 MMV023233 87 
PathogenBox_PlateD E03 MMV085230 86 
PathogenBox_PlateD E04 MMV085071 93 
PathogenBox_PlateD E05 MMV659004 92 
PathogenBox_PlateD E06 MMV676260 85 
PathogenBox_PlateD E07 MMV688364 71 
PathogenBox_PlateD E08 MMV032995 81 
PathogenBox_PlateD E09 MMV688279 66 
PathogenBox_PlateD E10 MMV688271 93 
PathogenBox_PlateD E11 MMV019790 53 
PathogenBox_PlateD F02 MMV009135 90 
PathogenBox_PlateD F03 MMV011765 91 
PathogenBox_PlateD F04 MMV024937 84 
PathogenBox_PlateD F05 MMV085499 75 
PathogenBox_PlateD F06 MMV023985 88 
PathogenBox_PlateD F07 MMV024195 91 
PathogenBox_PlateD F08 MMV676063 31 
PathogenBox_PlateD F09 MMV676186 77 
PathogenBox_PlateD F10 MMV688474 93 
PathogenBox_PlateD F11 MMV687812 42 
PathogenBox_PlateD G02 MMV007803 89 
PathogenBox_PlateD G03 MMV001059 65 
PathogenBox_PlateD G04 MMV011691 49 
PathogenBox_PlateD G05 MMV676877 78 
PathogenBox_PlateD G06 MMV663250 92 
PathogenBox_PlateD G07 MMV407539 79 
PathogenBox_PlateD G08 MMV688372 84 
PathogenBox_PlateD G09 MMV658993 71 
PathogenBox_PlateD G10 MMV676182 92 
PathogenBox_PlateD G11 MMV676411 93 
PathogenBox_PlateD H02 MMV007133 90 
PathogenBox_PlateD H03 MMV022478 92 
PathogenBox_PlateD H04 MMV024101 92 
PathogenBox_PlateD H05 MMV676881 87 
PathogenBox_PlateD H06 MMV024443 93 
PathogenBox_PlateD H07 MMV688469 84 
PathogenBox_PlateD H08 MMV023388 92 
PathogenBox_PlateD H09 MMV675968 94 
PathogenBox_PlateD H10 MMV675996 84 
PathogenBox_PlateD H11 MMV688980 17 
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PathogenBox_PlateE A02 MMV011229 93 
PathogenBox_PlateE A03 MMV676468 97 
PathogenBox_PlateE A04 MMV688771 15 
PathogenBox_PlateE A05 MMV687798 77 
PathogenBox_PlateE A06 MMV688775 75 
PathogenBox_PlateE A07 MMV676159 97 
PathogenBox_PlateE A08 MMV393144 11 
PathogenBox_PlateE A09 MMV007920  83 
PathogenBox_PlateE A10 MMV688270 72 
PathogenBox_PlateE A11 MMV019993 84 
PathogenBox_PlateE B02 MMV687794 95 
PathogenBox_PlateE B03 MMV676470 86 
PathogenBox_PlateE B04 MMV688938 97 
PathogenBox_PlateE B05 MMV689000 97 
PathogenBox_PlateE B06 MMV004168 97 
PathogenBox_PlateE B07 MMV676161 78 
PathogenBox_PlateE B08 MMV023183 93 
PathogenBox_PlateE B09 MMV047015 96 
PathogenBox_PlateE B10 MMV688795 96 
PathogenBox_PlateE B11 MMV688352 58 
PathogenBox_PlateE C02 MMV676398 89 
PathogenBox_PlateE C03 MMV676472 89 
PathogenBox_PlateE C04 MMV671636 80 
PathogenBox_PlateE C05 MMV676599 82 
PathogenBox_PlateE C06 MMV689244 97 
PathogenBox_PlateE C07 MMV688411 95 
PathogenBox_PlateE C08 MMV687765 89 
PathogenBox_PlateE C09 MMV020165 57 
PathogenBox_PlateE C10 MMV676524 85 
PathogenBox_PlateE C11 MMV611037 94 
PathogenBox_PlateE D02 MMV688766 9 
PathogenBox_PlateE D03 MMV200748 93 
PathogenBox_PlateE D04 MMV667494 77 
PathogenBox_PlateE D05 MMV028694 91 
PathogenBox_PlateE D06 MMV001499 97 
PathogenBox_PlateE D07 MMV688345 97 
PathogenBox_PlateE D08 MMV010545 89 
PathogenBox_PlateE D09 MMV023227 95 
PathogenBox_PlateE D10 MMV687700 71 
PathogenBox_PlateE D11 MMV676384 94 
PathogenBox_PlateE E02 MMV020289 94 
PathogenBox_PlateE E03 MMV002816 78 
PathogenBox_PlateE E04 MMV634140 85 
PathogenBox_PlateE E05 MMV030734 71 
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PathogenBox_PlateE E06 MMV689243 97 
PathogenBox_PlateE E07 MMV676358 84 
PathogenBox_PlateE E08 MMV687729 64 
PathogenBox_PlateE E09 MMV407834 64 
PathogenBox_PlateE E10 MMV687813 49 
PathogenBox_PlateE E11 MMV153413 97 
PathogenBox_PlateE F02 MMV019551 96 
PathogenBox_PlateE F03 MMV688552 92 
PathogenBox_PlateE F04 MMV016838 80 
PathogenBox_PlateE F05 MMV676270 86 
PathogenBox_PlateE F06 MMV688755 97 
PathogenBox_PlateE F07 MMV228911 59 
PathogenBox_PlateE F08 MMV272144 97 
PathogenBox_PlateE F09 MMV026313 97 
PathogenBox_PlateE F10 MMV161996 57 
PathogenBox_PlateE F11 MMV688543 81 
PathogenBox_PlateE G02 MMV146306 96 
PathogenBox_PlateE G03 MMV688557 94 
PathogenBox_PlateE G04 MMV021013 97 
PathogenBox_PlateE G05 MMV392832 85 
PathogenBox_PlateE G06 MMV688754 93 
PathogenBox_PlateE G07 MMV001561 97 
PathogenBox_PlateE G08 MMV658988 97 
PathogenBox_PlateE G09 MMV084864 92 
PathogenBox_PlateE G10 MMV676492 97 
PathogenBox_PlateE G11 MMV688415 76 
PathogenBox_PlateE H02 MMV688330 34 
PathogenBox_PlateE H03 MMV687796 27 
PathogenBox_PlateE H04 MMV688939 78 
PathogenBox_PlateE H05 MMV688978 97 
PathogenBox_PlateE H06 MMV688990 83 
PathogenBox_PlateE H07 MMV688273 29 
PathogenBox_PlateE H08 MMV393995 94 
PathogenBox_PlateE H09 MMV1236379 94 
PathogenBox_PlateE H10 MMV688550 82 
PathogenBox_PlateE H11 MMV495543 84 
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7.12 Appendix 10. Profiles and percentage anticrithidial activities of 
compounds in the GSK T.brucei box. 
	
Plate barcode Position Compound ID Inhibition (%) at 
100µM concentration 
G20SL2B A2 TCMDC-143074 100 
G20SL2B G7 TCMDC-143100 46 
G20SL2B B8 TCMDC-143121 53 
G20SL2B H9 TCMDC-143123 44 
G20SL2B A10 TCMDC-143128 53 
G20SL2B A7 TCMDC-143131 52 
G20SL2B E5 TCMDC-143132 57 
G20SL2B C11 TCMDC-143138 91 
G20SL2B D11 TCMDC-143154 49 
G20SL2B A9 TCMDC-143167 31 
G20SL2B E3 TCMDC-143172 84 
G20SL2B A3 TCMDC-143176 74 
G20SL2B H2 TCMDC-143199 63 
G20SL2B H7 TCMDC-143205 55 
G20SL2B B11 TCMDC-143206 21 
G20SL2B C7 TCMDC-143225 50 
G20SL2B E6 TCMDC-143230 40 
G20SL2B G9 TCMDC-143233 97 
G20SL2B E9 TCMDC-143240 65 
G20SL2B B6 TCMDC-143242 82 
G20SL2B F10 TCMDC-143251 71 
G20SL2B A11 TCMDC-143257 48 
G20SL2B F7 TCMDC-143263 100 
G20SL2B C9 TCMDC-143264 45 
G20SL2B G2 TCMDC-143265 73 
G20SL2B E8 TCMDC-143267 78 
G20SL2B C4 TCMDC-143270 78 
G20SL2B H3 TCMDC-143289 59 
G20SL2B H8 TCMDC-143290 32 
G20SL2B E2 TCMDC-143292 100 
G20SL2B E10 TCMDC-143307 72 
G20SL2B G8 TCMDC-143320 63 
G20SL2B B7 TCMDC-143323 89 
G20SL2B B4 TCMDC-143335 74 
G20SL2B B9 TCMDC-143337 59 
G20SL2B F11 TCMDC-143342 67 
G20SL2B G3 TCMDC-143343 52 
G20SL2B A8 TCMDC-143356 88 
G20SL2B D7 TCMDC-143359 73 
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G20SL2B D8 TCMDC-143361 68 
G20SL2B D10 TCMDC-143365 50 
G20SL2B D3 TCMDC-143378 74 
G20SL2B G5 TCMDC-143399 58 
G20SL2B H6 TCMDC-143424 67 
G20SL2B D5 TCMDC-143428 100 
G20SL2B F9 TCMDC-143444 80 
G20SL2B D2 TCMDC-143449 94 
G20SL2B C10 TCMDC-143453 59 
G20SL2B C8 TCMDC-143454 66 
G20SL2B G6 TCMDC-143457 94 
G20SL2B B5 TCMDC-143460 100 
G20SL2B F3 TCMDC-143462 90 
G20SL2B H10 TCMDC-143475 56 
G20SL2B G4 TCMDC-143493 60 
G20SL2B H5 TCMDC-143505 50 
G20SL2B F2 TCMDC-143510 76 
G20SL2B H11 TCMDC-143513 40 
G20SL2B C2 TCMDC-143515 99 
G20SL2B F6 TCMDC-143516 61 
G20SL2B A5 TCMDC-143533 97 
G20SL2B D9 TCMDC-143551 51 
G20SL2B D4 TCMDC-143556 62 
G20SL2B F5 TCMDC-143565 76 
G20SL2B A6 TCMDC-143572 76 
G20SL2B C6 TCMDC-143575 54 
G20SL2B E4 TCMDC-143578 72 
G20SL2B D6 TCMDC-143579 65 
G20SL2B C5 TCMDC-143581 36 
G20SL2B B10 TCMDC-143585 69 
G20SL2B G11 TCMDC-143587 77 
G20SL2B E11 TCMDC-143597 88 
G20SL2B A4 TCMDC-143609 98 
G20SL2B H4 TCMDC-143624 67 
G20SL2B G10 TCMDC-143638 77 
G20SL2B F4 TCMDC-143645 59 
G20SL2B B3 TCMDC-143080 95 
G20SL2B C3 TCMDC-143194 81 
G20SL2B B2 TCMDC-143273 68 
G20SL2B F8 TCMDC-143497 51 
G20SL2B E7 TCMDC-143569 84 
G20SL2C H10 TCMDC-142497 94 
G20SL2C A2 TCMDC-143073 99 
G20SL2C A9 TCMDC-143089 27 
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G20SL2C A11 TCMDC-143102 87 
G20SL2C E4 TCMDC-143104 89 
G20SL2C D8 TCMDC-143107 55 
G20SL2C G10 TCMDC-143111 89 
G20SL2C G2 TCMDC-143116 70 
G20SL2C G9 TCMDC-143125 100 
G20SL2C B10 TCMDC-143134 43 
G20SL2C D3 TCMDC-143146 68 
G20SL2C D2 TCMDC-143158 80 
G20SL2C E7 TCMDC-143173 69 
G20SL2C B6 TCMDC-143189 45 
G20SL2C C8 TCMDC-143195 10 
G20SL2C F8 TCMDC-143204 78 
G20SL2C F9 TCMDC-143210 80 
G20SL2C C10 TCMDC-143219 100 
G20SL2C B5 TCMDC-143220 91 
G20SL2C A7 TCMDC-143227 10 
G20SL2C A3 TCMDC-143228 16 
G20SL2C C6 TCMDC-143229 15 
G20SL2C C9 TCMDC-143231 58 
G20SL2C B9 TCMDC-143243 100 
G20SL2C A10 TCMDC-143250 85 
G20SL2C G4 TCMDC-143283 30 
G20SL2C E10 TCMDC-143294 49 
G20SL2C G7 TCMDC-143303 15 
G20SL2C F3 TCMDC-143326 67 
G20SL2C H2 TCMDC-143339 87 
G20SL2C D11 TCMDC-143341 46 
G20SL2C H3 TCMDC-143352 77 
G20SL2C C3 TCMDC-143357 56 
G20SL2C C5 TCMDC-143360 100 
G20SL2C D4 TCMDC-143363 100 
G20SL2C H11 TCMDC-143366 76 
G20SL2C H5 TCMDC-143368 23 
G20SL2C G5 TCMDC-143369 74 
G20SL2C A8 TCMDC-143370 90 
G20SL2C G8 TCMDC-143373 19 
G20SL2C C11 TCMDC-143374 88 
G20SL2C G11 TCMDC-143380 83 
G20SL2C E11 TCMDC-143386 80 
G20SL2C H6 TCMDC-143390 44 
G20SL2C D6 TCMDC-143393 65 
G20SL2C E2 TCMDC-143394 84 
G20SL2C D7 TCMDC-143400 28 
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G20SL2C B11 TCMDC-143401 90 
G20SL2C H4 TCMDC-143402 90 
G20SL2C F11 TCMDC-143412 12 
G20SL2C H7 TCMDC-143425 86 
G20SL2C F6 TCMDC-143435 87 
G20SL2C A6 TCMDC-143436 50 
G20SL2C E5 TCMDC-143438 50 
G20SL2C F4 TCMDC-143445 68 
G20SL2C E9 TCMDC-143446 79 
G20SL2C D10 TCMDC-143452 25 
G20SL2C G6 TCMDC-143456 62 
G20SL2C C4 TCMDC-143458 66 
G20SL2C B7 TCMDC-143496 61 
G20SL2C D9 TCMDC-143499 56 
G20SL2C E3 TCMDC-143525 72 
G20SL2C E6 TCMDC-143540 58 
G20SL2C E8 TCMDC-143543 88 
G20SL2C B4 TCMDC-143547 81 
G20SL2C A4 TCMDC-143580 12 
G20SL2C F2 TCMDC-143582 88 
G20SL2C C7 TCMDC-143589 63 
G20SL2C D5 TCMDC-143595 80 
G20SL2C G3 TCMDC-143596 82 
G20SL2C B8 TCMDC-143619 83 
G20SL2C H8 TCMDC-143634 12 
G20SL2C C2 TCMDC-143640 58 
G20SL2C F5 TCMDC-143641 93 
G20SL2C B2 TCMDC-143642 76 
G20SL2C B3 TCMDC-143643 80 
G20SL2C F7 TCMDC-143644 72 
G20SL2C F10 TCMDC-143648 57 
G20SL2C A5 TCMDC-143130 65 
G20SL2C H9 TCMDC-143526 94 
G211HCO D2 TCMDC-143226 14 
G211HCO C2 TCMDC-143316 99 
G211HCO F2 TCMDC-143330 20 
G211HCO G2 TCMDC-143377 73 
G211HCO A3 TCMDC-143382 70 
G211HCO H2 TCMDC-143392 92 
G211HCO B2 TCMDC-143468 82 
G211HCO E2 TCMDC-143646 91 
G211HCO A2 TCMDC-143163 29 
G211IMU E2 TCMDC-142716 81 
G211IMU G2 TCMDC-143079 93 
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G211IMU A2 TCMDC-143112 100 
G211IMU C2 TCMDC-143192 61 
G211IMU H2 TCMDC-143254 60 
G211IMU A3 TCMDC-143299 92 
G211IMU B2 TCMDC-143318 50 
G211IMU D2 TCMDC-143364 46 
G211IMU C3 TCMDC-143466 54 
G211IMU F2 TCMDC-143469 92 
G211IMU D3 TCMDC-143471 90 
G211IMU B3 TCMDC-143636 58 
G211IRO B2 TCMDC-143312 35 
G211IRO C2 TCMDC-143470 72 
G211IRO E2 TCMDC-143544 51 
G211IRO A2 TCMDC-143583 36 
G211IRO D2 TCMDC-143635 48 
G214GU7 B2 TCMDC-143312 28 
G214GU7 A2 TCMDC-143583 58 
 
 
7.13 Appendix 11. Profiles and percentage anticrithidial activities of 
compounds in the GSK T. cruzi box. 
 
Plate barcode Position Compound ID Inhibition (%) at 
100µM concentration 
G20SL2D H9 TCMDC-143081 70 
G20SL2D E11 TCMDC-143083 95 
G20SL2D E2 TCMDC-143088 100 
G20SL2D G5 TCMDC-143097 21 
G20SL2D C8 TCMDC-143108 55 
G20SL2D H4 TCMDC-143114 87 
G20SL2D G10 TCMDC-143135 91 
G20SL2D A5 TCMDC-143142 100 
G20SL2D G2 TCMDC-143143 57 
G20SL2D A6 TCMDC-143148 14 
G20SL2D A4 TCMDC-143149 100 
G20SL2D H3 TCMDC-143150 87 
G20SL2D A10 TCMDC-143152 100 
G20SL2D B4 TCMDC-143155 96 
G20SL2D G11 TCMDC-143156 68 
G20SL2D F2 TCMDC-143157 13 
G20SL2D H5 TCMDC-143161 67 
G20SL2D B2 TCMDC-143162 93 
G20SL2D E3 TCMDC-143178 74 
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G20SL2D A7 TCMDC-143187 37 
G20SL2D F3 TCMDC-143190 67 
G20SL2D C10 TCMDC-143200 67 
G20SL2D B10 TCMDC-143203 97 
G20SL2D E10 TCMDC-143207 96 
G20SL2D C3 TCMDC-143222 99 
G20SL2D H10 TCMDC-143224 70 
G20SL2D E6 TCMDC-143235 100 
G20SL2D F10 TCMDC-143241 10 
G20SL2D B5 TCMDC-143244 76 
G20SL2D E4 TCMDC-143247 89 
G20SL2D A11 TCMDC-143248 46 
G20SL2D B6 TCMDC-143253 94 
G20SL2D A9 TCMDC-143256 54 
G20SL2D D3 TCMDC-143258 26 
G20SL2D F9 TCMDC-143262 100 
G20SL2D G7 TCMDC-143272 94 
G20SL2D B9 TCMDC-143276 96 
G20SL2D D10 TCMDC-143279 96 
G20SL2D C11 TCMDC-143284 65 
G20SL2D B7 TCMDC-143300 68 
G20SL2D A2 TCMDC-143309 76 
G20SL2D H8 TCMDC-143313 14 
G20SL2D F7 TCMDC-143319 20 
G20SL2D H11 TCMDC-143324 84 
G20SL2D D9 TCMDC-143328 73 
G20SL2D B8 TCMDC-143329 100 
G20SL2D G4 TCMDC-143332 55 
G20SL2D D6 TCMDC-143346 68 
G20SL2D C2 TCMDC-143362 42 
G20SL2D D2 TCMDC-143384 26 
G20SL2D G6 TCMDC-143387 81 
G20SL2D E8 TCMDC-143405 80 
G20SL2D H7 TCMDC-143408 65 
G20SL2D D7 TCMDC-143409 95 
G20SL2D D8 TCMDC-143411 68 
G20SL2D C4 TCMDC-143415 100 
G20SL2D E7 TCMDC-143421 90 
G20SL2D G3 TCMDC-143434 18 
G20SL2D C5 TCMDC-143439 90 
G20SL2D D11 TCMDC-143461 100 
G20SL2D A3 TCMDC-143504 66 
G20SL2D D4 TCMDC-143507 47 
G20SL2D B11 TCMDC-143527 33 
118 
  
G20SL2D F8 TCMDC-143529 100 
G20SL2D A8 TCMDC-143535 55 
G20SL2D D5 TCMDC-143537 65 
G20SL2D F6 TCMDC-143541 100 
G20SL2D E9 TCMDC-143552 69 
G20SL2D F11 TCMDC-143555 93 
G20SL2D G9 TCMDC-143561 41 
G20SL2D C9 TCMDC-143598 54 
G20SL2D E5 TCMDC-143602 100 
G20SL2D G8 TCMDC-143605 8 
G20SL2D C7 TCMDC-143608 100 
G20SL2D H6 TCMDC-143611 84 
G20SL2D H2 TCMDC-143616 18 
G20SL2D B3 TCMDC-143617 35 
G20SL2D C6 TCMDC-143620 86 
G20SL2D F4 TCMDC-143632 87 
G20SL2D F5 TCMDC-143637 42 
G211GWY B2 TCMDC-143080 89 
G211GWY C5 TCMDC-143087 100 
G211GWY A7 TCMDC-143109 100 
G211GWY E2 TCMDC-143130 74 
G211GWY G5 TCMDC-143137 70 
G211GWY G3 TCMDC-143160 95 
G211GWY A3 TCMDC-143163 52 
G211GWY B3 TCMDC-143164 69 
G211GWY E6 TCMDC-143186 99 
G211GWY A6 TCMDC-143193 71 
G211GWY C2 TCMDC-143194 81 
G211GWY C3 TCMDC-143197 80 
G211GWY A2 TCMDC-143273 57 
G211GWY A4 TCMDC-143308 100 
G211GWY D3 TCMDC-143315 100 
G211GWY D6 TCMDC-143325 100 
G211GWY F4 TCMDC-143331 97 
G211GWY F6 TCMDC-143371 94 
G211GWY F3 TCMDC-143414 74 
G211GWY C4 TCMDC-143430 100 
G211GWY F2 TCMDC-143446 67 
G211GWY C6 TCMDC-143455 100 
G211GWY D4 TCMDC-143464 100 
G211GWY G4 TCMDC-143477 100 
G211GWY E4 TCMDC-143481 100 
G211GWY A5 TCMDC-143492 100 
G211GWY B6 TCMDC-143494 100 
119 
  
G211GWY D2 TCMDC-143497 85 
G211GWY H5 TCMDC-143498 100 
G211GWY G6 TCMDC-143506 100 
G211GWY G2 TCMDC-143526 75 
G211GWY E3 TCMDC-143539 100 
G211GWY D5 TCMDC-143542 100 
G211GWY H6 TCMDC-143550 100 
G211GWY E5 TCMDC-143562 100 
G211GWY H2 TCMDC-143569 63 
G211GWY H4 TCMDC-143590 100 
G211GWY B5 TCMDC-143593 100 
G211GWY H3 TCMDC-143599 96 
G211GWY B4 TCMDC-143601 100 
G211GWY F5 TCMDC-143614 100 
G211GWZ B2 TCMDC-123621 100 
G211GWZ G2 TCMDC-125222 100 
G211GWZ F2 TCMDC-139489 22 
G211GWZ E2 TCMDC-140766 33 
G211GWZ A3 TCMDC-143071 53 
G211GWZ F8 TCMDC-143082 68 
G211GWZ C9 TCMDC-143084 61 
G211GWZ A10 TCMDC-143103 22 
G211GWZ E6 TCMDC-143105 56 
G211GWZ E9 TCMDC-143120 71 
G211GWZ A9 TCMDC-143126 96 
G211GWZ C2 TCMDC-143127 100 
G211GWZ B10 TCMDC-143151 100 
G211GWZ G6 TCMDC-143153 44 
G211GWZ G9 TCMDC-143159 100 
G211GWZ C11 TCMDC-143179 18 
G211GWZ C6 TCMDC-143182 71 
G211GWZ H10 TCMDC-143191 62 
G211GWZ C3 TCMDC-143209 22 
G211GWZ H5 TCMDC-143232 67 
G211GWZ H8 TCMDC-143275 70 
G211GWZ G8 TCMDC-143282 57 
G211GWZ A4 TCMDC-143286 100 
G211GWZ F7 TCMDC-143288 39 
G211GWZ B3 TCMDC-143291 32 
G211GWZ D2 TCMDC-143298 13 
G211GWZ A6 TCMDC-143301 69 
G211GWZ H4 TCMDC-143302 56 
G211GWZ A11 TCMDC-143304 100 
G211GWZ E3 TCMDC-143310 100 
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G211GWZ B5 TCMDC-143311 33 
G211GWZ A2 TCMDC-143314 10 
G211GWZ D7 TCMDC-143317 45 
G211GWZ F10 TCMDC-143333 59 
G211GWZ B6 TCMDC-143334 60 
G211GWZ D3 TCMDC-143336 48 
G211GWZ B11 TCMDC-143338 17 
G211GWZ G11 TCMDC-143354 71 
G211GWZ C10 TCMDC-143372 76 
G211GWZ H11 TCMDC-143389 82 
G211GWZ E7 TCMDC-143403 44 
G211GWZ D4 TCMDC-143410 79 
G211GWZ G7 TCMDC-143416 100 
G211GWZ H2 TCMDC-143417 35 
G211GWZ F4 TCMDC-143422 100 
G211GWZ D6 TCMDC-143423 67 
G211GWZ F11 TCMDC-143426 85 
G211GWZ F3 TCMDC-143432 100 
G211GWZ D8 TCMDC-143437 88 
G211GWZ E8 TCMDC-143440 100 
G211GWZ A5 TCMDC-143463 69 
G211GWZ H9 TCMDC-143465 50 
G211GWZ H6 TCMDC-143467 95 
G211GWZ C7 TCMDC-143474 74 
G211GWZ E4 TCMDC-143476 79 
G211GWZ G5 TCMDC-143479 73 
G211GWZ F5 TCMDC-143484 45 
G211GWZ E5 TCMDC-143490 79 
G211GWZ A8 TCMDC-143495 100 
G211GWZ C4 TCMDC-143502 100 
G211GWZ B4 TCMDC-143511 100 
G211GWZ G10 TCMDC-143519 56 
G211GWZ A7 TCMDC-143520 95 
G211GWZ G3 TCMDC-143528 44 
G211GWZ D11 TCMDC-143530 67 
G211GWZ F9 TCMDC-143545 51 
G211GWZ C8 TCMDC-143546 61 
G211GWZ H7 TCMDC-143548 48 
G211GWZ E11 TCMDC-143549 93 
G211GWZ F6 TCMDC-143553 89 
G211GWZ E10 TCMDC-143559 76 
G211GWZ B9 TCMDC-143564 38 
G211GWZ C5 TCMDC-143588 52 
G211GWZ D10 TCMDC-143592 88 
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G211GWZ D5 TCMDC-143604 91 
G211GWZ D9 TCMDC-143613 58 
G211GWZ B7 TCMDC-143615 14 
G211GWZ H3 TCMDC-143623 81 
G211GWZ B8 TCMDC-143626 25 
G211GWZ G4 TCMDC-143631 73 
G211IMQ D2 TCMDC-143221 71 
G211IMQ C3 TCMDC-143293 89 
G211IMQ G2 TCMDC-143376 75 
G211IMQ B3 TCMDC-143379 90 
G211IMQ C2 TCMDC-143381 60 
G211IMQ B2 TCMDC-143385 60 
G211IMQ E3 TCMDC-143413 66 
G211IMQ E2 TCMDC-143433 57 
G211IMQ F3 TCMDC-143466 60 
G211IMQ H2 TCMDC-143606 98 
G211IMQ F2 TCMDC-143610 95 
G211IMQ D3 TCMDC-143612 100 
G211IMQ A3 TCMDC-143622 100 
G211IMQ A2 TCMDC-143625 100 
Q203FAM C2 TCMDC-143085 47 
Q203FAM A2 TCMDC-143118 44 
Q203FAM B2 TCMDC-143185 86 
Q203FAM D2 TCMDC-143500 77 
 
 
 
 
7.14 Appendix 12. Profiles and percentage anticrithidial activities of 
compounds in the GSK Leishmania box 
 
Plate barcode Position Compound ID Inhibition (%) at 
100µM concentration 
G211IMR B8 TCMDC-125387 83 
G211IMR C8 TCMDC-142900 100 
G211IMR B7 TCMDC-143075 96 
G211IMR F7 TCMDC-143098 82 
G211IMR E5 TCMDC-143099 82 
G211IMR F6 TCMDC-143101 84 
G211IMR B2 TCMDC-143129 100 
G211IMR E8 TCMDC-143133 75 
G211IMR E4 TCMDC-143139 81 
122 
  
G211IMR D5 TCMDC-143140 70 
G211IMR C5 TCMDC-143144 84 
G211IMR H6 TCMDC-143170 95 
G211IMR H3 TCMDC-143171 81 
G211IMR C4 TCMDC-143184 91 
G211IMR A7 TCMDC-143188 100 
G211IMR C2 TCMDC-143201 95 
G211IMR D3 TCMDC-143202 100 
G211IMR F8 TCMDC-143218 100 
G211IMR G7 TCMDC-143236 92 
G211IMR A8 TCMDC-143237 98 
G211IMR E2 TCMDC-143245 85 
G211IMR F4 TCMDC-143246 80 
G211IMR G2 TCMDC-143252 98 
G211IMR E3 TCMDC-143266 92 
G211IMR B6 TCMDC-143268 100 
G211IMR H4 TCMDC-143278 100 
G211IMR D7 TCMDC-143287 92 
G211IMR E7 TCMDC-143306 100 
G211IMR B4 TCMDC-143340 84 
G211IMR C7 TCMDC-143345 68 
G211IMR G6 TCMDC-143347 72 
G211IMR A4 TCMDC-143353 74 
G211IMR H7 TCMDC-143375 100 
G211IMR D8 TCMDC-143404 94 
G211IMR E6 TCMDC-143407 82 
G211IMR C3 TCMDC-143418 77 
G211IMR A5 TCMDC-143419 100 
G211IMR F2 TCMDC-143427 90 
G211IMR F3 TCMDC-143431 94 
G211IMR G4 TCMDC-143443 100 
G211IMR A6 TCMDC-143491 78 
G211IMR G5 TCMDC-143508 100 
G211IMR B3 TCMDC-143514 81 
G211IMR F5 TCMDC-143523 73 
G211IMR G3 TCMDC-143536 67 
G211IMR A2 TCMDC-143538 79 
G211IMR H2 TCMDC-143557 87 
G211IMR H5 TCMDC-143558 80 
G211IMR A3 TCMDC-143570 90 
G211IMR D2 TCMDC-143573 97 
G211IMR D4 TCMDC-143574 100 
G211IMR H8 TCMDC-143576 95 
G211IMR B5 TCMDC-143577 75 
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G211IMR C6 TCMDC-143591 92 
G211IMR G8 TCMDC-143600 100 
G211IMR B9 TCMDC-125387 69 
G211IMS D4 TCMDC-143163 66 
G211IMS A9 TCMDC-143164 75 
G211IMS C5 TCMDC-143197 77 
G211IMS H11 TCMDC-143315 98 
G211IMS D2 TCMDC-125160 89 
G211IMS G5 TCMDC-125826 100 
G211IMS A5 TCMDC-143086 57 
G211IMS A8 TCMDC-143094 100 
G211IMS G7 TCMDC-143106 96 
G211IMS B9 TCMDC-143110 99 
G211IMS F2 TCMDC-143113 100 
G211IMS E3 TCMDC-143115 98 
G211IMS B5 TCMDC-143119 71 
G211IMS H10 TCMDC-143124 72 
G211IMS B4 TCMDC-143136 100 
G211IMS C6 TCMDC-143141 76 
G211IMS H9 TCMDC-143145 100 
G211IMS A3 TCMDC-143147 96 
G211IMS F8 TCMDC-143165 100 
G211IMS F7 TCMDC-143166 100 
G211IMS E8 TCMDC-143168 76 
G211IMS B8 TCMDC-143169 73 
G211IMS A6 TCMDC-143174 97 
G211IMS G8 TCMDC-143175 93 
G211IMS H5 TCMDC-143181 56 
G211IMS A10 TCMDC-143196 82 
G211IMS D8 TCMDC-143208 91 
G211IMS D7 TCMDC-143214 74 
G211IMS A11 TCMDC-143223 92 
G211IMS D3 TCMDC-143239 100 
G211IMS C4 TCMDC-143249 74 
G211IMS B6 TCMDC-143255 94 
G211IMS D9 TCMDC-143259 78 
G211IMS D6 TCMDC-143261 78 
G211IMS D11 TCMDC-143269 59 
G211IMS F6 TCMDC-143271 100 
G211IMS D5 TCMDC-143274 100 
G211IMS F10 TCMDC-143277 99 
G211IMS H2 TCMDC-143280 93 
G211IMS C7 TCMDC-143281 99 
G211IMS G2 TCMDC-143295 92 
124 
  
G211IMS C8 TCMDC-143297 100 
G211IMS F5 TCMDC-143305 85 
G211IMS G3 TCMDC-143327 65 
G211IMS C10 TCMDC-143344 75 
G211IMS E11 TCMDC-143351 72 
G211IMS B2 TCMDC-143355 74 
G211IMS H7 TCMDC-143358 95 
G211IMS G4 TCMDC-143367 74 
G211IMS H8 TCMDC-143383 76 
G211IMS C9 TCMDC-143388 71 
G211IMS B10 TCMDC-143391 71 
G211IMS E10 TCMDC-143396 63 
G211IMS H6 TCMDC-143398 97 
G211IMS E2 TCMDC-143406 96 
G211IMS C3 TCMDC-143442 100 
G211IMS E5 TCMDC-143447 100 
G211IMS H4 TCMDC-143451 75 
G211IMS A2 TCMDC-143473 78 
G211IMS F4 TCMDC-143483 74 
G211IMS G6 TCMDC-143501 88 
G211IMS G9 TCMDC-143509 100 
G211IMS B11 TCMDC-143518 96 
G211IMS C11 TCMDC-143522 78 
G211IMS A7 TCMDC-143524 84 
G211IMS F3 TCMDC-143531 63 
G211IMS G10 TCMDC-143534 91 
G211IMS G11 TCMDC-143554 100 
G211IMS H3 TCMDC-143563 66 
G211IMS C2 TCMDC-143566 72 
G211IMS E7 TCMDC-143567 91 
G211IMS E9 TCMDC-143571 100 
G211IMS F9 TCMDC-143584 78 
G211IMS B7 TCMDC-143586 100 
G211IMS A4 TCMDC-143603 100 
G211IMS E4 TCMDC-143607 99 
G211IMS B3 TCMDC-143618 66 
G211IMS D10 TCMDC-143621 94 
G211IMS F11 TCMDC-143628 72 
G211IMS E6 TCMDC-143629 90 
G211IMT G4 TCMDC-124508 60 
G211IMT C3 TCMDC-142704 100 
G211IMT B3 TCMDC-143072 82 
G211IMT C5 TCMDC-143076 70 
G211IMT B5 TCMDC-143077 96 
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G211IMT E4 TCMDC-143078 80 
G211IMT C2 TCMDC-143117 65 
G211IMT A5 TCMDC-143211 79 
G211IMT A4 TCMDC-143212 100 
G211IMT C4 TCMDC-143213 82 
G211IMT D4 TCMDC-143215 77 
G211IMT B4 TCMDC-143216 96 
G211IMT D5 TCMDC-143217 89 
G211IMT H4 TCMDC-143285 100 
G211IMT A3 TCMDC-143296 96 
G211IMT H3 TCMDC-143350 66 
G211IMT E2 TCMDC-143397 100 
G211IMT F3 TCMDC-143429 66 
G211IMT G2 TCMDC-143448 94 
G211IMT D3 TCMDC-143478 74 
G211IMT D2 TCMDC-143480 66 
G211IMT H2 TCMDC-143482 70 
G211IMT E5 TCMDC-143488 100 
G211IMT F2 TCMDC-143517 100 
G211IMT F5 TCMDC-143521 90 
G211IMT A2 TCMDC-143532 74 
G211IMT F4 TCMDC-143568 100 
G211IMT B2 TCMDC-143594 81 
G211IMT G3 TCMDC-143633 78 
G211IMT E3 TCMDC-143647 100 
Q203FAN A4 TCMDC-134026 97 
Q203FAN D2 TCMDC-143090 98 
Q203FAN H2 TCMDC-143091 95 
Q203FAN A3 TCMDC-143092 93 
Q203FAN A2 TCMDC-143093 98 
Q203FAN B3 TCMDC-143095 91 
Q203FAN E2 TCMDC-143096 98 
Q203FAN F2 TCMDC-143238 97 
Q203FAN D3 TCMDC-143260 75 
Q203FAN G2 TCMDC-143348 90 
Q203FAN C3 TCMDC-143349 75 
Q203FAN G3 TCMDC-143459 69 
Q203FAN B2 TCMDC-143486 80 
Q203FAN F3 TCMDC-143487 97 
Q203FAN C2 TCMDC-143503 100 
Q203FAN H3 TCMDC-143512 66 
Q203FAN E3 TCMDC-143630 83 
 
 
